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Abstract 
Abstract 
Enzymatic halogenation occurs during the biosynthesis of more than 4,000 natural 
products. The presence of fluorinated natural products is much less common, with only 13 
reported to date. The bacterium Streptomyces cattleya is known to biosynthesise two 
fluorinated secondary metabolites, fluoroacetate and 4-fluorothreonine. The precursor to 
these secondary metabolites is known to be fluoroacetaldehyde. It had previously been 
shown that a fluorination enzyme mediates a reaction between S-adenosyl-L-methionine 
(SAM) and F to generate 5'-fluoro-5'-deoxyadenosine (5'-FDA). This is the first 
committed step on the biosynthetic pathway. The pathway between 5' -FDA and 
fluoroacetaldehyde had not been investigated in detail prior to the work carried out in this 
thesis. 
A purine nucleoside phosphorylase has been partially purified from cell-free extracts 
which catalyses the phosphorolytic cleavage of 5'-FDA to 5-fluoro-5-deoxY-D-ribose-l-
phosphate (5-FDRP). Substrate specificity shows a profile which shares a close similarity 
to bacterial 5'-methylthioadenosine phosphorylases (MTAP's). The identification ofa gene 
cluster encoding enzymes responsible for fluorometabolite biosynthesis shows the PNP 
gene located adj acent to the fluorinase gene, reinforcing the involvement of this enzyme in 
the fluorometabolite pathway. 
It is shown that 5-FDRP is converted to 5-fluoro-5-deoxY-D-ribulose-l-phosphate (5-
FDRibP) via an isomerase activity. The enzyme responsible for this transformation has 
been partially purified from cell free extracts (CFE's). Another metabolite was identified 
as 5-fluoro-5-deoxY-D-xylulose-l-phosphate (5-FDXyuP), a diastereoisomer of 5-FDRibP, 
which appears to be an adventitious product in CFE's of S. cattleya. 
Two DHAP dependent aldolases have been identified, one of which is a putative L-
fuculose-l-phosphate aldolase which catalyses conversion of 5-FDRibP to 
fluoroacetaldehyde. The other, an L-fructose 1,6-bisphosphate aldolase has been purified 
to homogeneity and catalyses an aldol reaction between DHAP and fluoroacetaldehyde to 
generate 5-FDXyuP. This enzyme is most probably one of primary metabolism. 
XVll 
Chapter 1 
1 Introduction 
Throughout the ages plant natural products have been used in traditional medicine. l 
Today, with marine organisms and other living creatures as additional sources of active 
compounds, the biosynthesis of natural products represents a major avenue to drug 
discovery and development. Indeed, a large portion of today's major drugs have their 
origins in nature. Over 25 % of all drugs have originated from natural products, and more 
than 80 % of the world's total population rely on natural extracts for primary healthcare,z 
It is therefore, not surprising that one of the most flourishing and rewarding frontiers in 
modem science is the study of the chemistry and biology of natural products. 
Natural products arise from routes other than normal metabolic pathways, mostly after a 
phase of active growth and under conditions of nutrient deficiency. Although plants are 
the best known source of secondary metabolites, bacteria, fungi and marine organisms are 
also sources of natural product synthesis. Most low molecular weight natural products fall 
into the categories; alkaloids, terpenoids, polyketides, glycosides and phenolic compounds. 
Large natural product molecules include the ribosomal and non-ribosomal peptides.3 The 
study of these natural products has played a major part in the development of organic and 
medicinal chemistry and has provided an understanding of the ecological role that these 
compounds have. Examples of biologically active natural products which have had 
significant medicinal applications include taxol 1,4 camptothecin 2,5 artemisinin 36 and 
shikonin 4.7 These are among the most powerful anticancer and antimalaria compounds to 
date (Figure 1.1). 
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Figure 1.1 Selected natural products; taxol1, camptothecin 2, artemisinin 3, shikonin 4, 
A potent subset of natural products are the organo-halogen compounds which are diverse 
and have attracted interest both from manufacturers and researchers. By way of 
introduction, the occurrence and biosynthesis of the halogenated natural products are 
reviewed. 
1.1 Biological halogenation of natural products 
Enzymatic incorporation of chlorine, bromine or iodine atoms occurs during the 
biosynthesis of more than 4,000 natural products (Gribble et at. 2004).8 These have been 
isolated from a variety of organisms such as bacteria, fungi, marine algae, litchens, higher 
plants, mammals and insects. Brominated metabolites are the most prevalent in the marine 
environment, whereas chlorine-containing metabolites are more predominant in terrestrial 
organisms. The presence of fluorinated and iodinated natural products is much less 
common. The presence of halogen atoms in organic compounds has been shown to be 
important for biological activity. For example, it is shown that the de-chloro derivative of 
2 
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the anti-tumour compound rebeccamycin 24 (see page 10) showed no antimicrobial 
activity towards different micro-organisms tested, in contrast to the chlorinated compound 
24.9 Figure 1.2 shows several examples of naturally occurring halogenated products. The 
structural diversity is considerable, ranging from poly-chlorinated products such as 
nordysidenin 510,11 to the highly toxic compound fluoroacetate 8. 12 
CI ~CI H~CI CI N 
.: CI CI : : 
:: A 0 /:;: 
~s 
H2N 
o 
5 6 
Br B Br)L~ 10H 
F 
7 8 
Figure 1.2 Examples of halogenated natural products; nordysidenin 5, diiodotyrosine 6 (G. 
cavolinii),8 bromoform 7 (marine algae) and fluoroacetate 8 (S cattleya). 
Although a large number of halogenated natural products have been isolated, it is only very 
recently that details have emerged on the mechanism by which the halogens, F, cr, Br-
and r are incorporated into organic compounds. For the past 35 years haloperoxidases 
were thought to catalyse all halogenation reactions. There is some evidence supporting the 
involvement of haloperoxidases in the production of some organohalogens, such as 
bromoform 7 biosynthesis in the algae Penicillus capitatus. The biosynthetic pathway 
appears to involve a bromoperoxidase. 13 However, elucidation of the reaction mechanism 
shows that these enzymes lack substrate specificity and regioselectivity.14,15 A re-
3 
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evaluation of enzymatic halogenation has occured in recent years with the discovery of 
different types of halogenating enzymes. 
1.1.1 Haloperoxidases 
Haloperoxidases are a group of enzymes that are able to catalyse the halogenation of 
organic compounds in the presence of halide ions and peroxides such as HzOz. The first 
halogenating enzyme was discovered while investigating the biosynthesis of the 
chlorinated metabolite caldariomycin 9 from Caldariomyces jumago. 16 It was observed 
that the enzyme required a chloride ion and hydrogen peroxide and was thus named a 
'chloroperoxidase,.17 In order to assay this enzyme, a spectrophotometric method was 
adopted which employed the synthetic substrate, monochlorodimedone 10, which is 
structurally similar to 2-chloro-l,3-cyclopentanedione 11, a late intermediate in 
caldariomycin 9 biosynthesis (Figure 1.3). 
CI CI o~o CI (a) HO""aOH o~o 
9 10 11 
CI CI ~ (b) o~o o~o ° ° .. H2°zlBr -
10 
Figure 1.3 (a) Chlorinated compounds; caldariomycin 9, monochlorodimedone 10 and 2-
chloro-l,3-cyc1opentanedione 11. (b), Dimedone assay for the haloperoxidase reaction. 
The assay has been used to identify haloperoxidases from a wide range of prokaryotes and 
eukaryotes,18 which have been further classified according to the halide source. 
4 
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Chloroperoxidases can use chloride, bromide and iodide whereas bromoperoxidases use 
only bromide and iodide; and iodoperoxidases only iodide. Haloperoxidases are unable to 
utilise fluoride as a halide source. 17 These enzymes can be further characterised into three 
distinct classes, based on their catalytic mechanism, those which contain a haem group, 
those which contain vanadium and those which do not contain metal ions, namely 
perhydro lases. 
Haem and vanadium containing haloperoxidases 
The chloroperoxidase from Caldariomyces fumago was shown to contain a haem group. 
During the catalytic cycle hypohalous acid (HOCI) is generated as the halogenating agent 
in the presence of H20 2 and halide ions. A different type of haloperoxidase was isolated 
from a marine algae and was found to require vanadium instead of iron for its halogenating 
activity.19 The reaction also produces hypohalous acid as the halogenating agent (Scheme 
1.1). Vanadium-dependent chloro- and bromo-peroxidases have subsequently been 
isolated from lichen, algae and fungi. 20 
H20 2 
Eoz-V'· ~ Enz-V 5<-OOH Br Enz-V 5+ -OBr 
H+ 
('\ ~ 
H+ H20 
H+ 
- ~ 
Br
3 
~ Br
2 
~ HOBr + Enz-V 
+A-H I-H,o 
A-Br 
Scheme 1.1 Enzymatic mechanism of vanadium containing haloperoxidases. 
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Per hydro lases 
Further types of halogenating enzymes are those that contain neither a haem group nor any 
metal ion. Although they require hydrogen peroxide for their halogenating activity, they 
are not peroxidases. These have been isolated from Streptomyces lividans and 
Pseudomonas fluorescens. 21 The protein structure shows a catalytic triad consisting of a 
serine, an aspartate and a histidine residue, indicating that they belong to the a/~ hydrolase 
family. The reaction mechanism proceeds whereby an acyl-enzyme intermediate is formed 
from the reaction of a short-chained carboxylic acid with the serine residue at the active 
site.22 The addition of H20 2 causes the perhydrolysis of the acyl-enzyme intermediate 
which results in the formation of peracids. These peracids oxidise halide ions to 
hypohalous acids which then act as the halogenating agent (Scheme 1.2).23 
Ser 
> Asp- His -- HO 
H+ 0>-CH
3 
° 
H+ 0>-CH
3 
° 
Ser 
Asp-His > 
° H20 }-CH3 
° 
R-CI R-H 
+ .. 
H20 
Scheme 1.2 Enzymatic mechanism of a perhydrolase,z3 
H20 2 
ser> 
Asp- His -- HO 
HO-O
rCH3 
° 
H+ I CI 
H+ 0-
HOCI + r CH3 
° 
Overall, the lack of substrate specificity and regioselectivity of these enzymes makes it 
unlikely that haloperoxidases and perhydrolases are involved in more regulated 
biosynthetic pathways for halometabolite formation. 
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1.1.2 FADH2-dependent halogenases 
Examination of the gene cluster involved in 7 -chlorotetracycline 13 biosynthesis identified 
a gene coding for a halogenation enzyme.24 The deduced amino acid sequence showed no 
similarity to haloperoxidases or perhydrolases, suggesting a different type of halogenating 
enzyme. Studies on the biosynthesis of the anti-fungal compound pyrrolnitrin 19 (page 8) 
from Pseudomonas fluorescens have shown two related genes coding for two halogenase 
enzymes. 25 These two halogenating enzymes were shown to be flavin-dependent with one 
of them having a sequence similarity to the halogenation enzyme involved in 7-
chlorotetracycline 13 biosynthesis. Members of this family have since been identified in 
vancomycin 12,26 calicheamicin,27 balhimycin,28 as well as pyoluteorin 1429 biosynthesis. 
Figure 1.4 shows several of these halogenated natural products in which regiospecific 
halogenation is most probably carried out by flavin dependent halogenases. 
HXJ"'" NH2 
OH 
o ·"'°ft". . ... OH ~/NH, 
OH OH 0 0 o 0 OH 0 
. CI 
~ 13 
OH 
~o ~ 1 N~O " •. NH,Me Cln HO~ IT N 0 H CI/'-~-'l(Y O=( H THO H 0 OH o 
H N 14 2 
11....:::;:1 OH 12 HO/~"'OH 
Figure 1.4 Examples of halogenated natural products involving F ADH2-dependent 
halogenases. 
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During the elucidation of pyrrolnitrin 19 biosynthesis, it was shown that there are two 
halogenating enzymes present which require F ADH2 for catalytic activity.30 Both of these 
enzymes were shown to exhibit low sequence homology to flavin dependent 
mono oxygenase enzymes?l The first of these, a tryptophan-7-halogenase (PmA) was 
shown to be responsible for the regioselective chlorination of tryptophan 15 to generate 7-
chlorotryptophan 16. The second halogenase (PmC) catalyses the regioselective 
chlorination of monodechloroaminopyrrolnitrin 17 in the 3-position of the pyrrole ring, 
generating aminopyrrolnitrin 18 (Scheme 1.3). 
~COOH ~ I I PrnA ~COOH N NH2 .. ~ I I 
H 
N NH2 
CI H 
15 16 
lpm" 
CI 
.. 
PrnC 
I' 
CI CI 
18 17 
IpmD 
CI 
CI 
19 
Scheme 1.3 Biosynthetic steps to pyrrolnitrin 19 in Pseudomonas fluorescens. 
Recently, J. Naismith and co-workers32 at St Andrews University reported the crystal 
structure of tryptophan 7 -halogenase (PmA) along with further biochemical studies which 
suggested a mechanism for regioselective chlorination. It was shown from crystallographic 
data that the cr ion binding site is over 10 A from 7-chlorotryptophan 16. Furthermore, 
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there was no indication of large conformational changes which could bring tryptophan and 
flavin together. It is proposed that the cr is positioned to make a nucleophilic attack on 
the flavin peroxide 21. This results in the formation of F AD-OH 22 and HOCI (Scheme 
1.4). 
FADH2 
R 
r(Y~x;~rO O2 V I NH 
N 
H 0 
(Y~f(NrO ~ NH N 
H 
o 
R 
I 0 NH 
N 
20 CI- Ho/L H+ 
CC~f(NrO 
H 0 
+ HOCI OH 
0 21 22 
",0/ 
()'~yNyo 
~N~NH 
+ HOCI o 
23 
Scheme 1.4 Predicted mechanism for the generation of HOC1.32 
The generated hypohalous acid (HOCI) is positioned in the active site where it travels 
along a 10 A tunnel towards tryptophan 15 to undergo an electrophilic aromatic 
substitution in a controlled regioselective manner (Scheme 1.5). 
K79 
'\+ 
"7)-H 
HO 
'CI 
HOOC 
-
NH2 
~79 
,N-H 
H H20 
0~346 
v-or-
H 
NH2 
K79 
'\ 
,N-H 
H HzO 
0~346 
CI HO 
NH2 
15 16 
K79 
'\+ 
N-H 
/ \ 
H H 
Scheme 1.5 Proposed mechanism of halogenation of tryptophan 15 at the 7 position.32 
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It is conceivable that the hypohalous acid mechanism applies to all flavin-dependent 
halogenases. For example in rebeccamycin 24 biosynthesis the halogenation reactions 
occur early in rebeccamycin 24 biosynthesis involving two genes (rebF) and (rebH), which 
encode a NADPH dependent flavin reductase and an F ADH2-dependent halogenase 
respectiveli3 (Scheme 1.6). This halogenation is of biological significance.34 
"J~o ",tto 
y -~~ CI 
RebH ~ OH ... .. 0=5 OH .. I ~ N CI 0 OH I ~ N (RebF) 
H 
HO 
H 
CI 
OH 
15 
16 
OMe 
24 
Scheme 1.6 Chlorination of tryptophan 15 as the initial step in rebeccamycin 24 biosynthesis. 
The protein rebH was shown to share a 55 % identity with the protein prnA involved in 
pyrrolnitrin 19 biosynthesis. It appears that RebFlRebH catalyses the regioselective 
chlorination of tryptophan 15 to 7-chlorotryptophan 16 in a similar manner to that shown 
in Scheme 1.4 and 1.5. 
Overall, FADH2-dependent halogenases appear to be responsible for the halogenation of 
aromatic substrates in secondary metabolite biosynthesis. However, for chlorinated natural 
products such as barbamide 2535 and syringomycin E 26/6 a separate mechanism exists for 
the chlorination of the un-activated aliphatic carbon centres (Figure 1.5). This is discussed 
in the next section. 
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HO......... N>-rH2 
HN~~'¢O 0 H II N NH ~N .. " 00 H HN )l OH 0 o:r:,c OH NH ~~ NH, 
(Y~JrY.oMe CI ~, o~~ylN~O ~r6HN ° 
V .. Ao ", CI~ .. ,O I N Y" S H 'I OH 0 -:?' 
\d I :::::..... 
25 26 
Figure 1.5 Chlorinated natural products barbamide 25 and syringomycin E 26. 
1.1.3 Chlorination by a non-haem a-keto glutamate dependent enzyme37 
There is a chlorination step during the biosynthesis of the natural product coronatine 30, a 
leaf toxin synthesised by the phytopathogenic bacterium Pseudomonas syringae. Walsh 
and co-workers37 have recently identified a halogenase, CmaB in which chlorination 
occurs at the unactivated methyl group during the biosynthesis of this natural product 
(Scheme 1.7). 
0 H'~ H\ ~ H'X ". OH OH 2 1", OH H H CmaB" CI CmaC .. :> Hj N~ 
"" 0 :. H 
27 28 29 30 
Scheme 1.7 The biosynthesis of coronatine 30, a leaf toxin. Coronatine 30 does not have a 
chlorine atom but it is chlorinated during the biotransformation of L-allo-isoleucine 27. 
The halogenase, CmaB is shown to catalyse the chlorination of the y-position of L-allo-
isoleucine 27 followed by a second enzyme (CmaC) which then catalyses the formation of 
11 
Chapter 1 
a cyclopropyl ring in 29 from 28. Together, both enzymes execute y-halogenation 
followed by intramolecular y-elimination. The generated cyclopropyl ring in 29 then 
undergoes several further reactions before the generation of coronatine 30. 
The enzyme, CmaB is shown to have sequence similarity to a-ketoglutarate (a-KG) 
dependent enzymes that contain non haem iron and use one Asp/Glu and two His side 
chains as ligands to oxygen-labile Fe2+.38,39 These enzymes typically perform oxygenation 
reactions, however CmaB performs chlorination rather than oxygenation at the unactivated 
y position of the amino acid substrate 27. Analogous genes have since been identified, 
involved in the biosynthesis of barb amide 25 and syringomycin 26 (Figure 1.5)?5,36 
A mechanism has recently been proposed by Walsh and co-workers in which CmaB 
mediates a radical pathway involving the prototypic high-valent oxo_iron40,41 (FeIV = 0) 
(Scheme 1.8). 
-OOC j: Hp CIH C R ;.---0"" I .. , His 2 _ . F . II 
product ° 0/ I e ........ a-K;-- y His Asp 
H
2
C/R y 
( 
1 OH ..• His ~ I'IV CI-Fe VI ........ Asp 
R = L-allo isoleucine 
R' ? • ):0," .. , His 
'. '1 
R /Fe I 
H3C/ ° ° I ......... Asp 
substrate HIS 
His /R 
~3C R' ° !r - ° H;, H C/R 3 His R "Iv CI-Fe I ........ Asp 
His 
CI R' "-.,..--0 '. II ..•. IV 
'" / II Fj ........... ASP 
.. ° His 
°2 ~ 
H C/ R 
3 
?2 His 
R'):O"' .. Fe" il 
/1 ........ Asp 
° His ° 
A co, 
Scheme 1.8 Proposed mechanism of halogenation catalysed by CmaB.37 
It appears that nature uses both F ADH2-dependent (Section 1.1.2) and non haem Fe2+ 
dependent enzymes to mediate halogenation reactions. For electron rich aromatic 
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substrates, F ADH2-dependent halogenases are used, which generate HOCI to undergo an 
electrophilic aromatic substitution in a controlled regioselective manner. For unactivated 
carbon centres halogenation is carried out by a radical mechanism using highly reactive 
iron-oxo species (Scheme 1.8). 
1.2 Biological fluorination 
Fluorine is the most abundant halogen in the Earth's crust with fluoride ion concentrations 
ranging from 270-740 ppm, compared to that of chlorine of 10-180 ppm.42 Although 
ranked the 13th most abundant of all the elements,43 only 13 fluorinated secondary 
metabolites have been identified to date. These have been found in both tropical plants and 
microorganisms. The absence of fluorinated natural products can be attributed to fluoride 
residing in an insoluble form and therefore being biologically unavailable.43 Fluoride exists 
predominantly as insoluble minerals (e.g fluorospar) and consequently fluoride levels in 
sea water are low at 1.3 ppm.42 This can be compared to chloride which is present at 
19,000 ppm. Other reasons for the paucity of fluorinated natural products reside in the 
unique properties of fluorine (Table 1.1).44-45 Fluorine is the smallest of all of the halogens 
with an atomic radius only slightly larger than hydrogen. Probably the most important 
factor restricting participation of fluoride in biochemical processes is the large heat of 
hydration of the fluoride ion.43 In the aqueous environment, fluoride is heavily solvated 
precluding it as a potent nucleophile for biochemical processes. The high heat of hydration 
is largely responsible for the substantial differences in redox potential between fluoride and 
other halogen ions and this excludes any type of halo peroxidase mechanism.43 
13 
Chapter 1 
Halogen, Heat of hydration, Standard redox potential 
x- X- [KJ mOri] (Eo) 
F- 490 -3.06 
cr 351 -1.36 
Br- 326 -1.07 
r 285 -0.54 
Table 1.1 Heat of hydration and standard redox potential for the halogens.44-45 
1.2.1 Fluorinated natural products from plants 
1.2.1.1 Fluoroacetate 
Fluoroacetate 8 was first isolated in 1943 by Marais46,47 from the South African plant 
Dichapetalum cymosum. 
fOH 
F 
8 
The inhabitants of the South African province 'Transvaal' had long recognised this plant as 
a hazard to livestock and had consequently named it 'gifblaar' (poison leaf). The young 
leaves of the Dichapetalum genus were reported to contain on average up to 2500 mg kg- l 
dry wt of fluoroacetate 8, with those from Dichapetalum braunii containing a staggering 
8000 mg kg- l dry wt. After the original discovery, many other species of the 
Dichapetalum genus have been shown to contain high levels of fluoroacetate 8 in their 
leaves, such as D. heudelotti,48 D. stuhlmannii49 and D. toxicarium.50 In Australia more 
than forty plant species from the Leguminosae genus have been shown to contain traces of 
fluoroacetate 8. 
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1.2.1.2 Fluorocitrate 
The high toxicity of fluoroacetate 8 is attributed to its in vivo conversion to (2R, 3R)-
fluorocitrate 31. 
HO C OH HOzC~COzH 
F 
31 
This transformation has be termed the 'lethal synthesis' (Peters et al).5! Many plants 
which accumulate low levels of fluoroacetate 8 have also been shown to contain trace 
levels of fluorocitrate 31. 52,53 Fluorocitrate 31 is biosynthesised after in vivo activation of 
fluoroacetate 8 to fluoroacetyl-CoA 32.53 This then combines with oxaloacetate 33 
catalysed by the citric acid cycle enzyme, citrate synthase. 53 It emerges that the enzymatic 
reaction is highly stereospecific and generates the only toxic stereoisomer, (2R, 3R)-
fluorocitrate 31.53 The metabolic product 35 is a competitive inhibitor of aconitase, the 
enzyme after citrate synthase on the citric acid cycle (Scheme 1.9). 
COzH HO,C~ ~ 
OH COzH { 
35 F 
° 
F0sCOA 
H H 
32 
yOzH 
HOF,~COzH _j~~J 
/0 
H 
fluoro-cis-aconitate 
34 
° 
+ HOzCJCOzH 
33 
Citrate synthase 
HOzC 'pH HOzC~COzH 
F 
31 
Scheme 1.9 The metabolic fate offluoroacetyl-CoA 32 with oxaloacetate 33. 
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The mechanism for aconitase inhibition involves a dehydration to give fluoro-cis-aconitate 
34, followed by an SN2' addition of hydroxide with loss of fluoride ion to form 4-hydroxy-
trans-aconitate 35.54 This product is a potent competitive inhibitor of the enzyme. 54 
Additionally, it has been suggested that fluorocitrate 31 covalently binds to proteins 
involved in citrate transport across the mitochondrial membrane. 55 The toxicity attributed 
to this latter process has been estimated to be 104 times more significant than aconitase 
inhibition alone.55 
1.2.1.3 Fluoroacetone 
Fluoroacetone 36 was first identified by Peters and Shorthouse56,57 after a series of 
experiments in the late 1960's exploring fluoride metabolism in the Australian plant 
Acacia georginae. 
o (lCH3 
F 
36 
These experiments showed up to a 34 % loss of the total fluoride ion (1 mM) originally 
present. 56,57 This was attributed to the biosynthesis of volatile organofluorine compounds.57 
Derivatisation with 2,4-dinitrophenylhydrazine gave a product which had an identical 
retention time on paper chromatography to that of fluoroacetone 36.57 However, as 
pointed out in the report, the derivatisation method could not distinguish between 
fluoroacetone 36 and fluoroacetaldehyde 48. 57 Based on the subsequently identified role 
of fluoroacetaldehyde 48 in fluorometabolite biosynthesis in S. cattleya (Section 1.4),78 it 
is plausible that the hydrazone derivative was actually that of fluoroacetaldehyde 48. 
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1.2.1.4 Fluorinated fatty acids 
co-Fluorooleic acid 37 was first identified and isolated by Peters and co-workers58- 60 in 
1959 from the seeds of the West African shrub D. toxicarium. 
F C~H 
37 
It was shown that ~80 % of the organic fluorine present in the seed oil was co-fluorooleic 
acid 37, with minor traces of co-fluoropalmitic acid (C16:0F). Re-analysis by Hamilton and 
coworkers61 using GC-MS has established a further five additional fluorinated acids, co-
fluoropalmitoleic (C16:1F), co-fluorostearic (C18:0F), co-fluorolinoleic (C18:2F), co-
fluoroarachidic (C20:0F) and co-fluoroeicosenoic acid (C18:1F). Threo-18-Fluoro-9,10-
dihydroxystearic acid has also been isolated from D. toxicarium, which is presumably a 
metabolite of co-fluorooleic acid 37. Scheme 1.10 shows the hypothetical pathway to these 
fluorinated fatty acids. 
10 CoASH 
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Scheme 1.10 Putative biosynthetic pathway to co-fluorofatty acids in D. toxicarium. 
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If the plant has the ability to generate and utilise fluoroacetyl-CoA 32 then it is envisaged 
that the biosynthetic pathway would follow conventional fatty acid biosynthesis. It is 
worth noting that the fluorine atom is only ever located on the terminal carbon (co), 
implying that a fluorinated analogue of a malonyl acyl carrier protein cannot be 
biosynthesised in this system. 
1.2.2 Fluorinated natural products from marine sources 
1.2.2.1 5'-Fluorouracil derivatives from the sponge Phakellia/usca 
Chlorine and bromine containing natural products are common from marine sources.62 
Recently, the first case of fluorine containing natural products from a marine source was 
reported by Xu and co-workers. 63 Extracts of the marine sponge Phakellia fusca Schmidt, 
which had previously been reported to yield various alkaloids,64,65 were shown to contain 
5-fluorouracil alkaloids 41-45 (Figure 1.6). 
0 0 0 0 0 :yF :yF :yF :yF :yF N I N I N I N I N I 
OAN OAN OAN OAN OAN 
HP''-oy HOy 
H HO~ HzNHN) 
CH3 O'CH 
0 
3 
41 42 43 44 45 
Figure 1.6 Fluorinated natural products from the sponge Phakellia!usca.63 
Two of these, 4364 and 4465 are known to possess anti-tumour activity.66 The other three 
derivatives were shown to be novel compounds, however there is some ambiguity about 
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the accumulation of these compounds in the sponge, suggesting the possibility that these 
compounds arise as a result of industrial contamination rather than de novo biosynthesis. 
1.2.3 Fluorinated natural products from bacteria 
1.2.3.1 Nucleocidin from Streptomyces caivlIs 
The fluorinated natural product nuc1eocidin 46 was the first organo-fluorine compound to 
be isolated from a bacterial source. This anti-trypanosomal antibiotic was originally 
isolated in 1957 from the fermentation broth of an actinomycete, Streptomyces calvus.67 
The isolated compound was initially identified as an adenine glycoside esterified with 
sulfamic acid,68 however it was not until 1969 that a re-analysis of the structure showed 
the presence of a fluorine atom at the 4' -position of the ribosyl ring system.69 
N:(:NH2 
o I' '-': N 
HN-g-O ~ I I 
2 II -x:J0 N -;:::J 
O 
" N 
F' 
He) cm 
46 
In 1976 the structure of nucleocidin 46 was confirmed unambiguously by total chemical 
synthesis.70 The site of fluorination at the C-4-position of the ribose ring makes this 
fluorometabolite an attractive source for a novel C-F bond forming enzyme. 
Unfortunately, attempts in recent years to re-isolate nuc1eocidin 46 from S. calvus have 
failed, possibly due to the repeated subculturing of stock strains of S. calvus and loss of the 
biosynthetic genes from the subcultured strains.7l It appears that we have lost the capacity 
to explore the biosynthesis of this natural product. 
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1.2.3.2 Fluoroacetate and 4-fluorothreonine from Streptomyces cattleya 
The actinomycete Streptomyces cattleya is recognised for its biosynthesis of the ~-lactam 
antibiotic thienamycin.72 This was the first naturally occurring ~-lactam antibiotic to be 
discovered what has a carbapenem ring system.73 In 1986, Sanada and co-workers12 
noticed that during the optimisation of thienamycin production, extracts of S. cattleya 
biosynthesised fluoroacetate 8 and 4-fluorothreonine 47. 
OH NCO; 
F NH3+ 
10 
F 
8 47 
Further examination showed that the media containing soy-bean casein had 0.7 % 
inorganic fluoride present. This was reinforced with control experiments in the absence of 
soy bean casein which showed no fluorometabo1ite biosynthesis. However, addition of 
fluoride (2 mM) restored the biosynthetic activity, showing a controlled production of 
fluoroacetate 8 and 4-fluorothreonine 47. During batch culturing of S. cattleya, 
fluorometabo1ite production was restricted to the stationary phase signifying fluoroacetate 
8 and 4-fluorothreonine 47 are secondary metabolites. This observation raised the 
possibility of a convenient biological system for exploring enzymatic C-F bond formation. 
1.3 Techniques used for studying the biosynthesis of natural products 
A number of techniques have been used to study biosynthetic pathways, which comprise of 
both biochemical and biological approaches. The biochemical approach can be 
differentiated into two main categories. Firstly, biosynthesis of secondary metabolites can 
be blocked at different stages on the pathway by using various chemical reagents which 
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inhibit the enzymatic steps of interest. This in tum, leads to the accumulation of the 
desired metabolic intermediate. Additionally, chemically prepared compounds can be 
added to cell-free-extracts (CFE's) to study substrate specificity and co-factor requirements 
for a particular enzyme. Alternatively, the synthesis of potential metabolic precursors 
which carry an isotopic label (e.g stable isotopes DC and 2H) can be administered to an 
organism in order to examine the isotopic incorporation of the desired metabolite, usually 
by NMR spectroscopy. 
A second method to elucidate secondary metabolic pathways involves mutational analysis. 
Here, mutants unable to express a particular gene on a pathway accumulate biosynthetic 
intermediates. Mutations can be induced by chemical mutagenesis, UV radiation and 
transposon insertion. The disadvantage with this approach is the random nature of 
mutagenesis. In the genomic age, one can use targeted mutagenesis to overcome the 
randomness (provided the DNA sequence of genes directing biosynthesis is known). 
1.3.1 Isotopic labelling 
Isotopic labelling has proven to be a very powerful technique for exploring biochemical 
pathways. Pioneering work by Schoenheimer and co-workers 74 demonstrated the first use 
of a stable isotope eH) in fatty acid biosynthesis. The incorporation of stable isotopes can 
be analysed by NMR spectroscopy and mass spectrometry, techniques which provide 
sensitive tools with which to resolve regiochemica1 and stereochemical incorporation 
patterns. Previously, radio-isotopic techniques had been employed. This has been 
demonstrated e.g. by Cowie and co-workers75 and in the extensive work of Roberts and co-
workers. 76 The main stable and radio isotopes used to study biosynthetic pathways are 
summarised in Table 1.2. 
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Isotope Relative natural abundance % Radiation emitted Half-life 
2H 0.015 stable 
3H <0.001 P 12.1 years 
l3e 1.1 stable 
14e <0.001 p 5700 years 
15N 0.37 stable 
180 0.2 stable 
32p <0.001 P 14.3 days 
Table 1.2 Isotopes used in biological studies 
Detection of radioisotopes is traditionally performed by decay-counting, in which radiation 
detection instruments can detect a p particle ejected from an atomic nucleus. However, a 
high degree of chemical purity is required in order to avoid errors from cross-
contamination. Furthermore, this approach offers limited regiochemical information. 
With the improved sophistication of NMR and MS methods, stable isotopes CZH, 13C) are 
much more commonly used in biosynthesis studies. For example, the incorporation of a 
\3e label into a secondary metabolite can be detected by enhancement of the resonances in 
the l3e NMR spectrum. In early studies on fluoroacetate 8 biosynthesis in S. cattleya, 
incorporations with l3e and 2H labelled glycine, glycerol, pyruvate and succinate were 
explored by Hamilton and co-workers.77 These labelling studies indicated that the 
glycolytic intermediates playa crucial role in fluorometabolite biosynthesis in S. cattleya. 
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1.3.2 19F NMR spectroscopy 
19F NMR is used in this thesis as a powerful analytical tool in facilitating the assay of 
fluorometabolite production in Streptomyces cattleya. The identity of fluorinated natural 
products (see Section 1.2.3.2) can be analysed by 19F NMR spectroscopy without the need 
of isolating the metabolite. The coupling of fluorine e9F) with hydrogen eH) allows the 
chemical environment of the fluorine to be determined. This can clearly be seen in Figure 
1.7, which shows the two fluorinated secondary metabolites, fluoroacetate 8 and 4-
fluorothreonine 47 from S. cattleya. 
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Figure 1.7 19F NMR spectra of (A), fluoroacetate 8 and (B), 4-fluorothreonine 47. 
In the case of fluoroacetate 8, the fluorine of the fluoromethyl group is a triplet in the 19F 
NMR spectrum. The corresponding spectrum B for 4-fluorothreonine 47 is a doublet of 
doublet of doublets ansmg from coupling to the ~ proton. The chemical shifts of 
fluoroacetate 8 (-216.9 ppm) and 4-fluorothreonine 47 (-231.5 ppm) are quite distinct from 
one another, making it possible to distinguish between these two, and other fluorinated 
metabolites. Furthermore, isotopic labelling of compounds can be identified by isotope 
induced shifts by proton decoupled 19F eH} NMR analysis. 
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1.4 Fluoroacetaldehyde as a biosynthetic intermediate in S. cattleya 
The discovery of 4-fluorothreonine 47 and fluoroacetate 8 production in S. cattleya 
prompted investigations into the biosynthesis of the C-F bond. Appropriate isotopic 
labelling studies carried out in the mid 1990's by Reid and co-workers78 led to the 
conclusion that fluoroacetate 8 was not a precursor of 4-fluorothreonine 47 and visa versa. 
This prompted further investigations which showed that a two-carbon fluorinated 
intermediate was the precursor to the fluorometabolites 8 and 47. Later, through additional 
isotopic labelling studies carried out by Moss and co-workers,79 it emerged that 
fluoroacetaldehyde 48 was the precursor to both of the secondary metabolites (Scheme 
1.11). 
0 0 H OH (0- S. cattleya (H S. cattleya (lyCO; .. .. 
F F F NH3+ 
8 48 47 
Scheme 1.11 Metabolic fate of fluoroacetaldehyde 48 in S. cattleya 
1.4.1 Fluoroacetaldehyde dehydrogenase from S. cattleya 
When fluoroacetaldehyde 48 and NAD+ were incubated in cell-free extracts of S. cattleya, 
fluoroacetate 8 was formed indicating an aldehyde dehydrogenase responsible for the final 
oxidative step.80 This was the first enzyme to be identified and purified in 
fluorometabolite biosynthesis (Scheme 1.12). 
fH 
F 
48 
Aldehyde 
dehydrogenase 
NAD+ 
fo 
F 
8 
Scheme 1.12 Biotransfonnation of fluoroacetaldehyde 48 to fluoroacetate 8. 
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Purification and characterisation of the enzyme revealed a tetramer with a native mass of 
200 l<Da and a pH optimum of 9.80 The enzyme was inhibited by iodoacetamide.8o The 
fact that this enzyme is expressed during the late exponential growth phase further suggests 
its involvement in metabolite biosynthesis. 80 A substrate specificity study of this enzyme 
showed a high affinity for fluoroacetaldehyde 48 (Km of 0.08 mM) and interestingly 
acetaldehyde is a poor substrate. 80 
1.4.2 PLP dependent threonine trans aldolase from S. cattleya 
Labelling studies and incubation experiments with CFE's showed that eHJ-
fluoroacetaldehyde 48 is a direct precursor of 4-fluorothreonine 47.79 Furthermore, the 
incubation of L-threonine, fluoroacetaldehyde 48 and PLP in a CFE of S. cattleya showed 
4-fluorothreonine 47 production by 19F NMR (Figure 1.8).81 
fluoroacetaldehyde 48 
'"''~'_N.''''''''' ~~J"",i~ ... , ... __ ._ .. 
I til Iii Iii i I I iff I i r i .' lit i j Iii I I I I ' i i ! 1 I Ii' { ii, 'i '. I~ ppm 
-229.2 ·229.6 ·ml.o ·2"30.4 ,23().S .:,ntl 
Figure 1.8 19F NMR spectrum recorded after a CFE was incubated with PLP, L-threonine and 
fluoroacetaldehyde 48. 81 
Purification of the enzyme led to the identification of a PLP-dependent threonine 
transaldolase. 82 A study on substrate specificity showed an absolute requirement for L-
threonine and fluoroacetaldehyde 48 with L-serine, L-cysteine, L-aspartate, L-allo-
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threonine and glycine showing no activity. The absolute requirement for PLP and L-
threonine indicates a novel threonine transaldolase. A proposed transaldolase type 
mechanism based on the requirement for PLP and L-threonine is shown in Scheme 1.13. 
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Scheme 1.13 Proposed mechanism of 4-fluorothreonine 47 production by a PLP dependent 
threonine transaldolase from S. cattleya. 82 
It is interesting to note from the mechanism that for every 4-fl.uorothreonine 47 molecule 
generated, a molecule of L-threonine is forfeited. This unusual occurrence poses the 
possibility that 4-fl.uorothreonine 47 may incorporate into a protein in place of L-threonine 
under metabolic stress. Studies on the biosynthesis of the chlorinated amino acid 4-
chlorothreonine in Pseudomonas syringae83 indicated L-threonine as a precursor. Clearly a 
common biosynthetic pathway may occur here, however for the S. cattleya enzyme, 
although chi oro acetaldehyde was a substrate, it was also a time dependent inhibitor. 
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1.5 Enzymatic synthesis of Carbon-Fluorine bond 
1.5.1 Introduction 
To date several types of C-X bond fonning enzymes (X = Cl, Br, I), operating by different 
mechanisms, have been identified. Most notably haloperoxidases (Section 1.1.1), FADH2-
dependent halogenases (Section 1.1.2) and non-haem iron(II) and a-keto-glutarate 
dependent halogenases (Section 1.1.3). These halogenating enzymes catalyse electrophilic 
or radical reactions. In order to understand enzymatic fluorination, the nature of the 
fluorinating species must be addressed. Firstly, the redox potential for the oxidation of 
fluoride (-3.06 V) to F+ renders it thennodynamically impossible for activation to F+ by a 
haloperoxidase. Additionally, the unique properties of fluorine, in comparison to other 
halogens, prevent the possibility of a radical fluorination process occurring. This leaves a 
possible nucleophilic halogenation reaction. Despite the weak nUcleophilicity of fluoride 
ion in an aqueous environment, a desolvated fluoride ion is a good nuc1eophile and would 
be a potent nucleophile for enzymatic C-F bond fonnation. 
1.5.2 Nucleophilic Fluorination 
Nucleophilic halogenation reactions are rare, having only been demonstrated for the 
methylation of Br-, cr and r by S-adenosyl-L-methionine methyl transferase.84 Withers 
and co-workers85 reported the first enzymatic C-F bond fonnation using mutant p-
glucosidases and p-mannosidases. The mutants were generated by site directed 
mutagenesis after replacing the catalytic glutamate residue in Agrobacterium sp. fJ-
glucosidase with alanine, glycine or serine. This in tum, arrested any possible glycosidic 
bond cleavage. However, when assayed with the appropriate 2,4-dinitrophenyl fJ-
glycoside 49 substrate in the presence of a high fluoride conc. (2 M), it was shown that 
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substantial glycosidic bond activity was restored. This was rationalised by fluoride ion 
preventing the intermediate oxocarbenium ion, which is normally stabilised by the missing 
carboxylate residue in the wild type enzyme. This generated an intermediate a-glycosyl 
fluoride 50 (Scheme 1.14). 
O~O -o:lo (.1 ( HO~O 
H "H 
HO t H~('O--R HO HO~-q"ODNP HO 0 HO~-Q OR O~. HO .. HO~ 
HO \ _ \ HO (f '\ HO 
49 
F" DNPOH '\ F 
H 50 H 
1 1 
~ (0 
51 
~ (0 
Scheme 1.14 Nucleophilic fluorination of 2,4-dinitrophenyl ~-glucoside 49.85 
The glycosidase mutants also catalysed nucleophilic halogenation of 2,4-dinitrophenyl p-
glucoside 49 with chloride and bromide (2 M). The order of halide reactivity was shown 
to be opposite to that expected. A comparison of kcaJkm values for mutated f1-g1ucosidase 
showed a reactivity order of F- > cr> Br-, opposite to that expected in aqueous solution. 
Therefore, it is possible that desolvation occurs in the active site of the enzyme. The 
catalysis of C-F bond formation by mutants of glycosidases, demonstrates the feasibility of 
a nucleophilic fluorination mechanism. 
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1.6 The fluorinase 
1.6.1 Identification of a fluorination enzyme from S. cattleya 
In 2002, a series of experiments was carried out by C. Schaffrath,86 (University of St 
Andrews), incubating whole cells, prepared under a variety of conditions with various co-
factors and fluoride ion. It was found that whole cell incubations when supplemented with 
glycerol and KF showed low levels of fluorophosphates in the culture medium after 5 days 
at 28°C (Figure 1.9). 
B-FADP 
-67 -68 -69 -70 -71 
monofluoro-phosphate 
(FP03 2-) 
-72 -73 ppm 
Figure 1.9 19F NMR spectrum of fluorophosphate production in resting cells of S. cattleya. 86 
Work by Ochoa87 in 1957 first described the enzymatic synthesis of fluorophosphates in 
mammalian cells when purified pyruvate kinase was incubated with ATP and fluoride ion 
in the presence of magnesium ions. Clearly a similar enzyme could participate in 
fluorophosphate formation, which may play a pivotal role in fluoroacetate 8 and 4-
fluorothreonine 47 biosynthesis. Although this was a tentative proposal, it was considered 
that the production of fluorophosphates could overcome some of the problems associated 
with water solvation of fluoride and provide an activated form of fluoride ion for transport 
into the cell and further metabolism. 
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Additional experiments were carried out which involved the incubation of ATP 52 and 
several other analogues (e.g UTP, GTP and CTP) with fluoride ion in a CFE of S. cattleya. 
It was found.that only ATP gave rise to the production of fluoroacetate 8 indicating the 
CFE converted inorganic fluoride to organo-fluorine in a novel biotransformation (Figure 
1.10). 
unassigned signals (td) 
/ ~~~ =~, =~) m~, ~~" D'O,' unassigned signals (td) fiuoroacetate 8 
Figure 1.10 19F NMR spectrum of CFE incubation with ATP 52 and fluoride ion.86 
The triplet (t) at -216 ppm was assigned as fluoroacetate 8 but the two remaining signals at 
-229.5 ppm and -229.7 ppm had never been observed in previous experiments. It was 
clearly possible that the first organo-fluoro compound formed is represented by one of the 
two unassigned fluorine signals. Both signals were shown to be triplets of doublets with 
coupling constants of 2 JH,F 47 and 3 JH,F 29 Hz, implying similar structures. Previous 
experiments with isotopically labelled [2-2H1, 2-180]-glycerol showed that the C-O bond is 
retained during fluoroacetate 8 and 4-fluorothreonine 48 biosynthesis. With these 
combined experimental observations a minimal structure for the two unassigned fluorine 
signals was established (Figure 1.11). 
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c:.!i tR2 47Hz HTU 'H 
F- 25 Hz 
Figure 1.11 Minimal structure to account for the unassigned organofluorine compounds 
At this stage it appeared most reasonable that ATP 52 was converted to 5'-fluoro-5'-
deoxyadenosine (5' -FDA) 54 by the action of a fluorination enzyme which could represent 
one of the unassigned fluorine signals. Subsequent cell free investigations showed that the 
amino acid L-methionine 56 enhanced fluorometabolite biosynthesis, especially the 
accumulation of the two unassigned fluorine signals. These results suggested that S-
adenosyl-L-methionine (SAM) 53 and not ATP 52 is involved in fluorometabolite 
biosynthesis. 
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The correlation between 52 and 53 to promote cell-free biosynthesis of fluorometabolites 
could be rationalised by the presence of the ubiquitous enzyme SAM synthetase which 
mediates a reaction between ATP 52 and L-methionine 56 to generate SAM 53.88 
Subsequent incubations involving SAM 53 and fluoride ion were conducted, which 
resulted in the biosynthesis offluoroacetate 8 (Figure 1.12).89 
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Figure 1.12 A 19F NMR time course showing fluoroacetate biosynthesis and two additional 
products, 5'-FDA 54 and compound A.89 
The preparation of a synthetic sample of 5'-FDA 54 for analytical comparison with the 
product of the enzyme reaction confirmed unambiguously that the product of the 
fluorination enzyme was 5'-FDA 54. The identity of the other fluorine signal (compound 
A) was determined by further incubations of CFE' s with SAM 53 and KF in the presence 
of iodoacetamide (Figure 1.13). Iodoacetamide inhibited one of the enzymes on the 
pathway preventing fluoroacetate 8 biosynthesis, and promoting the accumulation of 
compoundA. 
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Figure 1.13 A 19F NMR time course showing CFE incubated with SAM 53 and fluoride ion in 
the presence of iodoacetamide. 86 
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It was therefore possible by preparative HPLC using UV detection to obtain a purified 
sample of compound A. Analysis by 19F NMR and lH NMR confirmed all of the NMR 
characteristics of 5' -FDA 54, and that compound A was clearly a 5' -fluoro-5' -deoxyribo-
nucleoside. However, ES-MS gave a parent ion for compound A that was one atomic mass 
unit higher than 5' -FDA 54. This raised the possibility of an irreversible adventitious 
deaminase activity responsible for the transformation of 5' -FDA 54 to 5' -fluoro-5'-
deoxyinosine (5'-FDI) 55. Confirmation of this was achieved by an experiment carried out 
in labelled water (H2180) which gave a product which was now three atomic mass units 
higher than 5'-FDA 54 by ES-MS, showing 18-oxygen incorporation to generate e80]-5'-
FDI 55 from 5'-FDA 54. Also GC-MS analysis, after derivatisation with MSTFA, 
confirmed this unambiguously (Figure 1.14).90 
~e3Si ~e3Si 
Ni:NH 
« I ~N F~N N) Ni:° « I ~N F~N N) 
Me3Si-O O-Me3Si Me3si-o O-Me3Si 
MH+ = 486 amu MH+ =487 amu 
silyl derivative of 5'-FDA 54 [180]-5'-FDI = 489 amu 
silyl derivative of 5'-FDI 55 
Figure 1. 14 Silyl derivatives analysed by GC-MS (CI) of 5' -FDA 54 and 5' -FDI 55. 
Furthermore, it was found that when 5'-FDI 55 was re-incubated in an active CFE of S. 
cattleya it remained metabolically inert with no sign of fluoroacetate 8 biosynthesis. Thus 
5'-FDA 54 is an intermediate on the biosynthetic pathway, but 5'-FDI 55 is a shunt 
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product which cannot enter the pathway again. Scheme 1.15 shows a working hypothesis 
from the experiments carried out. 
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Scheme 1.15 Working hypothesis for enzymatic fluorination in a CFE of S. cattleya. 
1.6.2 Purification, crystal structure and properties of the fluorinase 
Having established a fluorination activity in S. cattleya,91 purification of the fluorinase was 
carried out by C. Schaffrath at the University of St Andrews.92 The enzyme was shown by 
gel filtration to have a native mass of 180 l<Da and a subunit mass of 32 l<Da as judged by 
SDS-PAGE. The identity and characterisation of the wild-type fluorinase on the basis of 
N-terminus amino acid analysis and trypsin digest led to the cloning of the fluorinase (jlA) 
gene. Purification and over-expression of the fluorinase has allowed a fuller 
characterisation of the activity. Kinetic analysis of the fluorinase was carried out by H. 
Deng, University of St Andrews93 which showed a catalytic rate constant (1<cat) of 0.07 
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min-I, a Michaelis constant (Km) for F of 2 mM and a Km for SAM 53 of 74 11M. The low 
affinity of fluoride ion for the enzyme indicated by its high Km presumably reflects the 
difficulty of the enzyme securing desolvated fluoride ion in the active site due to the high 
heat of hydration. Inhibitors of SAM-dependent enzymes such as S-adenosyl-L-
homocysteine (SAH) 5794 and sinefungin 5895 were explored as inhibitors of the fluorinase 
which showed a Ki of 29 11M for SAH 57 and sinefungin 58 showed weak inhibition 
(Figure 1.15). 
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Figure 1.15 Inhibitors of the fluorinase, SAH 57 and Sinefungin 58. 
The cloning and over-expression of the enzyme allowed crystals to be obtained that were 
suitable for X-ray crystallography which subsequently led to a crystal structure (1. 
Naismith and C. J. Dong).93,96 
The fluorinase structure revealed a homohexamer composed of a dimer of trimers (Figure 
1.16). The monomeric fold of the trimer was shown to have a unique quaternary structure 
with no obvious relationship to other protein superfamilies. The crystallised enzyme had 
SAM 53 bound and indicated that SAM 53 does not dissociate readily from the protein 
during purification. The structure also revealed that each of the trimers had three SAM 53 
molecules bound at the interface between each monomer. The recognition of SAM 53 is 
shown to be highly specific with each of the components (adenine ring, ribose ring and 
methionine) forming various hydrogen bonding contacts. It seems reasonable that these 
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contacts between SAM 53 and both monomers would drive closure of the protein domains 
to form the enveloped binding site. 
A B 
c 
Figure 1.16 Structure of the fluorinase; A, monomer. B, trimer with SAM bound at the 
interfaces . C, native hexameric structure as a dimer oftrimers.93 
The ribose ring of SAM 53 is held in an unusually planar conformation with hydrogen 
bonding between the 2' and 3' -hydroxyl groups and the carboxylate side group of Asp-16 
(Figure 1.17). 
Co-crystallisation of the fluorinase with SAM 53 and fluoride ion resulted in a trapped 
product complex with 5' -FDA 54 and L-methionine 56 at the active site. Comparisons of 
diffraction data before and after the fluorination reaction showed little difference in the 
binding of both structures except in the bond breaking/forming region. The sulfur atom is 
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displaced with the new C-F bond antiperiplanar to the old C-S bond. This suggests a 
substitution reaction (SN2) occurring with inversion of configuration. This stereochemical 
inversion was confirmed unambiguously by stereochemical studies. 97,98 
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Figure 1.17 5' -FDA 54 and L-methionine 56 bound to the active site offluorinase showing 
hydrogen bonding to the fluoromethyl group from Ser 158, and the anti relationship between the C-
F bond (red) and the disconnected C-S bond (dotted red) of SAM 53 that is indicative of an SN2 
reaction, 93 
Further analysis of the co-crystallised product structure showed the fluorine atom forming 
two short hydrogen bonds to the Ser158 residue. It is also of interest to note that no water 
molecules are detected in the vicinity of the fluorine atom, suggesting that fluoride 
incorporation into the active site must mean that the enzyme was able to strip the hydration 
sphere from fluoride as it progressed towards the reaction centre. Dehydrated fluoride ion 
is a potent nucleophile, the most nucleophilic of the halides, and therefore the enzyme has 
attained a balance between generating a sufficiently nucleophilic fluoride, and paying the 
full energy cost of dehydration. 
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Another feature of the product structure is the 3' -hydroxyl position on the ribose ring, 
which appears to have a role in directing fluoride ion towards the electrophilic C5' site by 
a hydrogen bonding interaction as illustrated in Figure 1.17. Insights into enzymatic C-F 
bond formation from QM and QM/MM ca1culations99 have recently shown that the 
fluorinase lowers the barrier for C-F bond formation by 39 kJ mOrl. The major 
contributing factor to this energy reduction is related to pre-organisation of the substrates 
in the active site. 
Further investigations on the fluorination enzyme led to the realisation that the enzyme 
works in reverse and that it could catalyse the conversion of 2'-deoxy-5'-FDA 59 
substrates to 2' -deoxy SAM 60 (Scheme 1.16). 
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Scheme 1.16 Reversibility of the fluorinase. 
Intuitively the reverse reaction appears a less achievable prospect as fluoride forms the 
strongest covalent bond to carbon. However, V max calculations, at saturating kinetics 
indicate a reaction at 113 of the rate of the forward reaction. 
The enzyme is very specific and not amenable to much structural variation in the substrate. 
However, the 2'-deoxy substitute 59 showed a ten-fold rate decrease by comparison with 
5' -FDA 54. This confirmed that the 2' -OH position is not absolutely essential for catalytic 
activity, however, the rate decrease does suggest the importance of hydrogen bonding 
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contacts (see Figure 1.17). In recent unpublished work the structure of the co-crystallised 
2-deoxy-5'-FDA-fluorinase complex shows that 2'-deoxy-5'-FDA 59 adopts a slightly 
different conformation to that exhibited by 5' -FDA 54 (Figure 1.18). 
Phe-156 
Phe-256 
Asp-16 
FigUioe 1.18 Structure of the 2'-deoxy-5'-FDA-fluorinase co-complex. Shown superimposed 
with 5'-FDA 53. 2-deoxy-5'-FDA 59 is coloured, C yellow, N blue, 0 red and F light blue. Shown 
superimposed is 5' -FDA 54 (C white, F light blue, N blue, 0 red). 
Additional experiments with L-selenomethionine (L-Se-met) 63 and 5'-FDA 54 show a six 
fold rate increase on comparison with L-methionine 56 and 5'-FDA 54. This rate increase 
is consistent with the increased nucleophilicity of selenium over sulfur. 
1.6.3 Chlorination by the fluorinase 
An interesting feature of the fluorinase is that it will accept chloride ion as a substrate also 
in a reversible reaction.loo This novel enzymatic chlorination operates by nucleophilic 
substitution rather than the reported electrophilic or radical mechanisms proposed for other 
halogenases (Section 1.1.2, 1.1.3). Early attempts to replace fluoride by chloride as a 
substrate with SAM 53 in the presence of the fluorinase failed to identify the product 5'-
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chloro-5' -deoxyadenosine (5' -ClDA) 61. Most recently, it was found that the inability to 
detect the chlorinated product was due to the equilibrium of the chlorination reaction lying 
extensively in favour of the substrate over the product. This was finally shown by 
adopting a coupled enzymatic strategy in order to drive the equilibrium in favour of the 
product. Scheme 1.17 shows two enzymatic routes which indicate that the fluorinase can 
process chloride ion as a substrate. Firstly, the fluorinase was coupled with an L-amino 
acid oxidase to remove the generated L-methionine 56 during the halide substitution 
reaction. This in tum led to the identification of the product 5' -ClD A 61, while inhibiting 
the reverse reaction. A second experiment involved the addition of adenyl acid deaminase 
in the presence of the fluorinase which resulted in the product 5' -chloro-5' -deoxyinosine 
(5' -ClDI) 62. 
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Scheme 1.17 Coupled enzymatic assay towards C-Cl bond formation. 
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Rates at saturating kinetics have indicated a preference for F over cr by a factor of 120. 
5' -ClD A 61 also emerged as a better substrate over 5' -FD A 54 in the reverse direction 
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with an eight fold rate increase. This rate enhancement is consistent with the C-CI bond 
being weaker than the C-F bond, and cr being a better leaving group. 
It was also demonstrated that incubation of 5' -ClDA 61 with fluoride ion and L-
selenomethionine 63 in the presence of the fluorinase resulted in the biotransformation of 
5' -ClDA 61 to 5' -FDA 54 (Scheme 1.18). This trans-halogenation reaction was monitored 
by analytical HPLC. It is interesting to note that Se-SAM 64 is shown to be transient 
during the experiment (Figure 1.19). 
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Scheme 1.18 Trans-halogenation reaction mediated by the fluorinase. 
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Figure 1.19 Trans-halogenation reactions catalysed by the fluorinase. 'oo 
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The substrate 5' -elDA 61 was co-crystallised (J. H. Naismith and A. McEwan, St 
Andrews University) with over-expressed fluorinase in the absence of L-methionine 56.100 
Figure 1.20 shows 5' -elDA 61 bound to the active site superimposed with the 5' -FDA 54 
structure. The conformation shows that the chlorine atom is displaced by 1.3 A relative to 
fluorine in 5' -FDA 54, consistent with its larger atomic radius. No significant 
conformational changes of the protein occurred upon 5' -elDA 61 binding, with only the 
substrate adjusting its position to accommodate the larger halogen. 
FigUl"e 1.20 Structure of the 5' -ClDA-fluorinase co-complex with hydrogen bonds and polar 
contacts to the protein shown. 5 ' -ClDA 61 is coloured, C white, N blue, 0 red and CI purple. The 
protein is coloured as the ligand except C is yellow. Shown superimposed is 5' -FDA 54 (C green, F 
orange, N blue) where the CI atom lies further away from the backbone amide of Ser 156.100 
This study also revealed a second conformation for 5' -elDA 61 on the enzyme where the 
chlorine has rotated out of the halogen binding pocket and adopted a conformation where it 
is accommodated in the empty L-methionine 56 sulfur binding site (Figure 1.21). Of 
course this second conformation is prohibited in the catalytic reaction when L-methionine 
56 is present. 
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Figure 1.21 The structure of 5' -ClDA 61 bound to the fluorinase showing both conformations 
of the chlorine atom. 
1.7 Positron Emission Tomography (PET) 
1.7.1 Introduction 
PET is a non-invasive imaging technique used to image metabolic activities in living 
tissues. 101 The technique uses radiotracers labelled with positron emitting radionuclides 
with various in vivo properties which permit imaging of the distributions of ligands in I' 
metabolising tissues. The most common PET radionuclides are lle, 18F, 150 and 13N 
which have half lives of 20, 110, 2 and 10 minutes respectively. 18F offers a number of 
advantages over the other radionuclides, due to its longer half-life (110 min). This in turn 
permits more time for radiochemical synthesis and purification for use in in vivo 
experiments. 
The most widely used radiotracer is C8F]-labelled 2-fluorodeoxyglucose (FDG) which has 
been routinely used in brain and tumour imaging. 102 Other PET labelled probes which 
could have potential for the imaging of tumours or adenosine receptors in the brain etc. are 
the adenosine derivatives which are products of the fluorinase reaction. The adenosine 
analogue 2' -fluoro-2' -deoxyadenosine has shown promising results in the evaluation of 
tumour cell proliferation. 103 Other adenosine analogues such as C8F] -5' -fluoro-5'-
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deoxyadenosine ([18F]-5'-FDA) 65 have been synthesised, however reported radiochemical 
yields were found to be less than 1 %.104 
1.7.2 Enzymatic methods for fluorine-18 labelling 
The recent isolation of the fluorinase from S. cattleya led to the exploration of this enzyme 
as a biocatalyst for potential fluorine-IS labelled 5'-FDA 65 studies. This may be 
advantageous as enzymes are chemospecific with very few side products generated, unlike 
chemical approaches. However, there are limited examples in the literature where 
biocatalysts have been used to incorporate radionuclides for PET applications. 
H. Deng and L. Martarello105 (GSK and Aarhus hospital, Denmark) reported the first 
enzymatic synthesis of [18F]_5' -FDA 65 using purified wild-type fluorinase (Scheme 1.19). 
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Scheme 1.19 Enzymatic radio-labelling of 5' -c 8p]_ fluoro-5' -deoxyadenosine 65. 
It was shown that using mg / ml quantities of wild-type fluorinase that a total radio-
chemical yield of ~ 1 % could be achieved. Although this is a low yield, it has been 
demonstrated more recently that use of more protein gives better yields. In recent 
unpublished work, the over-expressed fluorinase available now in mg's, gave 
radiochemical yields (RCY) of [18F]-5'-FDA 65 up to 95 %. A key development in 
optimising the efficiency of [18F]-5'-FDA 65 production was the positioning of the 
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equilibrium in favour of product over substrate. Two coupled enzymatic strategies were 
achieved in driving the reaction towards C8F]-5'-FDA 65 synthesis, similar to that shown 
in Scheme 1.17. The first approach was the coupling of the fluorinase to an L-amino acid 
oxidase which removed the co-produced L-methionine and therefore suppresses the reverse 
reaction. The second approach involved the coupling of the fluorinase to an adenosine 
deaminase to generate [18F]-5'-FDI 66 (Scheme l.20). This second approach also provided 
access to another labelled purine nucleoside [18F]-5'-FDI 66. With this type of coupled 
enzyme methodology other 18F-labelled products were prepared. This included the 
enzymatic synthesis of [18F]-5-FDR 68, a monosaccharide. The biotransformation of SAM 
53 to e8F]-5-FDR 68 was accomplished using a coupled enzyme strategy consisting of 
fluorinase, an immobilised PNP (donated by GSK) and a phytase (Scheme 1.20) giving an 
overall RCY of 40 %. 
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Scheme 1.20 Potential PET labelled probes synthesised by the fluorinase mediated methods. 
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The enzymatic approach towards the synthesis of PET labelled probes extends the use of 
the fluorinase as a biocatalyst. 
1.8 Metabolic fate of 5'-FDA in S. cattleya 
Work carried out by C. Schaffrath89 (University of St Andrews) investigated the metabolic 
fate of 5'-FDA 54 in S. cattleya. It was shown that the incubation of 5'-FDA 54 in a CFE 
resulted in the biotransformation to several fluorinated intermediates including 
fluoroacetate 8 and 4-fluorothreonine 47 (Figure 1.22). 
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Figure 1. 22 19F NMR time course of CFE incubated with 5' -FDA 54 at hourly intervals for 19 
hrs at 25 °C.89 
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A 19F NMR time course profile of an incubation of 5' -FDA 54 in a CFE showed a complex 
between fluoroacetaldehyde 48 and tris(hydroxymethyl)aminoethane 70, the constituent of 
Tris buffer. 
N~OHOH 
Hz 
OH 
70 
In addition it was shown that the CFE had the capacity to reduce fluoroacetaldehyde 48 to 
fluoroethanol 69 (Scheme 1.21). 
(H 
F 
48 
S. caffleya 
.. 
alcohol dehydrogenase 
?H 
F 
69 
Scheme 1.21 Biotransformation of fluoroacetaldehyde 48 to fluoroethanol 69. 
The presence of fluoroethanol 69 is attributed to an adventitious alcohol dehydrogenase 
that reduces fluoroacetaldehyde 48. The conversion of 5' -FDA 54 to the shunt product 5'-
FDI 55 arises from the action of a deaminase activity in S. cattleya. Some transient 
fluorinated intermediates are also visible in these experiments. For example, the 
unassigned signal at -227.2 ppm maybe an intermediate on the pathway beyond 5'-FDA 
54. The elucidation of the pathway between 5' -FDA 54 and fluoroacetaldehyde 48 
constitutes the major focus of this thesis. Scheme 1.22 shows the metabolites and enzymes 
involved in fluoroacetate 8 and 4-fluorothreonine 47 biosynthesis, prior to the work carried 
out in this thesis. 
47 
Chapter 1 
grn, HO HO"'~ 
serine HO 
1 
o 
O::'p 
• HO""'( 
I .... 0 
o 
OH 
1 
3-phosphoserine 3-phosphoglycerate _ ~ glyceraldehyde-3-
phosphate 
_ ROo NtNH2 
o-p-o_11 II II I -..;: N 1 p-o-p-o \ I 
-0 _I 1 -yOyN ~ o -0 U N 01(.----~ . -HO OH 
52 
1
C02 j H3N~1I111 L-Met 
F 
phosphoribosyl 
pyrophosphate 
NtNH2 
I.( I -..;: N 
j 
sedoheptulose-7 -
phosphate 
Nt
OH 
I.( I -..;: N 
t
NH2 
H3C- S + I.(N I -..;: N \iN) '''{'yN NJ . ~ Hc5 1H deaminase ,"'ON NJ fluorinase 
: . 
HO OH 54 
Hc5 1H 
55 
53 'j 
iH ~ L-threonine I (y ........ o - transaldolase 
, .:H,. ~ fH 
~O ~yd,'" 
(........ dehydrogenase 
F 'NAD+ 
unknown steps 
8 
Scheme 1.22 Overview of known metabolites and enzymes involved in fluoroacetate 8 and 4-
fluorothreonine 47 biosynthesis. 
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2 Identification of a purine nucleoside phosphorylase (PNP) involved in fluorometabolite biosynthesis in 
s. cattleya 
The fluorinase which catalyses the fonnation of the metabolic intennediate 5'-fluoro-5'-
deoxyadenosine (5' -FDA) 54, has been identified as the first committed step on the 
biosynthetic pathway towards the fonnation of the secondary metabolites fluoroacetate 8 
and 4-fluorothreonine 47.89 Fluoroacetaldehyde 48 was already known to be a precursor to 
both ofthese fluorinated secondary metabolites79 however, the fluorinated metabolites that 
exist between 5'-FDA 54 and fluoroacetaldehyde 48 remained to be characterised. The 
results described in this chapter indicate that 5-fluoro-5-deoxY-D-ribose-1-phosphate (5-
FDRP) 81 is the next fonned fluorometabolite after 5'-FDA 54 on the biosynthetic 
pathway.l06 The enzyme responsible for the conversion of 5'-FDA 54 to 5-FDRP 81 has 
been identified as a purine nucleoside phosphorylase (PNP). In order to understand the 
metabolic fate of 5'-FDA 54, a short overview on biochemical processes involving 
nucleosides is given below. 
2.1 Nucleoside metabolism in biological systems 
The nucleoside, adenosine is an important intennediate in several metabolic pathways, 
where it arises not only from the catabolism of nucleic acids and nucleoside co-factors, but 
also from S-adenosyl-L-methionine (SAM) 53 after transmethylation reactions. 107 
Activities of enzymes involved in adenosine metabolism have been well characterised in 
various organisms. Scheme 2.1 shows a selection of enzymes which contribute towards 
the metabolic fate of adenosine 71. 
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Scheme 2.1 Metabolic routes involving the biotransformation of adenosine 71. 
Hydrolase enzymes such as adenosine deaminase (E.C 3.5.4.3) participate in punne 
metabolism where they hydrolyse either adenosine 71 or 2'-deoxyadenosine to generate 
inosine 72 or 2' -deoxyinosine respectively.108 These enzymes are ubiquitous in all purine 
catabolic pathways. Other hydrolytic enzymes such as S-adenosylhomocysteinase catalyse 
the reversible addition of L-homocysteine and adenosine 71 to give S-adenosyl-L-
homocysteine (SAH) 57. These enzymes playa key role in regulating the intracellular 
levels of SAH 57 and homocysteine. 109 Another degradation route involves the 
phosphorylation of ribofuranosyl-containing nucleoside analogues at the 5 '-hydroxyl 
50 
Chapter 2 
position using ATP 52 or GTP as the phosphate donor. Such examples include the 
ubiquitous enzyme, adenosine kinase which functions as a salvage mechanism for 
returning adenosine to nucleic acids. 110 Other routes lead to the hydrolysis of the C-N 
glycosidic bond, for example via adenosine phosphorolysis which yields ribose-l-
phosphate 73 and adenine 75 by the action of a purine nucleoside phosphorylase 
(PNP).III,112 This is a common enzyme which contributes to the catabolism and recycling 
of nucleosides. The enzymatic reaction is specific for ~-nucleosides and the catalytic 
mechanism proceeds in a stereospecific manner to give only the a-ribose-l-phosphate 73. 
Hydrolysis of adenosine 71 to ribose 74 and adenine 75 by the action of a nucleosidase 
represents an alternative degradative pathway. I 13 
If the metabolism of 5'-FDA 54 proceeds along a similar pathway to that of adenosine 71, 
then it follows that there are four possible biotransformations that could represent the ,next 
enzymatic step on the fluorometabolite pathway. The deamination of 5' -FDA 54 is 
inconsistent with our experimental observation to give 5' -FDI 55. This is due to the fact 
that, as discussed in Section 1.6 and 1.8, the formation of the adventitious side product 5'-
FDI 55 remains metabolically inert in a CFE of S. cattleya. The phosphorylation of 5'-
FDA 54 at the 5' -position by a kinase activity is clearly redundant due to the C-F bond 
replacing C-OH in 5'-FDA 54. This leaves two alternative routes, both involving the C-N 
glycosidic bond cleavage. The first of these is a phosphorolysis reaction involving a PNP 
enzyme to yield 5-FDRP 81 and adenine 75. The other is a hydrolysis reaction with 
nucleosidase activity to yield 5-FDR 80 and adenine 75. In order to delineate these 
metabolic routes, it is instructive to review the L-methionine salvage pathway which is 
known to utilise both of these enzyme activities in two independent pathways. 
51 
Chapter 2 
2.1.1 L-Methionine salvage pathway 
The L-methionine salvage cycle is a ubiquitous biochemical pathway that maintains 
methionine 56 levels in vivo. It involves the recycling of the thiomethyl moiety of L-
methionine 56 through a degradation pathway that leads from S-adenosyl-L-methionine 
(SAM) 53 through methylthioadenosine (MTA) 76. 113 Scheme 2.2 outlines part of the 
pathway showing the two alternative routes involved in MTA 76 recycling. 
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Scheme 2.2 Section of the L-methionine salvage pathway showing two routes for the 
generation ofMTRP 78 from MTA 76. 
The more energy efficient pathway involves the phosphorolysis of MTA 78 to yield 
methylthioribose-l-phosphate (MTRP) 78 and adenine 75, catalysed by the enzyme 5'-
methylthio-5' -deoxyadenosine phosphorylase (MT AP). The existence of this metabolic 
route has been shown in mammals, as well as in bacteria and plants. 113 The second 
pathway splits this direct transformation into two steps; the first involves MTA 76 being 
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hydrolysed by the action of a nucleosidase to form adenine 75 and 5-methylthioribose 
(MTR) 77. The free sugar is then phosphorylated at the expense of ATP by a specific 
kinase to generate MTRP 78. This pathway has been characterised in the bacteria, 
Klebsiella pneumoniae l14 and Bacillus subtilis. 115 The product of both of these salvage 
routes, MTRP 78, is recycled back to L-methionine 56 (see detail in Section 3.1). 
2.2 Metabolic fate of 5'-FDA in S. cattleya 
The metabolism of 5'-FDA 54 by either of the routes outlined in Scheme 2.2, can be 
followed by UV, monitoring the release of adenine 75, in an HPLC assay. The method 
described below has been used throughout this chapter for detecting nucleosides and their 
corresponding bases. For the analysis of adenine 75 by HPLC, a C18 column was eluted 
with a gradient starting from 50 mM KH2P04 : MeCN (95:5) to 50 mM KH2P04 : MeCN 
(80:20) over 30 min and monitored at 254 nm116,117 (see Section 5.1.17). Using this 
method; it is also possible to detect 5'-FDA 54 and the shunt product 5'-FDI 55 
concurrently by HPLC. 
In order to detect the release of adenine 75, two key experiments were performed. Firstly, 
a CFE (500 {tl) was prepared according to the method described in Section 5.1.6, which 
was incubated with synthetic 5'-FDA 54 (100 {tl, 18.6 mM) at 37 DC for 16 hrs, and the 
assay solution was subsequently analysed by 19F NMR spectroscopy. The presence of 
fluoroacetate 8 and 4-fluorothreonine 47 in successful biotransformations confirmed that 
the CFE retained all of the biosynthetic activities. In supporting experiments, the CFE was 
incubated with 5'-FDA 54 at a lower concentration (1 mM) compared to the previous 
experiment. In these experiments the CFE (500 {tl) was incubated with 5' -FDA 54 (final 
conc. 1 mM) for only 1 hr at 37 DC and subsequently analysed by HPLC. The 
chromatogram for such an analysis is shown in Figure 2.1. 
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Figure 2.1 HPLC chromatogram showing (a), synthetic 5'-FDA 54 (control), (b), denatured 
CFE (control), (c), CFE incubated with 5' -FDA 54 for 1 hr at 37°C. 
The two chromatograms corresponding to a and b represent control experiments of a 
synthetic sample of 5'-FDA 54 and a denatured CFE respectively. The outcome of an 
incubation of the CFE with 5' -FD A 54 is reported by chromatogram c. The presence of 
5'-FDI 55 can clearly be seen from the incubation of 5' -FDA 54 due to a deaminase 
activity in the CFE. This was confirmed by co-injection experiments using a synthetic 
sample of 5' -FDI 55. The presence of adenine 75 from the incubation of 5' -FDA 54 in the 
CFE confirmed that C-N glycosidic bond of 5' -FDA 54 is cleaved. This was confirmed by 
co-injection using a synthetic sample. Also, the presence of the purine, hypoxanthine 79 
was observed, which can be attributed to deamination of adenine 75 by the presence of a 
possible adenine deaminase activity in S. cattleya. This was also confirmed by co-injection 
using a synthetic sample of hypoxanthine 79. Scheme 2.3 summarises the proposed 
metabolic fate of5'-FDA 54 in the light of these experimental observations. 
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Scheme 2.3 The metabolism of 5' -FDA 54 in a CFE of S. cattteya. Intermediate A corresponds 
to the next fluorinated metabolite on the pathway. 
It is concluded that the next intermediate after 5'-FDA 54 arises as a consequence ofC-N 
glycosidic cleavage of 5'-FDA 54. No fmiher intermediates were detected by HPLC, 
suggesting that the next fluorinated metabolite is not UV active. With this background it 
became necessary to determine the identity of intermediate A. 
2.2.1 The role of 5-fluoro-5-deoxy-n-ribose (5-FDR) 
F~OH 
HO OH 
80 
At the outset it appeared appropriate to explore a role for 5-FDR 80, a potential hydrolysis 
product of 5'-FDA 54 as a possible intermediate in fluorometabolite biosynthesis in S. 
cattleya. The CFE was first assayed by 19F NMR using synthetic 5'-FDA 54 to confirm 
the production of fluoroacetate 8 and 4-fluorothreonine 47. This ensured all of the 
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biosynthetic enzymes on the pathway were active. A synthetic sample of 5-FDR 80 was 
prepared by S. L. Cobb,118 University of St Andrews. This compound was tested as a 
biosynthetic intermediate by incubating it with an active CFE (500 JLl) of S. cattleya at a 
final concentration of 5.5 mM for 16 hrs at 37°C (Section 5.1.8). Figure 2.2 shows two 
19F NMR spectra at zero-time and after 16 hrs, with the first showing the 5-FDR 80 control 
with two characteristic fluorine signals, each a doublet of triplets corresponding to the ~-
anomer (-228.55 ppm, 2JF,H 47.0 and 3 JF,H 26.4) and the a-anomer (-230.86 ppm, 2JF,H 46.9 
and 3JF,H 26.3). The second spectrum shows the outcome after incubating 5-FDR 80 with 
the CFE for 16 hrs at 37°C. 
lH coupled 19p NMR spectrum (td) lH coupled 19p NMR spectrum (td) 
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Figure 2.2 19p CH} NMR showing 5-PDR 80 (control), overlaid with 5-PDR 80 incubated in 
a CPE of S. cattleya for 16 hrs at 37°C. Expansions are lH coupled 19p NMR spectra. 
This result clearly suggests that 5-FDR 80 is not metabolised in an active CFE of S. 
cattleya. No new fluorinated metabolites emerged and therefore 5-FDR 80 was not able to 
support the biosynthesis of fluoroacetate 8 and 4-fluorothreonine 47. It is therefore 
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concluded that 5-FDR 80 is not an intermediate on the fluorometabolite biosynthetic 
pathway in S. cattleya. The presence of a nucleosidase activity responsible for the release 
of adenine 75 from 5'-FDA 54 can clearly be ruled out. The alternative route which 
facilitates the cleavage of the C-N glycosidic bond of 5' -FDA 54 involving a 
phosphorolysis reaction was thus investigated. 
2.2.2 The role of 5-fluoro-5-deoxY-D-ribose-1-phosphate (5-FDRP) 
FH""'OPO:" 
HO OH 
81 
In order to explore 5-FDRP 81 as a possible biosynthetic intermediate on the 
fluorometabolite pathway, a reference sample was required. The chemical synthesis of 
ribose-I-phosphates is well documented in the literature. 119 However, a more convenient 
strategy towards the preparation of 5-FDRP 81 involved a chemo-enzymatic method using 
two commercially available enzymes. Firstly, an adenosine deaminase (BC 3.5.4.4, from 
Aspergillus species) was used for the conversion of 5'-FDA 54 to 5'-FDI 55 and then a 
bacterial PNP (BC 2.4.2.1 from E. coli) specific for 6-oxo nucleosides was used to generate 
the products 5-FDRP 81 and hypoxanthine 79. This enzyme showed sufficiently lax 
substrate specificity and could utilise 5' -FDI 55. Scheme 2.4 outlines the chemo-
enzymatic route used to prepare a sample of 5-FDRP 81. 
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Scheme 2.4 Chemo-enzymatic preparation of 5-FDRP 81 
In order to monitor each enzymatic step, a HPLC method was established for the detection 
of 5' -FD I 55 and hypoxanthine 79. The HPLC assay is outlined in detail in Section 5.1.17. 
Accordingly, the deamination of 5'-FDA 54 (18.6 mM) to 5'-FDI 55 using a commercial 
adenosine deaminase from Aspergillus species in phosphate buffer (50 mM, pH 6.8) was 
monitored until 100 % biotransformation was achieved. Typical chromatograms (a) to (b), 
are shown in Figure 2.3. The product 5'-FDI 55 was then incubated in the presence of an 
immobilised PNP (EC 2.4.2.1, E. coli) in phosphate buffer (50 mM, pH 6.8). Because the 
enzymatic preparation of 5-FDRP 81 using a PNP enzyme is a reversible process, it was 
not possible to obtain 100 % conversion to 5-FDRP 81. Extended incubations at 37°C 
generally achieved a maximum conversion of ~40-50 % (chromatogram (c), Figure 2.3). 
The product of this incubation was subsequently analysed by 19F NMR spectroscopy.118 
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HPLC traces illustrating (a) synthetic 5'-FDA 54, (b) 5'-FDA 54 incubated with 
adenosine deaminase and (c) 5' -FDI 55 incubated with immobilised PNP. 
2.2.3 Incubation of 5-FDRP in a CFE of S. cattleya 
5-FDRP 81 prepared as described in detail in Section 5.1.9 was used to explore its role as 
an intermediate on the fluorometabolite pathway by incubating this preparation with an 
active CFE of S. cattleya. As a consequence of its preparation, the 5-FDRP 81 sample also 
contained an excess of 5'-FDI 55 due to the reversibility of the PNP. However, from the 
control experiments it was already established that 5'-FDI 55 is not metabolised in the 
CFE. Accordingly, a sample of 5-FDRP 81 (200 f.LI) was incubated with the CFE (500 f.LI) 
for 16 hrs at 37 DC and the product subsequently analysed by 19F NMR to establish if 
organofluorine metabolism had occurred. The resultant spectrum is shown in Figure 2.4. 
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Figure 2.4 19F {lH} NMR spectra indicating fluorometabolite production after incubation of 
5-FDRP 81 (+5'-FDI 55) in a CFE of S. cattleya. 
The 19F NMR spectrum of the control experiment (zero time) shows the 5-FRDP 81, 5'-
FDI 55 mixture in the presence of a denatured CFE with their characteristic chemical shifts 
corresponding to 5-FDRP 81 (-230.78 ppm) and 5'-FDI 55 (-230.85 ppm) respectively. It 
is clear that under such control conditions both fluorinated compounds are stable indicating 
that no chemical degradation has occurred. In the second 19F NMR spectrum, the 
production of the two fluorinated secondary metabolites, fluoroacetate 8 and 4-
fluorothreonine 47 is obvious, confirming that 5-FDRP 81 supports the biosynthesis of 
these secondary metabolites in S. cattleya. The biosynthetic intermediates that exist 
between 5-FDRP 81 and fluoroacetaldehyde 48 are not observed by 19F NMR, suggesting 
that incubation for 16 hrs is sufficiently long to metabolise the remaining intermediates 
through to the end products, or that they are transient. 
In order to reinforce this result, another experiment was conducted to show that 5-FDRP 
81 is biosynthesised in S. cattleya. This involved the exogenous addition of an alkaline 
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phosphatase (EC 3.1.3.1 from bovine intestinal mucosa) to the CFE incubation. This 
phosphatase should hydrolyse any 5-FDRP 81 and result in the accumulation of the free 
sugar, 5-FDR 80. Synthetic 5-FDR 80 has already been shown to be metabolically inert in 
CFE's of S. cattleya. Therefore, the accumulation of 5-FDR 80 as a biotransformation 
product of 5-FDA 54 after addition of a commercial phosphatase activity, would clearly 
support the intermediacy of 5-FDRP 81 (Scheme 2.5). 
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Scheme 2.5 Summary of 5'-FDA 54 biotransformation in CFE's of S. cattleya with an 'added' 
alkaline phosphatase. 
Control experiments were first performed in order to show that phosphorolytic cleavage of 
5-FDRP 81 occurred using a commercial alkaline phosphatase from bovine intestinal 
mucosa. Accordingly, 5-FDRP 81 was prepared as outlined in Section 5.1.9 and the 
solution was supplemented with the alkaline phosphatase (20 {LI, 2 mg / ml) in phosphate 
buffer (50 mM, pH 6.8) and incubated at 37 DC for 16 hrs. 
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The analysis by 19F NMR spectroscopy showed a complete conversion of 5-FDRP 81 to 5-
FDR 80 with the two characteristic fluorine signals corresponding to the ~-anomer (-228.54 
ppm, 2Jp,H 47.3 and 3JF,H25.6) and the a-anomer (-230.85 ppm, 2Jp,H 47.3 and 3Jp,H 26.8). 
With this control established, a reaction was then performed in which an active CFE (500 
ILl) was incubated with 5'-FDA 54 (100 ILl, 18.6 mM) in phosphate buffer (50 mM, pH 6.8) 
but now supplemented with the phosphatase (20 ILl, 2 mg / ml). The incubation was carried 
out at 37°C for 16 hrs. (Figure 2.5b). 
lH coupled 19F NMR spectrum 
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Figure 2.5 19F CH} NMR spectra after incubation of (a) 5' -FDA 54 in a CFE of S. cattleya 
for 16 hrs at 37°C, (b) 5'-FDA 54 in a CFE supplemented with alkaline phosphatase for 16 hrs at 
37°C. 
The 19F NMR spectroscopy analysis (Figure 2.5b) resulted in three signals indicating the 
presence of three organo-fluorine compounds. Two of these signals corresponded to the 
two anomers of 5-FDR 80. No fluoroacetate 8 or 4-fluorothreonine 47 was produced 
during this biotransformation. Their biosynthesis had been arrested. This clearly 
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confinned the phosphorolytic cleavage of 5-FDRP 81 by the added alkaline phosphatase. 
In order to assign the remaining organo-fluorine signal (-230.88 ppm), HPLC analysis was 
carried out. This analysis indicated the presence of 5'-FDI 55 and the 19F NMR was 
consistent with this assignment. The presence of 5' -FDI 55 can be attributed again to 
adventitious deaminase activity in the CFE. 
In conclusion, the results from this section have demonstrated that 5' -FD A 54 IS 
metabolised to 5-FDRP 81 by the action of a PNP activity ina CFE of S. cattleya. 
2.2.4 Incubation of 2'-deoxy-5'-FDA in a CFE of S. cattleya. 
To explore the substrate specificity of the PNP in S. cattleya, 2'-deoxy-5'-FDA 59 was 
explored as a substrate to see if it is converted to 2-deoxy-5-FDRP 82. From previous 
literature it is known that 2-deoxy nucleosides can act as PNP substrates. 120 An active CFE 
(500 p,l) was incubated with synthetic 2'-deoxy-5'-FDA 59 (100 p,l, 18.6 mM) (prepared 
by S. L. Cobb)IIS for 16 hrs at 37°C. The resultant 19F NMR spectrum is shown in Figure 
2.6. 
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Figure 2.6 19F eH} NMR of a CFE incubated with 2-deoxy-5'-FDA 59. Expansions 
are 1H coupled 19F NMR spectrum. 
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Incubation of 2' -deoxy-5' -FDA 59 did not support secondary metabolite production 
deduced by the absence of fluoroacetate 8 and 4-fluorothreonine 47. From results obtained 
in Section 2.3.8, 2-deoxy-5-FDRP 82 is formed from the phosphorolytic cleavage of 2'-
deoxy-5'-FDA 59 by the action of a PNP. The fluorine signal at -230.60 ppm was 
confirmed as 5' -fluoro-2',5' -dideoxy-inosine (2' -deoxy-5' -FDI) 84 by HPLC analysis 
against a reference sample of 2' -deoxy-5' -FD I 84 prepared independently by the direct 
deamination of 2' -deoxy-5' -FDA 59 using a commercial adenosine deaminase from 
Aspergillus species. The final fluorine signal at -227.81 ppm was identified as 5-fluoro-
2,5-dideoxY-D-ribose (2-deoxy-5-FDR) 83 by comparison to a synthetic sample. 
Production of 2-deoxy-5-FDR 83 could arise from the presence of a phosphatase activity 
operating within the CFE. This adventitious activity is not present on the fluorometabolite 
pathway, as discussed in earlier experiments. 
In order to confirm this assumption, a sample of 2-deoxy-5-FDRP 82 was prepared by 
incubating a synthetic sample of 2'-deoxy-5'-FDI 84 with an immobilised PNP (EC 
2.4.2.1, E. coli). The generated product was subsequently treated with a commercial 
phytase enzyme (EC 3.1.3.8, Aspergillus ficuum) to remove the I-phosphate group of 2-
deoxy-5-FDRP 82. The sample was then re-analysed by 19F NMR and all of the 2-deoxy-
5-FDRP 82 had converted to the free sugar 2-deoxy-5-FDR 83. 
The fact that 2' -deoxy-5' -FDA 59 cannot support the CFE biosynthesis of the fluorinated 
secondary metabolites fluoroacetate 8 and 4-fluorothreonine 47 suggests that a 2-0H group 
on the ribose ring is essential for further metabolism of the fluorinated sugar phosphate 
intermediate, 5-FDRP 81. Overall, the results obtained are summarised in Scheme 2.6. 
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Scheme 2.6 Summary of2'-deoxy-5'-FDA 59 biotransformation in CFE's of S. cattleya 
With the presence of a PNP in S. cattleya now established the next objective was to purify 
the enzyme and these results are discussed in due course. Firstly however a general review 
on PNP enzymes is presented. 
2.2.5 Purine nucleoside phosphorylase (PNP) 
Purine nucleoside phosphorylases (PNP's) catalyse the reversible phosphorolysis between 
inorganic phosphate and the glycosidic bond of purine ribo- and deoxyribo-nucleosides 
and their analogues. 120 This phosphorolysis generates the free purine and a (deoxy) ribose-
I-phosphate sugar. These enzymes are perhaps the most thoroughly studied members of 
the nucleoside phosphorylase (NP-I) family. The biochemical significance of glycosidic 
bond cleavage in purines by the phosphorolytic mechanism is most apparent in the purine 
salvage pathway, which make use of nucleobases and nucleosides as precursors in the 
production of nucleotides, 121,122 Previous studies have shown that there are two distinct 
classes of purine nucleoside phosphorylases namely NP-I and NP_2. 123 Members of the 
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NP-I class are structurally either homotrimers or homohexamers made up of subunits of 
~31 lilla and ~26 lilla respectively. Enzymes belonging to the NP-I family can be further 
classified according to their substrate specificity and amino-acid sequences. Trimeric PNPs 
specific for guanine and hypoxanthine (2'-deoxy) ribonucleosides are present in 
mammalian species. The hexameric PNPs, accept a broader range of substrates including 
adenine, guanine and hypoxanthine (2' -deoxy) ribonucleosides. These are mainly prevalent 
in bacterial species, although Escherichia COli,123 Bacillus subtilis, I 24 and B. 
stearothermophilus l25 appear to have both trimeric and hexameric forms. Other members 
of the NP-l family include uri dine phosphorylase (UP; EC 2.2.2.3) and 5'-deoxy-5-
methylthioadenosine phosphorylase (MT AP; EC 2.4.2.28). UP has been shown to be 
specific for uri dine nucleosides although it also accepts its 2' -deoxy analogues. 126 The 
enzyme functions as a hexamer with identical subunits corresponding to a molecular mass 
of approx. 27.5 lilla. MT AP, which is specific for the purine nucleoside analogue 5'-
deoxy-5' -methylthioadenosine, is known to function mainly in a trimeric form with 
identical subunits of approx. 30 kDa. MT AP has been isolated and characterised from 
bacterial and mammalian species. 127,128,129 Members of the NP-II family are those 
enzymes that display a dimeric quaternary structure. Members of this family accept both 
thymidine and uridine in lower organisms, III but are specific for thymidine in higher 
. . 1 d' hili speCIes, mc u mg umans. 
2.3 Purification of a PNP from S. cattleya 
2.3.1 Assay for PNP activity in S. cattleya 
In order to purify the PNP enzyme from S. cattleya CFE, a suitable enzyme assay was 
required. Due to the strong chromophores of 5'-FDA 54 and adenine 75, a UV-HPLC 
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method was used to assay for PNP activity in S. cattleya. The method was based on the 
assay outlined in Section 5.1.17, and is used throughout this section when assaying for 
PNP activity. It was found that during the early stages, purification of the PNP activity 
was confounded by the fact that 5'-FDI 55 and hypoxanthine 79 were also generated due to 
the simultaneous presence of the deaminase activity as previously discussed. Therefore, in 
the initial stages, purification was assayed by monitoring the levels of hypoxanthine 79, 
adenine 75, 5'-FDI 55 and 5'-FDA 54 in the same HPLC chromatogram (Figure 2.7). 
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Figure 2.7 HPLC chromatogram of hypoxanthine 79, adenine 75, 5'-FDI 55 and 5'-FDA 54 
elution respectively. 
2.3.2 Step 1: Ammonium sulfate precipitation 
In the first stage of the PNP purification, the crude cell-free extract (~4 mg / ml) was 
SUbjected to ammonium sulfate precipitation to salt out the desired protein. It was shown 
that addition of (NH4)ZS04 to the CFE at concentrations of 35-50 % contained the desired 
PNP activity. No PNP activity was detected in any of the other fractions. The protein 
pellet could be used directly for further purification or alternatively stored at -80°C. 
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The assay was perfonned by incubating this partially purified protein extract (100 J.tl) with 
5'-FDA 54 (1 mM) in phosphate buffer (50 mM, pH 6.8) for 7 hrs at 37°C. The sample 
was then heated to 100°C for 3 min and the precipitated protein removed by 
centrifugation. For HPLC analysis, the supernatant (20 J.tl) was automatically injected in 
duplicates onto a reverse phase CI8 column (Figure 2.8). 
adenine 75 
/ 
hypoxanthine 79 
"" 
5'-FDA 54 
5'-FDI 55 
/ 
--A '- "- ~ 
o min 15 
Figure 2.8 PNP assay: HPLC showing the products of a partially purified fraction incubated 
with 5'-FDA 54 at 37 DC for 7 hrs. 
The assay shows that during the initial purification stages, in addition to the PNP activity, 
the accumulation of the shunt products 5'-FDI 55 and hypoxanthine 79 also indicate the 
presence of deaminase activity in the extract. 
2.3.3 Step 2: Hydrophobic interaction chromatography 
The second stage of the PNP purification involved passing the protein down a phenyl HP, 
(40 ml) column. Separation involves exploiting a hydrophobic attraction between the 
stationary phase and the protein. The stationary phase consists of small non-polar phenyl 
groups attached to a hydrophilic polymer backbone. The sample is loaded in a buffer 
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containing a high concentration of a non-denaturing salt (e.g. ~)2S04)). The proteins 
are then eluted as the concentration of the salt in the buffer is decreased. 
Accordingly, the (Phenyl lIP, 40 ml) column was equilibrated with phosphate buffer (50 
mM, pH 6.8), supplemented with 1 M ~)2S04. Since the protein sample contained 
~)2S04, prior treatment of the sample wasn't necessary. The protein pellet was re-
dissolved in the starting buffer (5 ml, ~21 mg / ml) and filtered through a 0.45 11m filter to 
remove any particulate matter: The filtrate was applied by injection (5 ml) to the 
equilibrated phenyl lIP column. The column was washed with 2 column volumes of the 
equilibrated starting buffer (flow rate of 2 ml / min) and subsequently eluted over a 
stepwise gradient from 1 M to 0 M ~)2S04 at a continuous flow rate of 2 ml / min. A 
typical chromatogram for such an analysis is shown in Figure 2.9. 
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FigUl'e 2.9 Phenyl HP (40 ml) chromatogram obtained after second stage purification. 
The elution profile monitored at 280 nm in Figure 2.9 shows several protein peaks eluting 
at various stages during the purification protocol. The eluted fractions (4 ml) were assayed 
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for PNP activity by incubation of the eluent (100 I,d) with 5 '-FDA 54 (1 mM) at 37°C for 
7 hrs. PNP active fractions were shown to elute at the end of the gradient (highlighted 
area) indicating a high affinity of the enzyme towards the hydrophobic resin. The average 
volume which contained PNP activity was 12 ml with a protein concentration of ~0.5 mg / 
ml. No activity was detected in any of the other peaks. A substantial amount of protein 
did not bind to the column under the described conditions showing the removal of protein 
contaminants. However, the majority of protein was shown to elute from the column 
during the stepwise gradient at a concentration of phosphate buffer (50 mM, pH 6.8), 
supplemented with 0.4 M (NH4)2S04. Overall, the purification using hydrophobic 
interaction chromatography removed a substantial amount of undesired protein, and was an 
effective protocol. 
2.3.4 Step 3: Ion exchange chromatography 
The partially purified extract from Section 2.3.3 was subjected to anion exchange 
chromatography. This method is based on the binding of charged proteins to oppositely 
charged groups attached to an insoluble matrix. It follows that to bind a protein to an anion 
exchange column; the pH of the mobile phase must be above its pI in order to carry a net 
negative charge. Protein elution is achieved by a gradient of increasing salt (e.g NaCI) 
concentration. The fractions containing the PNP activity after Step 2 purification were 
pooled together (12 ml) and concentrated to (2 ml) by centrifugation. The concentrated 
protein was then passed through a desalting column (HiTrapTM desalting, 5 ml, Amersham) 
and re-concentrated to ~2 ml by the same method. 
A strong anion exchange column (Q, 5 ml, Amersham Biosciences) was equilibrated with 
tris buffer (50 mM, pH 7.2) and loaded with the desalted protein sample (2 ml) containing 
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the PNP activity. The column was then eluted using a stepwise salt gradient to tris buffer 
(50 mM, pH 7.2) supplemented with 1 M KCI over 50 ml at a flow rate of2 ml / min. The 
chromatogram in Figure 2.10 shows several protein peaks eluting at various stages during 
the protocol. 
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Figure 2.10 Anion exchange chromatogram, (Q column, 5 ml). The highlighted area represents 
PNP activity. 
The resultant chromatogram shows several peaks eluting during the application of the 
stepwise gradient. Incubation and analysis of each fraction for PNP activity indicated the 
presence of active fractions eluting after 250 mM KCI gradient (highlighted area). The 
volume which contained the activity was ~8 ml with a protein concentration of ~ 0.3 mg / 
ml. No PNP activity was detected in any of the other protein fractions. It is evident that 
there is no base line separation between the observed peaks surrounding the active PNP 
fractions indicating other proteins are still present. 
71 
Chapter 2 
2.3.5 PNP analysis by SDS PAGE 
The partial purification of the PNP enzyme during each of the purification steps (1 -3) was 
monitored by SDS-P AGE. Figure 2.11 shows the protein purity progressing through the 
three purification steps. 
97 kDa 
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31 kDa 
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o 1 2 3 
Figure 2.11 SDS PAGE gel (4-12 % acrylamide) showing pooled active protein fractions 
containing PNP activity during each purification step. Lanes: 0 molecular markers 1, ammonium 
sulfate precipitation (35-50 %); 2, hydrophobic interaction chromatography, 3, anion exchange 
chromatography. 
2.3.6 Production of 5-FDRP from the partially purified PNP 
The partially purified PNP (100 Ill, 0.5 mg / ml) solution was supplemented with 5' -FDA 
54 (1 mM) in phosphate buffer (10 mM, pH 6.8) for 16 hrs at 37°C. The sample was then 
heated to 100°C for 3 min and the precipitated protein removed by centrifugation. 
Analysis of the supernatant by HPLC confirmed the phosphorolytic cleavage of 5' -FDA 54 
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due to the presence of adenine 75. Subsequently, the resulting supernatant was lyophilised 
and analysed by GC/MS after N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) 
treatment which was carried out (Dr. J. Hamilton, University of Belfast). The mass 
spectrum obtained from GC/MS analysis is shown in Figure 2.12. 
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Figure 2.12 GC-MS spectrum of MSTF A derivative of 5-FDRP 85 chemical ionization (CI). 
Ion fragment m/z 505 is from (M" - CH3)' 
The resultant mass spectrum exhibits the mlz 505 ion which indicates the loss of CH3 from 
the persilyl derivative of 5-FDRP 85. Several of the other signals can be attributed to other 
ion fragments of the derivatised sample. This result indicates the presence of 5-FDRP 81 
after the incubation of 5' -FDA 54 with partially purified PNP. Further analysis to support 
the observed result, was obtained by ESI-MS of a non derivatised sample of 5-FDRP 81. 
This is shown in Figure 2.13 . 
73 
Chapter 2 
IDD· TOFMS LeT 
:e-N f( I '-':N F~}::( NJ 
HO OH 
55 
m/z (-vel = 269 
<:'li, 
F~"OP03H ' .. ' Z}t93 . n,.o~ 
H61H ~ I 
81 Inc» ~ 
m/z (-vel = 231 2nC2 
~U,01. " 
26~.10 
2£9.13 
2l:J:'SS 
~8.&>; l':(},~ 
170.83 
::rtO.t~? 
L' IJ5.<>4 19~CQ ~n$7 ~O!Q .~e~ 1~1.01 • Ii ; (> . , I , Utf! 
" :In Ail flO !f) 100 1211 140 IfiD I DD 2~ no \'40:1110 JOD n~ ~'() l~O J80 .ao 
Figure 2.13 ESI-MS (-ve) spectrum of 5-FDRP 81 (M-H) and 5' -FDI 55 (M-H) , 
The analysis by ESI-MS shows an mlz signal at 231 in -ve mode, The mass of 5-FDRP 81 
is 232, and therefore the mlz 231 ion is consistent with the mono anion, The strong mlz 
signal at 269 is assigned to [5' -FDI-Hr 55. This result clearly shows the simultaneous 
presence of the deaminase activity in the partially purified PNP extract after hydrophobic 
interaction chromatography. However, these activities separate after anion exchange 
chromatography. Overall, this analysis supports the observed result from GC-MS, further 
confirming production of 5-FDRP 81 from 5'-FDA 54 by this enzyme. 
2.3.7 Monitoring the PNP reaction by 19F NMR 
In order to study the PNP biotransformation of 5' -FDA 54 to 5-FDRP 81 in real time, a 19F 
NMR time course experiment was calTied out in an NMR tube. Accordingly, partially 
purified PNP (500 ILl, ~0.5 mg / ml) in phosphate buffer (50 mM, pH 6.8) was taken 
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directly after anion exchange chromatography and was supplemented with 5'-FDA 54 (l00 
tLl, 18.7 mM). The progress of the reaction was monitored by recording 19F{lH} NMR 
(470 MHz) spectra at one hour intervals over 8 hrs at 25°C. Figure 2.14 shows the stacked 
19F NMR time course resulting from the biotransformation. 
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Figure 2.14 19F eH} NMR time course, recorded hourly for 8 hrs, of the partially purified PNP 
extract incubated with 5'-FDA 54 at 25 0c. 106 
The resultant 19F eH} NMR shows a product signal at -230.75 ppm appearing after just 1 
hr of incubation. ESI-MS analysis showed this signal corresponds to 5-FDRP 81, with a 
steady increase in 5-FDRP 81 formation over a 5 hr period. The signal begins to level off 
after 5 hrs, possibly due to the reversibility of the PNP reaction. HPLC analysis showed no 
deaminase activity was observed from the partially purified PNP extract indicating its 
removal after anion exchange chromatography. Overall, the NMR data are consistent with 
the previously observed results from HPLC and MS. 
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2.3.8 Substrate specificity of the partially purified PNP 
There has been a lot of interest in exploring PNP substrate specificity and developing PNP 
enzymes as biocatalysts for the regio- and stereo-selective synthesis of purine 
nucleosides. 13o However, the number of nucleosides generated is limited due to the 
relatively narrow substrate specificity of PNP's.13l These enzymes are specific for purine 
nucleosides in the p-configuration and exhibit a strong preference for ribosyl-containing 
nucleosides relative to the corresponding analogues containing the arabinose, xylose or 
lyxose stereoisomers. 132 Having a partially purified PNP from S. cattleya which acts on a 
novel substrate, it was of some interest to explore the specificity of this PNP relative to 
those previously described. 
The substrate specificity of the PNP was evaluated using a range of substrate analogues. 
Firstly, the enzyme was partially purified by anion exchange chromatography as outlined 
in Section 2.3.4. This protein extract (l00 ILl, 0.3 mg / ml) was incubated with a range of 
different nucleoside analogues at a final conc. of 1 mM in phosphate buffer (50 mM, pH 
6.8) for 16 hrs at 37 DC. After this time, the sample was heated to 100 DC for 3 min and the 
precipitated protein was removed by centrifugation. Control experiments were also carried 
out in the absence of protein, in the absence of the purine nucleoside, and also in the 
absence of phosphate in the buffer (50 mM, pH 6.8). For the HPLC analyses, 20 ILl of the 
clear supernatant was injected directly onto the C18 column. In order to assess whether the 
individual nucleosides acted as substrates, detection of the appropriate purine provided an 
indication that phosphorolyic cleavage had occurred. The nucleosides were either prepared 
by S. L. Cobbl18 or could be purchased commercially. The various nucleoside analogues 
were modified at five different sites designated Rl to R5 (Scheme 2.7). The results are 
highlighted in Table 2.1 and the Table indicates the range of nucleosides that were tested 
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as potential substrates. Positive substrate activity is denoted with a (+), and no activity 
with (-). 
R5 
R5 (N0N Nt Jl .. A ~ I N ~ N R4 NA) , R1~ N R4 R1~OPO, 
Rl ~R3 ~( PNP 
R2 R3 
HOPOl-
Scheme 2.7 Schematic representation of PNP activity and substrate analogues (see Table 2.1). 
R1 R2 R3 R4 R5 Substrate 
* 5'-fluoro-5'-deoxyadenosine 54 F OH OH H NH2 + 
5'-fluoro-5'-deoxyinosine 55 F OH OH H OH 
*2,5 dideoxy-5'-fluoroadenosine 59 F OH H H NH2 + 
* 2-amino-5'-fluoro-5'-deoxyadenosine 91 F OH OH NH2 NH2 + 
*5'-chloro-5'-deoxyadenosine 88 CI OH OH H NH2 + 
*2,5-dideoxy-5'-chloroadenosine 86 CI OH H H NH2 + 
2-chloroadenosine 96 OH OH OH CI NH2 + 
*2-amino-5'-chloro-5'-deoxyadenosine 97 CI OH OH NH2 NH2 + 
* 5 '-bromo-5'-deoxyadenosine 89 Br OH OH H NH2 + 
adenosine 71 OH OH OH H NH2 + 
2-deoxyadenosine 87 OH OH H H NH2 + 
* 3 '-deoxyadenosine 99 OH H OH H NH2 
* 5'-deoxyadenosine 90 H OH OH H NH2 + 
*2',5'-dideoxyadenosine 98 OH OH H H NH2 + 
2-aminoadenosine 94 OH OH OH NH2 NH2 + 
2-amino-2-deoxyadenosine 95 OH OH H NH2 NH2 + 
adenosine monophosphate 92 PO/- OH OH H NH2 
5'-thiomethyl-5' -deoxyadenosine 76 MeS OH OH H NH2 + 
*5'-acetyl-5'-deoxyademosine 93 OAc OH OH H NH2 
inosine 72 OH OH OH H OH 
Table 2.1 Substrate specificity of the PNP for various nucleoside analogues; (+) indicates a 
substrate and (-) indicates no detectable activity. * Prepared by S. L. Cobb.l18 
The results from Table 2.1 show that the partially purified PNP did not accept either of the 
6-oxopurine ribonucleosides, 5'-FDI 55 and inosine 72 as substrates. As discussed earlier, 
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5' -FDI 55 was shown to be metabolically inert in a CFE of S. cattleya, consistent with the 
result observed here. The inability of this enzyme to use 6-oxopurine nucleosides as 
substrates suggests that it shares a close resemblance to that of an MT AP .133,134 With 
nucleosides containing the 2'-deoxyribofuranose moiety such as compounds 59, 86 and 87, 
excellent activity was observed by HPLC. Clearly this PNP prefers a ribofuranosyl or 2' -
deoxyribofuranosyl group in the ~ configuration, consistent with other such enzymes. 110 
The PNP from S . cattleya appears to be particularly permissive in terms of the substituents 
allowed at the C-5' position of the ribose ring, accepting the nucleosides 71, 88, 89,90 and 
76. The acceptance of OH, Cl, Br, Hand MeS at this position indicates that the active site 
pocket receiving these residues is not particularly specific for fluorine. The various size of 
these substituents (e.g Br, MeS) suggests a large binding pocket. However, bulkier groups 
such as those on nucleosides 92 and 93, which contain a charged phosphate and an acetyl 
group respectively at C-5' show no phosphorolytic cleavage. Nucleoside analogues such 
as 91, 94, 95, 96 and 97 which are modified with NHz and Cl at the C-2 position of the 
purine ring show phosphorolytic cleavage. This observation opens up the possibility of 
exploring the sYflthesis of nucleosides such as the prodrug, 9-~-D-arabinofuranosyl-2-
fluoroadenine (F -dAdo) 100 by biotransformation. 
t
NH2 
N ~ I ~N HO~OVN A u N F 
HO OH 
100 
This compound is used in cancer treatment that utilises gene therapy to liberate the 
cytotoxic base 2-fluoroadenine. 135,136 In conclusion, these studies have shown that the 
substrate specificity of the partially purified PNP from S. cattleya has a significant 
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similarity to that of a bacterial MTAP. The wide variation of C-5' substituent tolerated, 
indicates that this enzyme is not particularly specific for the fluorinated substrate 5' -FDA 
54. 
2.3.9 Reversibility of the PNP 
It is well documented that PNP enzymes catalyse reversible C-N glycosidic bond 
formation to generate nucleoside bases from their corresponding purine base and a-ribose-
1-phosphate. 132 In order to explore the reversibility of the PNP from S. cattleya, a coupled 
enzyme assay was utilised which consisted of the adenosine deaminase (Aspergillus 
species, EC 3.5.4.3) and two PNP enzymes, one from a commercial source and the other 
from S. cattleya. The experiments were carried out by first preparing a sample of 5-FDRP 
81 from 5' -FDA 54 using the commercial adenosine deaminase and a bacterial PNP (E. 
coli, EC 2.4.2.1) (Section 5.1.9). It was anticipated that the addition of the partially 
purified PNP extract from S. cattleya to this reaction, supplemented with adenine 75 would 
generate the nucleoside 5'-FDA 54. Scheme 2.8 outlines the proposed route to explore the 
reversibility of the PNP. 
~N+~ F}~:(JLN) 
----
deaminase HO OH 
54 
Nt
OH 
!( 1 "N F~N N) 
HO OH 
55 
t
NH2 
N !( 1 "N F~N N) 
He) ·OH 
54 
N~N 
!( -t .. J N N 
H 79 
commercial PNP 
HOP032- / 
s. cat/leya PNP 
t
NH2 
N "N 
!( IJ 
N N H 
75 
F~".oPO: 
HO OH 
81 
Scheme 2.8 Coupled enzyme assay exploring the reversibility of the PNP from S. cattleya. 
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Analytical HPLC was used to monitor the progress of each biotransformation step during 
the course of this assay. 5'-FDA 54 (18.5 mM) was incubated with adenosine deaminase 
for 16 hrs at 37°C. The resulting HPLC chromatogram shown in Figure 2.15(a) indicated 
100 % conversion to the product 5'-FDI 55. The enzymatically synthesised 5'-FDI 55 
(18.5 mM) was supplemented with an immobilised bacterial PNP from E. coli (gift from 
Galaxo Smith Kline) and incubated for 16 hrs at 37°C. 
(a) 
(b) 
hypoxanthine 79 
~ 
(c) 
hypoxanthine 79 
~ 
____________ --J~ 
adenine 75 
/ 
5'-FDI 55 
/'" 
5'-FDI 55 
~ 
5'-FDI 55 
/'" 
5'-FDA 54 
/ 
I I 
o min 15 
Figure 2.15 HPLC chromatogram showing (a), 5'-FDA 54 incubated with adenosine 
deaminase for 16 hrs at 37 DC. (b), incubation of an immobilised PNP to the enzymatically 
prepared 5'-FDI 55 for 16 hrs at 37 DC. (c), incubation ofPNP from S. cattteya with 5-FDRP 81 (+ 
5' -FDI 55) and adenine 75. 
The reSUlting HPLC trace in Figure 2.15(b) shows the phosphorolytic reaction yielding a 
~40 % conversion to hypoxanthine 79 (+5-FDRP 81). With this established, the 5-FDRP 
81 product was subjected to the final step which involved the addition of the partially 
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purified PNP (100 /LI, 0.3 mg / ml) from S. cattleya to 5-FDRP 81 and adenine 75 (3.7 
mM). The reaction was incubated for 16 hrs at 37°C. The resulting chromatogram in 
Figure 2.15( c) clearly shows the presence of a fourth peak which was identified as 5' -FDA 
54. This result was reinforced by 19F NMR spectroscopy and ES-MS, which showed that 
the PNP reaction is reversible. 
Having demonstrated that the S. cattleya PNP is reversible it became interesting to explore 
the reversibility of the enzyme using purine analogues. Accordingly, a series of 
experiments was conducted by exploiting the assay outlined above. The analogues and 
results are shown in Table 2.2. Each of the purine bases (3.7 mM) was incubated with 5-
FDRP 81 in the presence of the partially purified PNP. Analytical HPLC was used to 
monitor the reaction and determine the presence of newly formed nucleosides. 
N~N 
f -l .. AR4 N N H 
R4 R5 Substrate 
adenine 75 H NH2 + 
hypoxanthine 79 H OH 
6-methylpurine 102 H CH3 
6-chloropurine 103 H CI 
2-amino-6-purinethiol 104 NH2 SH 
2,6-diaminopurine 101 NH2 NH2 + 
2-amino-6-chloropurine 106 NH2 CI 
2,6-dichloropurine 107 CI CI 
punne 105 H H 
Table 2.2 Substrate specificity of the PNP from S. cattleya with 5-FDRP 81. 
The results show that only the purine bases adenine 75 and 2,6-diaminopurine 101 were 
accepted as substrates. These observations were verified by co-injection experiments using 
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synthetic standards. The purine analogues 102, 103, 104, 105 which were all substituted at 
C-6, with CH3, CI, SH and H respectively, were not substrates. This result emphasises the 
importance of the NH2 group at C-6 of the purine ring for activity. Overall, the generation 
of novel halogenated purine analogues was not possible due to the substrate constraints 
encountered with the PNP from S. cattleya. 
2.3.10 Generation of SAM analogues using the fluorinase and PNP in reverse 
It was shown in Section 1.6.2 that the fluorinase operates in reverse, generating SAM 53 
and inorganic fluoride from 5'-FDA 54 supplemented with L-methionine 56. It was 
particularly interesting that the enzyme will also utilise 2' -deoxynucleoside substrates, 
which enables biotransformations to novel 2-deoxy-SAM 60 analogues. With this 
established, it was considered that the substrate specificity of the fluorinase be further 
explored in the reverse direction by generating halo-nucleoside substrate analogues using 
the PNP from S. cattleya. This would in tum, generate potential SAM 53 analogues. One 
such application of structural analogues of SAM 53, with modifications in the amino acid, 
sugar, or base portions of the molecule is their use as either inhibitors and I or substrates 
for the study of SAM-dependent methyltransferases. 137 In order to explore the generation 
of SAM 53 analogues; a coupled enzymatic reaction was used which exploited the 
reversible reactions of the PNP and the fluorinase from S. cattleya. 
A series of halogenated nucleosides was first prepared by exploiting the method outlined in 
Section 2.3.9. The newly synthesised halogenated nucleosides could be tested as 
fluorinase substrates by incubating the enzyme with the halogenated nucleoside and L-
methionine 56. Scheme 2.9 outlines the strategy taken for the generation of the modified 
SAM 53 analogues by exploiting the reverse reaction. 2-
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Scheme 2.9 Coupled enzymatic synthesis for the preparation of SAM 53 analogues using both 
partially purified PNP and the fluorinase in reverse from S. cattleya. 
Accordingly, the generated halo-nucleoside was supplemented with the fluorinase (100jLI, 
10 mg / ml) and L-methionine 56 (10 mM), and incubated for 16 hrs at 37 DC. After this 
time, the sample was denatured by heating to 100 DC for 3 min and the precipitated protein 
was removed by centrifugation. Analysis of the supernatant by HPLC showed that it was 
possible to generate 2-amino-2-deoxy SAM 114 and 2-amino SAM 115 analogues from 
the corresponding halogenated (chlorinated or fluorinated) nucleoside. 
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In addition to HPLC analysis, ESI-MS along with co-injection experiments using synthetic 
standards confirmed the presence of the generated SAM 53 analogues. An example of 
such an analysis is shown in Figure 2.16, which shows the formation of2-amino-SAM 115 
from the corresponding nucleoside, 2-amino-5'-FDA 111 using the coupled enzymatic 
reaction. The ES-MS analysis confirmed an mlz of 414 (M-Hr corresponding to 2-amino-
SAM 115 which supports the observed HPLC results. 
hypoxanthine 79 
2,6-diaminopurine 101 
5'-FDI55 
{/ 
2'-amino-5'-FDA 111 1 ;-amino-sAM 115 
IJ A B '------''---------'1\.1 
A 
~----- -.. --
o min 25 
Figure 2.16 HPLC traces showing (A) (5-FDRP 81, 5' -FDI 55) mixture incubated with 2,6-
diarninopurine 101 with partially purified PNP for 16 hrs at 37 DC . (B) Supplemented with L-
methionine 56 in the presence of the fluorinase for 16 hrs at 37 DC. 
This was only a preliminary study. Further investigation is needed to exploit this coupled 
enzyme method to generate other SAM 53 analogues. One possibility is to use the E. coli 
PNP which is known to have broader substrate specificity, accepting both 6-amino and 6-
oxopurine nucleosides.136 This could generate more potential nucleoside substrates for the 
fluorinase, and subsequent access to novel SAM analogues. 
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2.4 Fluorometabolite gene cluster in S. cattleya 
The search for the genes encoding enzymes responsible for natural fluorine-containing 
metabolites has been a key challenge over the last few years. Recently, the cloning93 of the 
fluorinase gene (jlA) in collaboration with Dr Joe Spencer and Dr Fanglu Huang at the 
University of Cambridge has led to the DNA sequencing of a further 11 putative open 
reading frames (ORFs) adjacent to fiA. Sequence similarities/identities indicate that 
several of these genes may be involved in fluorometabolite biosynthesis in S. cattleya. Of 
particular interest is the gene fiB located immediately upstream of fiA which encodes a 
protein of 299 amino acids and has a high degree of sequence similarity to a purine 
nucleoside phosphorylase (PNP) (see Section 2.4.1). Therefore, it is likely that the first 
two genes of the fluorometabolite pathway are together on the chromosome in S . cattleya. 
The fiB gene and its product are discussed in the next section. Figure 2.17 shows the 
cluster of genes centred around the fiA gene, all of which have been tentatively assigned a 
function based on known protein sequences. 
fiE flO flC fiB flA flF 
•• 
ORF 
fiE 
flO 
flC 
fIB 
f/A 
f/F 
fiG 
f/H 
fli 
f/J 
flK 
f/L 
-----I.~ .. ~.~ ... 
Length aa 
222 
216 
397 
299 
299 
185 
234 
467 
489 
131 
139 
225 
fiG flH fll flJ flK flL 
... . .. 
Putative function 
DNA binding regulatory protein 
Dehalogenase/Phosphatase 
MFS permease 
PNP 
fluorinase 
DNA binding regulatory protein 
DNA binding regulatory protein 
Na+/H+ antiporter 
Homocysteine lyase 
DNA binding protein 
Thioesterase/acyltransferase 
DNA binding regulatory protein 
Figm'e 2.17 ORFs and map ofthejllocus with tentative functions assigned. 
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It is noteworthy that the genes encoding the already purified fluoroacetaldehyde 
dehydrogenase and threonine transaldolase enzymes, which are involved in the latter stages 
of the fluorometabolite pathway, are absent from this gene cluster. The genes encoding 
these enzymes must therefore be part of another unidentified locus on the chromosome. 
2.4.1 PNP sequence analysis 
A database search using the BLAST program revealed that the putative PNP encoded 
within the fl cluster belongs to a family of 5' -methylthioadenosine phosphorylases 
(MTAPs). MTAP is known to be a key component in the L-methionine salvage pathway as 
previously discussed. Its function is to metabolise 5' -methylthioadenosine (MT A) 76 in the 
methionine salvage pathway (see Section 3.1).113,114 
Analysis of the sequence similarity between FIB and several homologues showed a high 
degree of identity with MTAPs. For example, this putative PNP shows a 53 % identity and 
68 % sequence similarity to a putative MT AP from G. metallireducens. This putative PNP 
is similar to putative MTAP's present in Actinomycetes such as S. coelicolor and S. 
avermitilis, (52 % and 50 % identity respectively). Figure 2.18 illustrates the sequence 
alignment of FIB and its orthologues. 
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Figure 2.18 
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Sequence alignment of FiB with putative PNP's from bacteria. Residues that are 
highly conserved appear in red, and those weakly conserved in blue. 
The fiB gene was cloned into the pET28a( +) plasmid with an N-terminal His-Tag at the 
University of Cambridge, and the gene was over-expressed. The purified enzyme was able 
to catalyse the phosphorolytic cleavage of 5' -FDA 54 to adenine 75 and 5-FDRP 81 in an 
identical manner to the partially purified PNP from wild type in S. cattteya. This analysis, 
along with the location of the fiB gene adjacent to the fiA gene clearly suggests the 
involvement of this PNP in fluorometabolite biosynthesis. Although this protein was 
successfully overexpressed, it is largely insoluble. It became an objective in St Andrews to 
obtain the pET 28a(+) construct containing thefiB gene to try and increase the solubility of 
the desired protein. 
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2.5 Expression and purification of a PNP from S. cattleya 
2.5.1 Protein expression trials 
For expression of the PNP, the pET28a(+) plasmid containing the fiB gene was used to 
transform competent E. coli host cells (Section 5.1.27.2). Small scale expression trials (10 
ml) were first performed in order to determine optimum conditions. The transformed E. 
coli host cells were selected on antibiotic-containing LB agar plates. Single colonies were 
picked and grown in 10 ml of growth medium at 37°C and shaken at 200 rpm for ~12 hrs. 
After this time, aliquots (100 ILl) were used to inoculate fresh growth medium (10 ml) for 
the overexpression trials. Expression was induced using various IPTG concentrations once 
the cell density had reached an OD6oo of ~ 0.5. During the protein expression trials, 
numerous variables were altered in order to try and optimise in vivo expression of soluble 
protein. These variables are discussed below. 
The following induction temperatures were used to try to limit the insoluble aggregation of 
the desired protein; 30°C, 25 °c, 18°C, 16 °c, 12°C and 10 °c. Reducing the temperature 
is a general strategy employed for the solubilisation of proteins. 138 This can be explained 
by a number of important factors, including, a slower rate of protein synthesis and changes 
in the folding kinetics of the polypeptide chain. 
Another important strategy that has shown success in production of high amounts of active 
proteins is the use of different growth media including e.g growth additives such as 
NaCl. 139 Additionally, glucose which is present in most rich media is shown to repress 
induction of the lac promoter by lactose. 140 For these reasons, the following media were 
used; Luria-Bertani (LB) medium, tryptone phosphate medium, terrific broth and 
Overnight Express™ Autoinduction System 1 (Novagen). 
Inducing with lower concentrations of IPTG has also shown success in increasing protein 
solubility.141 This approach can be explained by a reduction in translation rates which leads 
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to an increased chance of protein folding into a native state. Accordingly, the following 
IPTG concentrations were used; none (leaky expression); 0.1 mM, 0.2 mM, 0.4 mM, 0.6 
mM, 0.8 mM and 1 mM. 
The choice of expression host can significantly increase the activity and amount of target 
protein present in the soluble fraction. The following strains were used; BL21(DE3), 
BL21Star™, BL21(DE3)pLysS, BL21 (DE3)pLysE, Rosetta(DE3) and C43(DE3). All of 
these variables were tested and protein production was analysed by SDS-PAGE. 
For SDS-PAGE analysis, cells were first harvested by centrifugation (14,000 rpm I 5 min) 
and the cell pellet was re-suspended in buffer (20 mM Tris-HCI, pH 7.5). The resultant re-
suspended cell pellet was disrupted by ultrasonication, at 60 % duty cycle for 10 sec and 
the cell debris removed by centrifugation (14,000 rpm I 5 min). The insoluble fraction, 
along with the soluble and non-induced sample was analysed. 
The results showed that under most of the conditions tested, high expression levels of PNP 
resulted, however, the majority of the protein was found in the insoluble cell fraction as 
judged by SDS-PAGE (Mw: ~36 ld)a) and trypsin digest MALDI-TOF mass spectrometry. 
The results presented in Figure 2 .19( a) show three of the specialised host strains used to try 
and improve soluble expression of the PNP, however, in each case, the majority of the 
desired protein formed insoluble aggregates. Among these, the E. coli mutant strain 
C43(DE3) which has contributed significantly to soluble expression of difficult 
recombinant proteins,142 also proved ineffective. The results in Figure 2.19(b) show the 
Overnight Express ™ Autoinduction System which is optimised for tight expression, 
control and induction at high cell density also resulted in low levels of soluble PNP over 
various induction temperatures and lengths of incubation. This again is observed in the 
insoluble protein fraction. 
89 
Chapter 2 
1 2 3 4 5 678 123 5 6 7 8 9 10 
PNP / 
Figure 2.19 (a) SDS-PAGE showing expression trials of the PNP using three different 
expression hosts, BL21(DE3), Rosetta 2(DE3) and C43(DE3). Lanes 1; SDS markers, 2; 
BL21(DE3) Insoluble fraction, 3; Soluble fraction, 4; Rosetta2(DE3) Soluble fraction, 5; Insoluble 
fraction, 6; C43(DE3) Insoluble fraction, 7; Soluble fraction, 8; SDS markers . 
(b) SDS-PAGE showing Overnight Express™ Autoinduction System induced at 16 °C. Lanes 1; 
insoluble fraction, 22 hr, 2, soluble fraction, 22 hr, 3, soluble fraction, 25 hr, 5, insoluble fraction, 
27 hr, 6, soluble fraction, 27 hr, 7, insoluble fraction, 29 hr, 8, soluble fraction, 29 hr, 9, insoluble 
fraction, 31 hr, 10, soluble fraction, 31 hr. 
The expression trials that relied on leaky protein expression rather than IPTG induction to 
gain soluble protein were also unsuccessful in generating soluble protein. Additionally, E. 
coli strains that prevent leaky expression, such as BL21 (DE3)pLysS and 
BL21 (DE3)pLysE did not yield high levels of soluble protein. Induction temperature trials 
between 10°C - 37 DC, did result in an improvement in soluble protein expression, 
particularly at 10°C. The over-expressed protein is unlikely to be toxic to the bacteria as 
the expression did not prevent cell growth, as judged by the increase in OD600 during 
protein expression. 
In summary, although only low levels of soluble PNP protein could be obtained, 
particularly from low induction temperatures, it was considered that large scale protein 
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expression would yield reasonable soluble protein concentrations for further purification. 
Therefore, conditions were optimised after these trials, and expression was scaled up to 
500 ml cultures using BL21(DE3). Section 5.1.27.3(b) outlines the protocol for larger 
scale expression which resulted in ~ 13.5 g of cells from 5 L, with a total soluble protein of 
approximately 412 mg. 
2.5.2 Purification of overexpressed PNP 
PNP was purified using a three step purification protocol involving a metal chelate (NiS04 
charged resin, fast flow sepharose, Amersham Biosciences) and gel filtration (Superdex 
200, 60 x 16, Amersham Biosciences) chromatography. The protocol that was used is 
outlined in Section 5.1.27.3(c). The metal chelating column purified the N-terminal Histag 
protein which resulted in ~30 mg protein after a 250 mM imidazole elution. The resultant 
HisTag protein was cleaved with thrombin by incubation for 20 hrs at 4 DC and the 
resulting protein was reapplied to the nickel column for further purification. This resulted 
in approximately 4 mg protein. Figure 2.20 shows an SDS-P AGE gel highlighting various 
stages during PNP purification. 
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14 kDa 
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1234567 
PNP 
Figure 2.20 SDS-PAGE showing the protein after various stages during the purification of the 
PNP. 1; molecular markers, 2; insoluble fraction, 3; soluble fraction, 4; 250 mM imidazole elution, 
5; thrombin cleavage, 6; 30 mM imidazole elution (2nd nickel column), 7; 250 mM imidazole 
elution (2nd nickel column). 
The final step in the purification protocol used a Superdex 200, (60 x 16, Amersham 
Biosciences) gel filtration column, which was pre-equilibrated with tris buffer (50 mM, pH 
7.5) containing 0.3 M NaCl. Fractions containing PNP were pooled and concentrated to 
give a total of 3 mg of purified PNP in 1 ml of tris buffer. The resulting SDS-P AGE gel 
and ES-MS of the purified protein are shown in Figure 2.21. 
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(a) SDS-PAGE showing purified FIB after gel filtration. Lanes 1; molecular 
markers, 2; gel filtration purification (b) ES-MS spectmm showing cleaved PNP. 
The SDS-PAGE gel shows the PNP purified to homogeneity, showing an estimated mass 
of 33 IcDa by comparison with standards. An accurate mass of the purified recombinant 
(Gly-Ser-His)-PNP protein was determined by EST-MS to be 31 ,897 Da. This is in very 
close a!:,Tfeement to the calculated value of 31,894 Da from the gene sequence. The native 
mass of the enzyme was detennined using a HiLoad 16160 S uperdex 200 gel filtration 
column which was calibrated using the reference proteins in Section 5.1.22. The native 
mass is approximately 80-90 kDa indicating that the enzyme is probably a homotrimer. 
The method described in Section 5. 1.17 was used to assay the purified PNP protein by 
incubating 5' -FDA 54 (1 mM) with 100 flg of purified PNP in phosphate buffer (10 mM, 
pH 6.8) for 30 min at 37°C. After this time, the protein was denatured at 100 °C for 3 min 
and the precipitated protein was removed by centrifugation. Control experiments were 
carried out in the absence of 5' -FDA 54 and phosphate buffer (10 mM, pH 6.8), and also in 
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the absence of purified FIB. The reaction was followed by HPLC analysis of the 
supernatant (20 JLI) by monitoring for adenine 75 release (Figure 2.22(a)). Further analysis 
was carried out by 19F NMR spectroscopy after incubation of 5'-FDA 54 (5 mM) with 200 
JLg of FIB in phosphate buffer (10 mM, pH 6.8) and incubating for 7 hrs at 37°C (Figure 
2.22(b )). Additionally, ES-MS analysis was performed on the product; ES-MS, 5-FDRP 
81 mlz231 (M-Hr. 
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Figure 2.22 (a) HPLC chromatogram and (b), 19F CH} NMR spectrum of purified FIB 
incubated with 5'-FDA 54 in phosphate buffer (10 mM, pH 6.8). 
The successful over-expression and purification of the PNP has led to sufficient protein to 
carry out initial crystallisation trials. This work is ongoing in collaboration with Professor 
J. Naismith, University of St Andrews. 
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2.6 Conclusion 
It has been shown that in S. cattleya, a purine nucleoside phosphorylase (PNP) is present 
which is able to catalyse the reversible phosphorolysis of the glycosidic bond of 5' -FDA 
54 to 5-FDRP 81. Investigations using a CFE have shown that the incubation of 5-FDRP 
81 by an enzymatic preparation led to the accumulation of fluoroacetate 8 and 4-
fluorothreonine 47. The identity of this enzyme activity has led to a partially purified PNP 
from S. cattleya after ammonium sulfate precipitation, hydrophobic interaction 
chromatography and ion exchange chromatography respectively. 
A study with this partially purified PNP has revealed a narrow substrate specificity and a 
profile which shares a close similarity to bacterial 5' -methylthioadenosine phosphorylases 
(MTAP's). The coupling of the fluorinase and the PNP to generate SAM 53 analogues has 
been achieved, and this may have utility for the preparation of novel SAM 53 analogues. 
In collaboration with Dr Joe Spencer (University of Cambridge), a gene cluster encoding 
enzymes responsible for fluorometabolite biosynthesis in S. cattleya has been identified by 
sequencing out from the fiA (fluorinase) gene. The fiB gene encoding a putative purine 
nucleoside phosphorylase (PNP) was identified adjacent to the fluorinase (flA) gene. The 
catalytic behaviour is identical to that purified de novo, and its location adjacent to the fiA 
gene indicates that it is involved in fluorometabolite biosynthesis. Over-expression and 
purification of the PNP has been achieved and initial crystallisation trials are underway. 
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3 Identification of an isomerase activity on the fluorometabolite pathway in S. cattleya 
The metabolic conversion of 5-FDRP 81 to fluoroacetaldehyde 48 in fluorometabolite 
biosynthesis remains to be characterised at a biochemical level. The results described in 
this chapter show that 5-fluoro-5-deoxY-D-ribulose-l-phosphate (5-FDRibP) 121 is the 
intermediate formed after 5-FDRP 81 on the fluorometabolite pathway. The enzyme 
responsible for this transformation is shown to be a 5-fluoro-5-deoxY-D-ribose-l-phosphate 
isomerase. The biotransformation of FDRibP 121 to fluoroacetaldehyde 48 is unclear; 
however, biochemical evidence is presented which suggests that the diastereoisomer of 
121, 5-fluoro-5-deoxY-D-xylulose-l-phosphate (5-FDXyuP) 126 is the remaining 
unidentified metabolite. In order to gain an insight into the potential biosynthetic pathway 
for the metabolism of 5-FDRP 81, the methionine salvage pathway is revisited. 
3.1 L-Methionine salvage pathway 
It was shown in Section 2.1.1 that MTA 76 is metabolised to 5-MTRP 78 by two 
independent routes. I 13 The first involves the action of a PNP activity to yield 5-MTRP 78 
from MTA 76. The second route involves hydrolysis of MTA 76 by a nucleosidase 
activity to yield MTR 77 which is subsequently phosphorylated by the action of a kinase to 
give MTRP 78. The next transformation involves formation of 5-methylthio-5-deoxY-D-
ribulose-I-phosphate (MTRibP) 116 via an isomerase activity. This was first unravelled 
by Abeles and co-workers in K. pneumoniae.143-147 Recently, the genes involved in this 
transformation and subsequent steps have been discovered in B. subtilis. 115 Within this 
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gene cluster is the gene for MTRP isomerase,148 which has a protein sequence similar to 
that of a eukaryotic initiation factor eIF -2B. 149,150 Scheme 3.1 outlines the recycling of 
methionine in Bacillus subtilis. 115 
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L-Methionine salvage pathway: Intermediates and enzymes in blue outline a 
proposed pathway analogous to fluorometabolite biosynthesis in S. cattteya. 
Several enzymes responsible for the transformation of MTRibP 116 to L-methionine 56 
have been identified. The first of these involves the dehydration ofMTRibP 116 catalysed 
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by a dehydratase to yield the diketone product 2,3-diketo-5-methylthiopentyl-1-phosphate 
(DK-MTP-1-P) 117. This enzyme is shown to belong to a large cluster of proteins that 
form Class II aldolases. Amongst this cluster is L-ribulose-5-phosphate-4-epimerase which 
emphasises the importance of the ribulose backbone for recognition by enzymes of this 
class. DK-MTP-1-P 117 is converted to 2-hydroxy-3-keto-5-methylthiopentene (DHK-
MTPene) 119 via the intermediate 2-hydroxy-3-keto-5-methylthiopentenyl-1-phosphate 
(HK-MTPenyl-1-P) 118, by an enolase/phosphatase. The final two steps in the L-
methionine salvage pathway appear to be ubiquitous to all organisms that grow in the 
presence of dioxygen. The first involves the enzymatic oxidation ofDHK-MTPene 119 by 
an aci-reductone dioxygenase enzyme to yield 2-keto-4-methylthiobutyrate (KMTB) 120. 
The final step involves the transamination of KMTB 120 to L-methionine 56 via an 
aminotransferase. For example, in K. pneumoniae this enzyme generates L-methionine 56 
from KMTB 120 and tyrosine from its keto acid precursor. I 15 
3.1.1 5-Methylthio-5-deoxy-n-ribose-1-phosphate isomerase 
A sequence alignment of the MTRP isomerase from B. subtilis with related protein 
sequences suggests that it belongs to a family of eukaryotic initiation factors, EIF-2B.114 
Members of EIF-2B function as important regulators of protein translation initiation. In 
eukaryotic translation, the initiation factor is involved in GTP/GDP exchange and is a 
member of GTP-dependent regulators. lSI Analysis of the sequence similarity between the 
MTRP isomerase from B. subtilis and related protein sequences from Streptomyces 
coelicolor, Streptomyces avermitilis and Sacchromyces cerevisiae (Ypr118W) are shown 
in Figure 3.1. 
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Figure 3.1 MTRP isomerase sequence alignments . Residues that are highly conserved appear 
in red, and those weakly conserved in blue. 
This highlights a high degree of conserved residues between genes from the Streptomyces 
species assigned as putative translation initiation factor EIF-2B subunits based on sequence 
homology, and the B. subtilis MTRibP isomerase. For example, the S. coelicolor EIF-2B 
shows a 32 % identity and 52 % similarity to MTRP isomerase from B. subtilis. This 
observation tentatively suggests that the identified proteins are related to MTRibP 
Isomerases. Recently, the crystal structure of a protein (Ypr1l8w) from Saccharomyces 
cerevisiae,152 showed to be a MTRP isomerase related to regulatory EIF-2B subunits. 
This enzyme is the yeast ortholog of the MTRP isomerase from B. subtilis with a reported 
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sequence similarity of 37 %. Another recent report outlines the crystallisation and 
preliminary structure analysis of a MTRP isomerase from Bacillus subtilis. 153 
3.2 The metabolism of 5'-FDA in a CFE of S. cattleya 
In order to elucidate the remaining fluorinated intermediates on the biosynthetic pathway 
to fluoroacetaldehyde 48, the biotransformation of 5-FDA 54 to fluoroacetate 8 was 
examined in real time in CFE's of S. cattleya. Accordingly, an active CFE (500 JLl) was 
supplemented with 5'-FDA 54 (100 JLl, 18.6 mM) at 37 DC and the progress of the 
biotransformation was followed by 19F NMR at one hour intervals over a period of 9 hrs. 
The resulting 19F NMR time course is shown in Figure 3.2, which clearly shows a number 
of organo-fluorine compounds generated from 5'-FDA 54. The secondary metabolites 
fluoroacetate 8 (-216.94 ppm) and 4-fluorothreonine 47 (-231.56 ppm) are shown, 
indicating that the CFE retains all of its biosynthetic activities. The fluorine signal 
emerging after 6 hrs at -224.44 ppm has previously been identified as fluoroethanol 69, 
which accumulates from the action of an adventitious alcohol dehydrogenase activity in S. 
cattleya acting on fluoroacetaldehyde 48. Expansion of the 19F NMR spectrum after 4 hr 
incubation reveals a further four organo-fluorine compounds. The presence of 5-FDRP 81 
(-230.80 ppm) and 5'-FDI 55 (-230.88 ppm) are clear due to PNP and deaminase activities 
respectively (see Section 2.2). The absence of 5'-FDA 54 (-230.92 ppm) highlights its 
rapid conversion due to the simultaneous action of the previously mentioned enzymes. 
The precursor to the fluorinated secondary metabolites, fluoroacetaldehyde 48 (231.04 
ppm), is also apparent after four hours from its transformation by the unknown steps after 
5-FDRP 81. The remaining two organofluorine signals at -231.35 ppm and -228.21 ppm 
corresponding to intermediates A and B remain to be characterised. It is therefore 
100 
Chapter 3 
conceivable that these two unidentified intermediates are the remaining £luoro-metabolites 
between 5-FDRP 81 and fluoroacetaldehyde 48. 
IH coupled l YF NMR spectrum of 
signal-228.21 ppm recorded after 4 hours. 
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Figure 3.2 
cattleya. 
19F {lH} NMR spectra time course spectra of 5' -FDA 54 incubated in a CFE of S. 
Expansion is IH coupled 19F NMR spectrum, showing region -230.10 ppm to -232.00 ppm. 
From the 19F NMR spectra time course in Figure 3.2 the transformation of 5-FDRP 81 to 
the next intermediate remains elusive. No direct relationship could be established between 
5-FDRP 81 and the two unidentified intermediates. However, from the results in Section 
2.2.3 it was clear that the remammg intermediates are metabolised after overnight 
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incubation of a CFE with 5'-FDA 54. This shows that both unidentified organo-fluorine 
signals are not shunt products on the pathway. 
In order to study the transformation of 5-FDRP 81 to the next intermediate more closely, 
an experiment was conducted which involved the use of a less concentrated CFE 
(0.1 g cells / ml versus 0.2 g cells / ml). 19F NMR spectra were recorded in real time, after 
the incubation of an active CFE (500 JLl, 0.1 g cells / ml) with a synthetic sample of 5'-
FDA 54 (l00 JLl, 18.6 mM) at hourly intervals for five hrs at 37°C. The resultant 19F 
NMR spectra time course is shown in Figure 3.3. 
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19F CH} NMR spectra time course of a CFE incubated with 5' -FDA 54 
The biotransformation of 5'-FDA 54 to 5-FDRP 81 and 5'-FDI 55 is clear after 1 hr due to 
the simultaneous activity of the PNP and deaminase respectively. The transformation of 5-
FDRP 81 is shown to proceed to intermediate A (-231.34 ppm) which appears after 2 hrs 
of incubation and accumulates over time. It is unclear if intermediate A proceeds directly 
to B in this 19F NMR time course. The intermediate fluoroacetaldehyde 48 is transient 
during the time course making it difficult to deduce a direct relationship between 
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intermediate A and fluoroacetaldehyde 48. Therefore, it was anticipated that a clearer 
insight to the downstream section of the pathway might be unravelled by the addition of 5-
FDRP 81 to a CFE. 
3. 3 The metabolism of 5-FDRP in a CFE of S. caUleya 
A cell free biotransformation of 5-FDRP 81 was explored. Accordingly, 5-FDRP 81 (200 
Ill) was prepared by the method established in Section 5.1.9, and was incubated with a 
CFE (500 Ill). 19F NMR spectra were recorded at hourly intervals for six hrs at 37°C. The 
resulting spectra are shown in Figure 3.4. 
5'-FDI 55 
5-FDRP81 ~ intermediate A 
fluomaoeM' 8 ~ ~ 1 / _:~~~~p§~: ;:,,' 6h, -=:~~g~:~: ", 
I' , , ";'0' , , '.2)0": : , :.2;50: : ':2;:~: , ''':50: ~ , Ohr 
ppm(ft) 
5-FDR 80 from control 
Figure 3.4 19p CH} NMR spectra time course of a CPE incubated with 5-PDRP 81. 
After one hour of incubation the emergence of an organo-fluorine signal at -231.30 ppm is 
apparent. This signal corresponds to intermediate A which was previously observed in 
Figure 3.2 and 3.3 in incubations with 5'-FDA 54. During the time course the intensity of 
this signal increases. Although fluoroacetaldehyde 48 does not accumulate in this 
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experiment, presumably as it is transient, the formation of fluoroacetate 8 is apparent. No 
signal corresponding to intermediate B emerges suggesting that this compound is also 
transient in the experiment. Scheme 3.2 describes a working hypothesis of the metabolic 
fate of 5' -FDA 54 according to the CFE results so far. 
Scheme 3.2 
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Working hypothesis for the metabolic fate of 5' -FDA 54 from CFE studies. 
The data suggest a direct transformation of intermediate A to B, and then B is metabolised 
to fluoroacetaldehyde 48. Alternatively there is a transformation of intermediate A to 
fluoroacetaldehyde 48, and then fluoroacetaldehyde 48 generates intermediate B. It is 
clearly important to identify intermediate A to begin to resolve these scenarios. An 
important strategy towards identifying the remaining intermediates involves blocking 
individual steps along the biosynthetic pathway to encourage the build up of intermediates. 
Therefore it was anticipated that the addition of various enzyme inhibitors such as EDT A 
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and iodoacetamide might selectively block key steps in the latter stages of the 
biotransformation. 
3.3.1 Effect of iodoacetamide on the fluorometabolite production 
It has previously been shown that iodoacetamide inhibited fluoroaceta1dehyde 
dehydrogenase activity, preventing fluoroacetate 8 production in CFE's.80,86 
Iodoacetamide generally inhibits enzymes with free thio1 groups. However it may inhibit 
other enzymes and result in the accumulation of A or B. Therefore, an active CFE (500 111) 
was pre-incubated with iodoacetamide (final conc.10 mM) for 25 minutes at 37°C. After 
this time, 5'-FDA 54 (100 111, 18.6 mM) was added to the reaction and incubated for 7 hrs 
at 37°C (Figure 3.5(ii)). 
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fluoroacetate 8 5'-FDI 55 
/ 
intermediate B 
lH coupled 19F NMR spectrum 
~ ij ij ~ ~ ~~ ~ ~ ~ ~ ij 
\ I I I I I) I I I J I 
5-FDRP 81"" Lill. "~' 5'-FDI 55 
"" ' '/ 
"J l _~lliJ ~~~ 
_._- m_ ._- , I , j 
~ 
intermediate A 
/ 
4-fluorothreonine 47 
/ 
IL.-
(i) 19F CH} NMR spectrum of 5'-FDA 54 incubated with CFE for 7 hrs at 37 DC. 
(ii) 19F CH} NMR spectrum ofCFE incubated with 5'-FDA 54 for 7 hrs at 37 DC in the presence of 
iodoacetamide. 
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A control experiment, shown in Figure 3.5(i), indicates the production of fluoroacetate 8 
and 4-fluorothreonine 47 indicating that the CFE retains all of the biosynthetic activities on 
the pathway. However, in the presence ofiodoacetamide (Figure 3.5(ii)), fluoroacetate 8 (-
216.97 ppm) and 4-fluorothreonine 47 (-231.61 ppm) no longer accumulate. Although the 
experiment arrested fluorometabolite production, there was no evidence of the 
accumulation of either A or B or fluoroacetaldehyde 48 (Figure 3.5(ii)). Both 5'-FDI 55 
and 5-FDRP 81 also accumulated in this experiment. This was confirmed by HPLC 
analysis (Figure 3.6). 
metabolites 
fromCFE 
~ 
hypoxanthine 79 
/ ,denine75 
/ 
I - - --.~-.~.~-
o min 
5'-FDI 55 
5'-FDA 54 
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15 
Figure 3.6 HPLC chromatogram of CFE incubated with 5'-FDA 54 for 5 hrs at 37°C in the 
presence of iodoacetamide. 
The presence of 5' -FD I 55 was confirmed by co-inj ection using a synthetic sample. The 
presence of adenine 75 and hypoxanthine 79 in the sample was also obvious by HPLC and 
their presence can be attributed to the simultaneous action of PNP and deaminase activities 
(Section 2.2). The remaining signal in the 19F NMR spectrum corresponded to 5-FDRP 81. 
To firmly establish this, the experiment was repeated with the addition of 5-FDRP 81 to a 
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CFE. Subsequent 19F NMR analysis showed that the signal at -230.78 ppm (5-FDRP 81) 
was reinforced. 
Overall the results from this experiment show that the next enzyme responsible for the 
transformation of 5-FDRP 81 is inhibited by iodoacetamide, as 5-FDRP 81 accumulates. 
3.3.2 Effect of EDT A on fluorometabolite production 
EDTA chelates metal ions and generally inhibits metal requiring enzymes. An active CFE 
(500 ILl) was pre-incubated with EDTA (final cone. 30 mM) for 25 minutes. After this time 
5-FDRP 81 (150 ILl) was added and the reaction incubated for 16 hrs at 37 0c. The 
resulting 19F NMR spectrum is shown in Figure 3.7. 
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Figure 3.7 19F {IH} NMR spectrum of (5'-FDI 55 + 5-FDRP 81) incubated with CFE and 
EDTA for 16 hrs at 37°C. Expansion is IH coupled 19F NMR spectrum. 
In the presence of EDTA, fluoroacetate 8 and 4-fluorothreonine 47 no longer accumulate. 
Although the experiment arrested secondary metabolite production, there was no evidence 
for the accumulation of fluoroacetaldehyde 48. Three fluorine signals are apparent in 
Figure 3.7, two of these can be assigned to 5-FDRP 81 and 5'-FDI 55 based on previous 
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observations (Section 3.2). The third signal had the same chemical shift as intermediate A, 
identified in previous CFE experiments. Clearly this result suggests that EDTA inhibits 
the enzymes responsible for the biotransformation of intermediate A and that they require a 
metal ion as a cofactor. Intermediate B did not accumulate in this reaction. Scheme 3.3 
summarises the developing hypothesis. 
deaminase 
N:e
OH 
(( I "N F~N ) 
He) OH 
:e
NH2 
N (( I "N F~N ) 
He) OH 
54 
55 
shunt product 
PNP 
Intermediate B 
F~""OPO:-
i ~ ~ 
ED? \ 
'"'ecmed;a'e A E~TA. \ ! 
HO OH F 
81 48 
Scheme 3.3 Overview of EDTA effect on fluorometabolite production. 
3.4 5-Fluoro-5-deoxY-D-ribulose-l-phosphate as a biosynthetic 
intermediate 
If the transformation of 5-FDRP 81 to intermediate A proceeds along a similar line to that 
shown from the isomerisation of 5-MTRP 78 in the methionine salvage pathway (Section 
3.1), then the product generated would be 5-fluoro-5-deoxY-D-ribulose-l-phosphate (5-
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FDRibP) 121. This is an attractive prospect as 5-FDRibP 121 is an ideal substrate for an 
aldolase (see Chapter 4). An aldolase could mediate a retro-aldol reaction to give 
fluoroacetaldehyde 48, which has already been established as a biosynthetic intermediate. 
Scheme 3.4 illustrates the isomerisation catalysed by such a putative isomerase. 
Scheme 3.4 
FW"PPO: 
HO OH .. keto-Isomerase 
81 
OH 0 
~OPO:-
F OH 
121 
Intermediate A 
Proposed biotransformation of 5-FDRP 81 in S. cattleya. 
3.4.1 Enzymatic preparation of 5-fluoro-5-deoxy-n-ribulose 
Aldolases have been widely used to prepare a variety of modified carbohydrates, 
particularly ribuloses. 154 However, following the pioneering work by Bock and co-
workers,155 an alternative to the aldolase based method has involved xylose isomerase (EC 
5.3.1.5).156 5'6-Aldofuranoses are isomerised to open-chain ketosesl57-159 and this enzyme 
has been shown to catalyse the isomerisation of various aldofuranoses such as D-erythrose, 
as well as homologous C-5 modified D-ribose derivatives. Ebner and co-workersl60 have 
shown that 5-FDR 80 is a substrate for the xylose isomerase (Scheme 3.5). 
Scheme 3.5 
F~OH 
HO OH 
80 
(Ee 5.3.1.5) MOH 
F OH 
122 
Enzymatic reaction catalysed by xylose isomerase in presence of 5-FDR 80. 
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The product 5-fluoro-5-deoxY-D-ribulose (5-FDRib) 122 is the de-phosphorylated 
analogue of 5-FDRibP 121, our proposed biosynthetic intermediate. Therefore, it seemed 
appropriate to compare the product generated from the xylose isomerase reaction, 5-FDRib 
122 with the de-phosphorylated intermediate A from S. cattleya. If both compounds are 
the same, this would provide proof of structure. The addition of a phosphatase to the 
accumulated intermediate A will result in the hydrolysis of the phosphate ester to give 122. 
Scheme 3.6 outlines the experimental strategy. 
2-FV"'OPO, _= __ 
He) OH keto-Isomerase 
81 S. catt/eya 
F~OH 
He) 'OH 
xylose Isomerase 
(EC 5.3.1.5) 
80 
OH 0 
~OPO:-
F OH 
121 
(intermediate A) 
j phosphatase (EC 3.1.3.1) 
MOH 
F OH 
122 
Scheme 3.6 Two complementary routes towards the synthesis of 5-FDRib 122. 
Xylose isomerase (EC 5.3.1.5 from Streptomyces murinus) was used for the production of 
5-FDRib 122 from 5-FDR 80. In order to perform the reaction, a synthetic sample of 5-
FDR 80 prepared by Mayca Onega,161 University of St Andrews, was obtained and 
incubated in the presence of xylose isomerase. A 19F NMR time course experiment was 
conducted, in real time by incubation of 5-FDR 80 (final cone. 4.7 mM) with immobilised 
xylose isomerase and spectra recorded at hourly intervals for six hrs at 60 °c. The 
resulting 19F NMR spectra are shown in a stacked format in Figure 3.8. 
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The results from the control experiment show the presence of the two anomers of 5-FDR 
80, (~-anomer -228.47) (td, 2 }P,H 47.3 and 3 }P,H 25.8), (a-anomer -230.78) (td, 2}p,H 47.3 and 
3 JF,H 27.3). Upon close inspection the depletion of these fluorine signals is obvious with 
the concomitant emergence of a third signal at -231.17 ppm (dt, 2}p,H 46.9 and 3 JF,H 20.6). 
The identity of this signal is assumed to correspond to the isomer product, 5-FDRib 122. 
Incubation times longer than 6 hrs did not result in further product formation, presumably 
due to the reversible xylose isomerase reaction reaching equilibrium. 
IH coupled 19F NMR spectrum 
recorded after 5 1m 
~ ~ ~ ~ 
I I I I 
5-FDRSO 
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Figure 3.8 19p eH} NMR time course of 5-PDR 80 incubated with xylose isomerase. 
Expansions are IH coupled 19p NMR spectra. 
A second series of experiments involved the formation of intermediate A from S. cattleya. 
An experiment was conducted in which an active CFE (500 ILl) was pre-incubated with 
EDTA (final cone. 30 mM) for 25 minutes. After this time, 5-FDRP 81 was added to the 
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pre-incubated sample and the reaction was monitored at hourly intervals again for 6 hrs at 
37°C (Figure 3.9). 
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Figure 3.9 (a) 19p {lH} NMR time course of a CPE incubated with 5-PDRP 81 and EDTA. 
(b) lH coupled 19p NMR spectrum after 6 hrs, expansion of region -230.10 ppm to -231.80 ppm. 
The resulting stacked 19F NMR spectrum shows the starting material 5-FDRP 81 and 
residual 5' -FDI 55. A fluorine signal is apparent at -228.44 ppm in the control experiment 
which remains metabolically inert during the time course. The identity of this signal was 
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shown to be 5-FDR 80, which is probably the result of an adventitious phosphatase activity 
present from the crude immobilised PNP. A third fluorine signal is shown to emerge after 
one hour incubation, with an increase in intensity over the 6 hrs. The signal corresponds to 
intermediate A. 
Each of the resulting 19F NMR samples from the time course in Figure 3.9 was 
supplemented with a phosphatase (EC 3.1.3.1, from bovine intestinal mucosa) (20 tLI, 10 
mg / ml) and incubated for a further 2 hrs at 37°C. The results are presented in Figure 
3.10. 
IH coupled 19F NMR spectra after 6 hrs incubation at 37°C 
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Figure 3.10 19F {lH} NMR time course after addition of a phosphatase to the 19F NMR samples 
from the time course in Figure 3.9. Expansions are IH coupled 19F NMR spectra. 
The two signals at -228.45 ppm (dt, 2Jr,H 47.0 and 3JF,H 26.4) and -230.74 ppm (dt, 2JF,H 
47.3 and 3 Jr,H 26.8) correspond to the two anomers of 5-FDR 80. This can be explained by 
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the hydrolysis of the phosphate ester of umeacted 5-FDRP 81. The addition of 
phosphatase also resulted in a small change in the chemical shift in the 19F NMR signal 
from -231.32 ppm to -231.18 ppm consistent with the notion that intermediate A contained 
a phosphate group. To confirm this unambiguously the product of the xylose isomerase 
reaction; 5-FDRib 122 was added to the de-phosphorylated product obtained from the 
CFE's from Figure 3.10. The compounds were identical as judged by 19F NMR as shown 
in Figure 3.11. 
5'-FDI 55 
(a) / 
5-FDRSO 5-FDRSO 
5-FDRib 122 
I' J> m (II) 
(b) 5-FDRSO 
~I 5-FDRSO 
5-FDRib 122 
~ 
PI'''' (11) 
(c) 
5-FDRib 122 
/ 
ppm 1ft) 
Figure 3.11 19F CH} NMR spectra of (a) CFE incubated with 5-FDRP 81 and EDTA for 16 hrs 
at 37 DC, supplemented with phosphatase. (b) 5-FDR 80 incubated with xylose isomerase for 3 hrs 
at 60 DC. (c) Spectrum from (a) and (b) combined. 
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These results indicate that the de-phosphorylation product of intermediate A and the 
enzymatically prepared 5-FDRib 122 are identical. This reinforces the presence of an 
isomerase activity in S. cattleya which is responsible for the formation of the 
phosphorylated sugar, 5-FDRibP 121. 
3.4.2 The role of 5-fluoro-5-deoxy-n-ribulose 
The role of 5-FDRib 122 was explored as a possible intermediate on the biosynthetic 
pathway in S. cattleya. It was of interest to establish if 5-FDRib 122, a potential de-
phosphorylated product of 5-FDRibP 121 could support the biosynthesis of fluoroacetate 8 
and 4-fluorothreonine 47. A chemo-enzymatic preparation of 5-FDRib 122 was carried 
out using xylose isomerase (Section 5.1.13) to obtain a sample for incubation studies. Due 
to the reversible nature of the xylose isomerase reaction, 5-FDR 80 was also present in the 
reaction product. However, from control experiments it is already established that 5-FDR 
80 is metabolically inert in CFE's of S. cattleya. Accordingly, an active CFE (500 JLI) was 
incubated with this 5-FDRib 122 (100 JLI) preparation for 16 hrs at 37 °C (Figure 3.12). 
5-FDR 80 
~5-FDRib 122 
/ 
I 
r 
I-------,---m-ml-------,---~_,----------,--- f j I 
·215.0 ·220.0 ·225.0 -230.0 ·2350 
ppm (f1) 
Figure 3.12 19F {lH} NMR spectrum of 5-FDRib 122 incubated in a CFE. 
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The resultant 19F NMR spectrum shows the control experiment with three main organo-
fluorine signals corresponding to the two anomers of 5-FDR 80 and the 5-FDRib 122 
product. The subsequent experiment involving the addition of 5-FDRib 122 to a CFE 
showed no change. It is therefore concluded that 5-FDRib 122 does not support the 
biosynthesis of fluoroacetate 8 and 4-fluorothreonine 47. 
Overall, the results described in this section emphasize the importance of the phosphate 
group on 5-FDRibP 121 for fluorometabolite biosynthesis. 
3.5 Purification of the isomerase 
3.5.1 Assay for detection of isomerase activity 
A 19F NMR assay was employed to monitor the conversion of 5-FDRP 81 to 5-FDRibP 
121 catalysed by the isomerase. The assay was based on the method outlined in Section 
5.1.25, and was used at each purification stage. 
3.5.2 Step 1: Ammonium sulfate precipitation 
The first stage of protein purification after CFE generation, involved the addition of 
ammonium sulfate (NH4)2S04 to salt out the desired protein. It was previously shown to 
be an important step during PNP purification (Section 2.3.2), and was considered an 
attractive step to initiate isomerase purification. Four (NH4)2S04 cuts were used for 
precipitations (0-35 %, 35-50 %, 50-60 %, 60-80 %). After (NH4)zS04 addition to the 
CFE, the solution was left to stir for 20 min at 4 DC. After this time the precipitated protein 
was removed by centrifugation (14, 000 rpm / 20 min) and the supernatant used for the 
next (NH4)2S04 cut. Each of the (NH4)zS04 cuts was assayed in the following way. 
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Partially purified CFE (200 JLI) was supplemented with 5-FDRP 81 prepared from the 
method outlined in Section 5.1.9 and incubated for 16 hrs at 37 0C. The resulting samples 
were analysed by 19F NMR and can be seen in Figure 3.13. 
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" 
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5-FDRP 81 
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Figure 3.13 19p CH} NMR spectra of ammonium sulfate cuts incubated with 5-PDRP 81. 
The data shows that the 35-60 % cut contained all of the biosynthetic enzymes and 
cofactors to support fluoroacetate 8 and 4-fluorothreonine 47 biosynthesis. The isomerase 
activity is contained predominantly in the 35-50 % cut with a minor amount in the 50-60 % 
cut. No activity was detected in any of the other fractions, which only contained 5-FDRP 
81 and 5'-FDI 55. The transfonnation of 5-FDRP 81 to 5-FDRibP 121 could not be 
detected in real time; therefore, an experiment was conducted in a similar manner to that in 
Section 3.3.2 which involved the addition of EDTA. The 35-50 % cut (l00 JLI) was pre-
incubated with EDTA for 25 min at 37 °C. After this time, the pre-incubated sample was 
supplemented with 5-FDRP 81 and incubated for 16 hrs at 37 °C. Analysis by 19F NMR 
spectroscopy (Figure 3.14) shows the 35-50 % cut was able to support the synthesis of 5-
FDRibP 121. This indicates that the addition of a metal ion cofactor is not required for 
isomerase activity. 
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Figure 3.14 19p {'H} NMR spectrum of 35-50% (NH4)2S04 cut incubated with 5-PDRP 81 and 
EDTA for 16 hrs at 37°C, 
The two organo-fluorine signals apparent in the resultant spectrum are assigned to 5' -FD I 
55 and 5-FDRibP 121. The presence of 5'-FDI 55 was additionally confirmed by HPLC 
and co-injection experiments using a synthetic sample. 
3.5.3 Step 2: Hydrophobic interaction chromatography 
It was shown in Section 2.3.3 that hydrophobic interaction chromatography proved to be a 
successful second step during PNP purification. The application of this technique towards 
isomerase purification was explored, based on the previous protocol. Consequently, a 
(Phenyl HP, 40 ml) column was equilibrated with phosphate buffer (50 mM, pH 6.8) 
supplemented with 1 M (NH4)2S04. The 35-50 % (NH4hS04 precipitate was re-dissolved 
in equilibration buffer (6 ml, 20 mg I ml) and applied to the column and subsequently 
eluted according to Section 2.3.3. The resulting protein elution chromatogram is shown in 
Figure 3.15. 
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Figure 3.15 Step 2: Phenyl HP (40 ml) chromatogram obtained after a second stage 
purification. 
The chromatogram shows several protein fractions eluting during the purification protocol. 
The eluted fractions were analysed by 19F NMR spectroscopy after incubation of each 
fraction (200 fll) with 5-FDRP 81 (16 hrs at 37°C). Isomerase activity was shown to elute 
at the end of the gradient (highlighted area), indicating a strong affinity to the resin. 
Overall, purification by hydrophobic interaction chromatography proved to be a successful 
technique as it removed a substantial amount of undesired protein. 
3.5.4 Step 3: Size exclusion chromatography 
For the next purification step, size exclusion chromatography was explored. This involves 
the separation of proteins according to molecular weight. Proteins that have a higher 
molecular weight are eluted faster than those with lower molecular weights. An advantage 
of using size exclusion at this stage is that the active isomerase fraction from the 
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hydrophobic interaction chromatography (mC) only requires concentrating prior to 
injection. 
The protein (2 ml, ~8 mg / ml) was applied to a pre-equilibrated Superdex 200 column at a 
flow rate of 1 ml / min. Figure 3.16 shows the resulting chromatogram obtained after 
purification by size exclusion chromatography. 
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Figure 3.16 Step 3: Chromatogram obtained by size exclusion chromatography usmg a 
Superdex 200 column (120 ml) after injection of 2 ml sample from HIC purification. 
Fractions were assayed for isomerase activity and the activity was found to elute between 
72 - 80 ml (highlighted area) with a protein concentration of ~ 0.5 mg / ml. Although base 
line separation wasn't achieved, a substantial amount of undesired protein was removed. 
Further purification was clearly required to move towards a pure protein. 
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3.5.5 Step 4: Anion exchange chromatography 
Anion exchange chromatography was now explored to purify the active fractions further 
following the protocol in Section 2.3.4 for PNP purification. The combined active 
fractions from step 3 (8 ml) were concentrated (2 ml) by centrifugation. The concentrated 
protein was then passed through a desalting column (HiTrapTM desalting, 5 ml) and re-
concentrated to ~ 2 ml by the same method. 
I The 2 ml sample was loaded onto the strong anion exchange column (Q, 5 ml, Amersham 
Biosciences) pre-equilibrated with tris buffer (50 mM, pH 7.2) . Elution was achieved by a 
stepwise gradient following the PNP protocol. The elution profile is shown in Figure 3.17. 
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Figure 3.17 Step 4: Chromatogram obtained by anion exchange using a Q, 5 ml column after 
injection of (2 ml) from size exclusion purification. 
Each fraction was assayed for isomerase activity using the assay outlined in Section 5.1 .25. 
This showed that the desired activity eluted after 250 mM KCI addition with a total protein 
concentration of 1. 5 mg / ml. It is clear from the trace in Figure 3.17 that further 
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purification is needed. Only a small proportion of undesired protein was removed in this 
step and it is evident that that the desired protein is not yet homogenous. 
3.5.6 Isomerase analysis by SDS-PAGE 
Each stage of the protein purification was monitored by SDS-P AGE and is shown in 
Figure 3.18. 
1 2 3 0 
97 kDa 
66 kDa 
55 kDa 
36 kDa 
31 kDa 
21 kDa 
14 kDa 
6 kDa 
Figure 3.18 SDS PAGE gel (4-12% acrylamide) showing active protein fractions containing 
isomerase activity during each purification step. Lanes : 0, molecular markers 1, hydrophobic 
interaction chromatography, 2, size exclusion chromatography, 3, anion exchange chromatography. 
In the end a partially purified fraction that was able to catalyse the isomerisation of 5-
FDRP 81 to 5-FDRibP 121 was obtained. 
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3.6 Metabolic fate of 5-FDRibP in S. cattleya 
This section details work that was carried out to investigate the subsequent metabolism of 
5-fluoro-5-deoxY-D-ribulose-l-phosphate (5-FDRibP) 121 within S. cattleya. It was 
previously shown that intermediate B was formed in CFE incubations from 5' -FDA 54. 
This led to two plausible routes to account for intermediate B formation, either from 5-
FDRibP 121 or from fluoroacetaldehyde 48 (Scheme 3.7). 
Scheme 3.7 
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Possible relationships between 5-FDRibP 121 and intermediate B in S. cattleya 
Firstly, it is possible that 5-FDRibP 121 undergoes enzymatic epimerization to afford its 
diastereoisomer (intermediate B), which is then metabolised via a dihydroxyacetone 
phosphate dependent aldolase to give fluoroacetaldehyde 48. The alternative pathway 
assumes that intermediate B is a shunt metabolite and not involved directly in the 
fluorometabolite pathway. In this case intermediate B is formed from fluoroacetaldehyde 
48 by the action of an adventitious DHAP aldolase operating in the CFE. Although both 
routes are plausible, the identity of intermediate B as a diastereoisomer of 5-FDRibP 121 
became a research focus. 
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3.6.1 Enzymatic preparation of 5-fluoro-5-deoxy-n-xylulose 
Xylose isomerases exhibit a wide substrate tolerance and have been shown to catalyse the 
isomerisation of 5-fluoro-5-deoxY-D-xylose (5-FDX) 124 to 5-fluoro-5-deoxY-D-xylulose 
(5-FDXyu) 125 as shown in Scheme 3.8. 154 
o OH F~v! ~se Isomerase 
M H (EC 5.3.1.5) 
HO 0 Mg2+ 
124 
OH 0 
F~OH 
OH 
125 
Scheme 3.8 Enzymatic reaction of xylose isomerase in the presence of 5-FDX 124. 
A synthetic sample of 5-FDX 124 was used (prepared by Mayca Onega, University of St 
Andrews)161 as a substrate and was incubated with xylose isomerase (EC 5.3.1.5). A time 
course experiment was conducted following the reaction at hourly intervals for 5 hrs at 60 
°c. The resulting 19F NMR spectra are shown in Figure 3.19. 
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Figure 3.19 19F CH} NMR time course of xylose isomerase incubated with 5-FDX 124. 
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The two fluorine signals at -228.49 ppm and -230.57 ppm represent the two anomers of 5-
FDX 124. A third organo-fluorine signal accumulates at -228.53 ppm (dt, 2JF,H 47.0 and 
3 JF-H 15.9) over the 5 hrs. This signal corresponds to the expected product 5-FDXyu 125, 
as deduced by comparison with the literature. 1s4 It was envisaged that 5-FDXyu 125 could 
now be prepared in S. cattleya by phosphatase activity on intermediate B. Comparison 
with 5-FDXyu 125 from the xylose isomerase reaction would confirm its structure. 
Scheme 3.9 outlines the two routes taken to identify 5-fluoro-5-deoxY-D-xyulose-l-
phosphate (5-FDXyuP) 126 as intermediate B. 
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(EC 3.1.3.1) 
MOH 
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Scheme 3.9 Proposed routes towards the synthesis of 5-FDXyu 125. 
Accordingly, 5'-FDA 54 was incubated in a CFE for 8 hrs at 37°C. After this time the 
sample was heated to 100°C for 3 minutes and the precipitated protein removed by 
centrifugation. 19F NMR analysis showed the presence of intermediate B (-228.22 ppm). A 
phosphatase from bovine intestinal mucosa was then added to the sample and the reaction 
was incubated for 2 hrs at 37°C. The resulting 19F NMR spectra showed a new signal at -
228.49 ppm. The identity of the dephosphorylated product from S. cattleya was then 
confirmed by comparison with the reference sample of 5-FDXyu 125 produced 
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independently from 5-FDX 124 via the xylose isomerase protocol. 19F NMR analysis of 
both reaction products showed signals with identical chemical shifts and coupling 
constants. To reinforce this result, the samples were admixed and again they were 
identical. In conclusion, it appears that intennediate B is the diastereoisomer of 5-FDRibP 
121. 
3.6.2 The role of 5-fluoro-5-deoxy-n-xylulose 
5-FDXyu 125 was explored as a biosynthetic intennediate on the fluorometabolite 
pathway. It was shown in Section 3.4.2 that 5-FDRib 122 remains metabolically inert in a 
CFE and is therefore unable to support secondary metabolite production. Having a chemo-
enzymatic method for the synthesis of 5-FDXyu 125 it was of interest to see if this 
compound is metabolised in a CFE of S. cattleya. Consequently, 5-FDXyu 125, prepared 
as described above, was incubated in a CFE of S. cattleya. This transfonnation was 
analysed by 19F NMR spectroscopy, however there was no change and 125 was 
metabolically inert (Figure 3.20). 
lH coupled 19F NMR spectrum 
ij" ij ~~ ~ ~~ ~~. 
i III III II 5-FDXyu 125 
lH coupled 19F NMR spectrum 
ij" 
I 
~ L/ 5-FDX 124 
AJuU~LJ 
Lh~l~,. 16hrs 
"--?-' Control 
·226,0 -227.0 -228.0 -229.0 -230.0 -231.0 -232.0 -233.0 -234.0 
ppm (f1) 
Figure 3.20 19F eH} NMR spectra ofCFE incubated with 5-FDXyu 125 for 16 hrs at 37 DC. 
Expansions are lH coupled 19F NMR spectra. 
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The result clearly demonstrates that the addition of 5-FDXyu 125 to a CFE resulted in no 
further fluorinated metabolites. The only signals present were those corresponding to the 
two anomers of 5-FDX 124 and 5-FDXyu 125 in the starting material. This reinforces that 
the phosphorylated sugars are required intermediates in fluorometabolite biosynthesis (see 
Chapter 4). 
3.7 Conclusion 
It has been revealed that in S. cattleya, a 5-fluoro-5-deoxY-D-ribose-l-phosphate isomerase 
in present which catalyses the transformation of 5-FDRP 81 to 5-fluoro-5-deoxY-D-
ribulose-I-phosphate (5-FDRibP) 121. The intermediate 5-FDRibP 121 was identified after 
comparison to a reference sample prepared by a chemo-enzymatic route using a xylose 
isomerase. Accordingly, the dephosphorylation of 5-FDRibP 121 from S. cattleya by the 
action of a commercial phosphatase gave the free sugar, which was correlated to a 
reference sample. These experiments reinforce 5-FDRibP 121 as an intermediate in 
fluorometabolite biosynthesis. 
The identity of this isomerase from S. cattleya has led to a partially purified protein extract 
by ammonium sulfate precipitation, hydrophobic interaction chromatography, size 
exclusion chromatography and anion exchange chromatography. 
The biotransformation of 5-FDRibP 121 to fluoroacetaldehyde 48 remains unclear. The 
experimental data presented in this chapter suggest two alternative pathways. Firstly, a 
direct transformation of 5-FDRibP 121 to intermediate B, and then B is metabolised to 
fluoroacetaldehyde 48. The alternative pathway involves a direct transformation of 5-
FDRibP 121 to fluoroacetaldehyde 48, and then fluoroacetaldehyde 48 generates 
intermediate B in an adventitious reaction. 
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The identity of intermediate B was shown to be 5-fluoro-5-deoxY-D-xylulose-l-phosphate 
(5-FDXyuP) 126, a diastereoisomer of 5-FDRibP 121. Such sugars are well known 
products of dihydroxyacetone phosphate dependent aldolases and the reverse aldol reaction 
could clearly generate fluoroacetaldehyde 48. This is discussed in Chapter 4. 
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4 DHAP aldolases from S. cattleya 
This chapter describes the identification of two dihydroxyacetone phosphate (DHAP) 
dependent aldolases, one of which is involved in fluorometabolite biosynthesis in S. 
cattleya and generates fluoroacetaldehyde 48 from 5-fluoro-5-deoxY-D-ribulose-l-
phosphate (5-FDRibP) 121. The other, an L-fructose 1,6-bisphosphate aldolase (L-fruA) 
has been purified to homogeneity and appears to be responsible for the formation of 5-
fluoro-5-deoxY-D-xylulose-l-phosphate (5-FDXyuP) 126, a diastereoisomer of 121, that is 
not an intermediate on the pathway. By way of introduction, a short review of DHAP 
aldolases is given below. 
4. 1 Dihydroxyacetone phosphate (DHAP) dependent aldolases 
DHAP dependent aldolases catalyse the reversible aldol reaction of DHAP 123 and an 
aldehyde acceptor. There are four possible stereochemical outcomes all of which are 
catalysed by different enzymes and the four DHAP dependent aldolases have enjoyed a 
significant level of interest in biotransformations because of their capacity to construct two 
stereo genic centres in one reaction.162-166 Scheme 4.1 illustrates these stereochemical 
outcomes. All four of these aldolases possess a high specificity for DHAP 123, but show 
tolerance for a variety of different aldehyde electrophiles. 
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Scheme 4.1 L-Fuculose-1-phosphate aldolase (L-FucA) (E.C. 4.1.2.17), L-Rhamnulose-1-
phosphate aldolase (L-RhuA) (E.C. 4.1.2.19), L-Tagatose 1,6-bisphosphate aldolase (L-TagA) (E.C. 
4.1.2.40) and L-Fructose 1,6-bisphosphate aldolase (L-FruA) (E.c. 4.1.2.13).167,168 
DHAP dependent aldolases are either Class I or Class II depending on their mechanism, 
although they catalyse identical reactions. 168 Class I aldolases form a Schiff-base 
intermediate. 169 These aldolases are generally homotetrameric enzymes found III 
eukaryotes or higher organisms, although Class I aldolases have been reported III 
prokaryotes. 170 The generally accepted catalytic reaction of Class I aldolases, proceed via 
the formation of an iminium intermediate between a lysyl group at the active site and the 
carbonyl of DHAP 123. 171 ,172 A general mechanism for the Class I fructose 1,6-
bisphosphate aldolase is shown in Scheme 4.2. 
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Scheme 4.2 General mechanism for Class I L-fructose 1,6-bisphosphate aldolase (L_FruA).169 
Class II DHAP dependent aldolases are generally found in prokaryotes and lower 
eukaryotic organisms such as yeast, fungi and algae. 173 These enzymes are homodimeric 
and require a divalent metal ion, usually Zn2+ as an essential Lewis acid cofactor. They are 
inhibited by chelating compounds such as EDTA which sequester the Zn2+. 174 The 
mechanism of the Class II enzymes which is highlighted in Scheme 4.3 is less well 
understood than that of the Class I enzymes.175 Scheme 4.3 shows an L-fuculose-l-
phosphate aldolase (L-FucA) which catalyses the condensation of L-Iactaldehyde 132 and 
DHAP 123. 
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Scheme 4.3 Mechanism of the Class II DHAP dependent aldolase. 176 
4.2 Stereospecificity of two DHAP aldolases using fluoroacetaldehyde 
as the substrate 
Chapter 3 discussed the identification of two diastereoisomers, 5-FDRibP 121 (Compound 
A) and 5-FDXyuP 126 (Compound B). Previous knowledge of the stereochemical course 
ofDHAP aldolases with non fluorinated substrates indicate that L-FucA generates the (3R, 
4R) stereoisomer 128,176-178 This would be the anticipated stereochemistry of 121, the 
product from the isomerase reaction in S. cattleya as shown in Section 3.4, Compound B 
(126), the other diastereoisomer identified equates to the stereoisomer with the (3S, 4R) 
127 configuration,179 generated by L-FruA. Therefore, both aldolases could be present in 
the cell free extract (CFE). Scheme 4.4 outlines the predicted stereo selectivity of the two 
aldolases from the CFE using fluoroacetaldehyde 48 as a substrate. 
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Scheme 4.4 The stereochemical relationships of the two predicted aldolases in the S cattleya 
CFE. 
4.2.1 The role of an L-fuculose-1-phosphate aldolase (L-FucA) on the 
flu oro metabolite pathway in S. cattleya 
L-FucA, the enzyme that would give the predicted stereoisomer, 5-FDRibP 121 is not 
commercially available. However, a pTrcHis C plasmid containing the Class I L-FucA 
gene from E. coli was available from LGC PromoChem. This enzyme was overproduced 
and purified according to the protocol outlined in Section 5.1.28. The product of this aldol 
reaction, 5-FDRibP 121 could be compared to the assigned 5-FDRibP 121 from S. cattleya. 
The aldol reaction was carried out in phosphate buffer (700 j-tl, 50 mM, pH 6.8) containing 
fluoroacetaldehyde 48 (20 mM + residual fluoroethanol69) and DHAP 123 (10 mM). The 
reaction was initiated by the addition of L-FucA (200 j-tl, 0.4 mg / ml) and incubated at 37 
°C for 1 hr. The sample was denatured by heating to 100 °C for 3 min and the precipitated 
protein removed by centrifugation. The clear supernatant was supplemented with 100 j-tl 
ofD20 and analysed by 19F NMR. A typical 19F NMR spectrum of the resultant product is 
shown in Figure 4.1. 
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Figure 4.1 19p eH} NMR spectra showing DHAP 123 (10 mM) and fluoroaceta1dehyde 48 
(20 mM) incubated with L-PucA for 1 hr at 37°C. 
19p NMR analysis of the aldol reaction with L-FucA showed the presence of 
fluoroacetaldehyde 48 and residual fluoroethanol 69. However, two new 19F NMR signals 
were observed at -228.21 ppm (dt, 2Jp,H 47.0 Hz 3 JF,H and 16.0 Hz) and -231.34 ppm, (dt, 
2JF,H 47.0 and 3Jp,H 16.0) which were absent from the control. The major -228.21 ppm 
signal was not anticipated during this reaction, however, it is possible that this signal 
corresponds to a diastereoisomer of 121. The chemical shift and coupling constants for the 
minor signal at -231.34 ppm clearly correlate to 5-FDRibP 121. To support this, as before 
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(Section 3.4), an experiment was performed, whereby the product was converted to the free 
sugar by the action of a phytase (EC 3.1.3.8, from Aspergillus jicuum). 
Accordingly, the product was lyophilised to remove the majority of residual 
fluoroacetaldehyde 48 and fluoroethanol 69. The lyophilised sample was then incubated in 
700 pJ phosphate buffer (50 mM, pH 6.8) and treated with the phytase. This resulted in a 
small shift in the fluorine signal from -231.34 ppm to -231.12 ppm, consistent with in vitro 
phosphate hydrolysis. The organo-fluorine signal at -231.12 ppm was then correlated to 5-
FDRib 122 by comparison with a reference sample. This was prepared from a synthetic 
sample of 5-FDR 80 by the action of xylose isomerase (see Section 5.1.13). Scheme 4.5 
outlines the correlation strategy leading to 5-FDRib 122, by these two different routes. 
0 0 OH 0 ( HO~OPO:- ~OPO:-+ 
F L-FucA F OH (EG.4.1.2.17) 
48 123 121 I Ph"", (EG.3.1.3.8) 
F\yoH frJLOH xylose Isomerase 
.... ' .. (EG. 5.3.1.5) HO OH F OH 
80 122 
Scheme 4.5 Working hypothesis leading to the formation of 5-FDRib 122 
19F NMR analysis of both enzymatic routes showed the presence of a signal at -231.12 
ppm (dt, 2JF,H46.9 and 3JF,H 20.6) (Figure 4.2 (a) and (b)). The samples were admixed and 
re-analysed by 19F NMR spectroscopy. The results confirmed that both signals were 
identical; indicating that 5-FDRib 122 is a common fluorinated product from both routes. 
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Figure 4.2 19p NMR spectra of (a), L-PucA incubated with DHAP 123 and fluoroacetaldehyde 
48 in the presence of a phytase enzyme and (b), xylose isomerase incubated with 5-PDR 80. 
These experiments suggest that the L-FucA aldolase from E. coli is not stereoselective. 
The identity of the major isomer is possibly a diastereoisomer of 121 (or its enantiomer). 
The minor product appears to be, 5-FDRibP 121, the stereoisomer relevant to the 
fluorometabolite pathway. 
The next objective was to examine further if this L-FucA produced 5-FDRibP 121 matched 
the S. cattleya product and was not for example an enantiomer (Section 3.4). A comparison 
of the chemical shift and splitting pattern (by 19F NMR spectroscopy) of 5-FDRibP 121 
prepared using the over-expressed L-FucA aldolase with the identified metabolite 5-
FDRibP 121 from the fluorometabolite pathway in S. cattleya showed both fluorine signals 
to be identical. To show that they are the same enantiomer, an experiment was conducted 
whereby commercial L-FucA was added to a pre-incubated CFE, which contained 5-
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FDRibP 121. A reduction of the fluorine signal (-231.34 pm) assigned to 121, with an 
increase in fluoroacetaldehyde 48 was envisaged. 
Therefore, a CFE of S. cattleya was incubated with 5'-FDA 54 for 6 hrs at 37 DC. The 
resultant denatured sample was analysed by 19F NMR which showed the CFE retained all 
of its biosynthetic activities. (Figure 4.3, Spectrum (a)). L-FucA (100 ILl, 0.2 mg / ml) was 
then added to the sample recorded in Spectrum (a) and incubated for 1 hr at 37 DC. The 
resulting 19F NMR spectrum is shown in Spectrum (b), Figure 4.3. 
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Figure 4.3 IH coupled 19F NMR spectra (expansion of region -230.5 ppm to -231.8 ppm) 
containing CFE incubated with 5'-FDA 54 for 6 hrs at 37°C (Spectrum a), and incubation with L-
FucA for 1 hr at 37°C. (Spectrum b). 
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Spectrum (a) shows a 19F NMR expansion illustrating most of the fluorinated intermediates 
on the biosynthetic pathway. After treatment with L-FucA (Spectra (b)), it is evident that 
5-FDRibP 121 (-231.34 ppm) is significantly diminished and that fluoroacetaldehyde 48 (-
231.08 ppm) levels have increased, consistent with L-FucA accepting the S. cattleya 
product as a substrate. 
4.2.2 The role of an L-fructose 1,6-bisphosphate aldolase (L-FruA) on the 
flu oro metabolite pathway in S. cattleya 
It appeared appropriate now to explore the presence of a L-FruA aldolase in CFE's of S. 
cattleya, which would catalyse the formation of compound B, assigned as 5-FDXyuP 126. 
A commercial Class I L-FruA from rabbit muscle was used to prepare a reference sample 
of 5-FDXyuP 126. Accordingly, the aldol reaction was carried out in phosphate buffer 
(700 Ill, 50 mM, pH 6.8) containing fluoroacetaldehyde 48 (20 mM + residual 
fluoroethanol 69) and DHAP 123 (10 mM). The reaction was initiated by the addition of 
L-FruA (20 Ill, 2 mg / ml) and incubated at 37 DC for 1 hr. The sample was then denatured 
by heating to 100 DC for 3 min and the precipitated protein removed by centrifugation. The 
clear supernatant was supplemented with 100 III of D20 and analysed by 19F NMR. A 
typical 19F NMR spectrum of the resultant product is shown in Figure 4.4. 
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Figure 4.4 19F {,H} NMR analysis of L-FruA incubated with DHAP 123 (10 mM) and 
fluoroacetaldehyde 48 (20 mM) for 1 hr at 37°C. Fluoroethanol 69 is a contaminant of 48. 
The resulting 19p NMR spectrum clearly indicates the presence of a new fluorine signal at 
-228.20 ppm (dt, 2JF,H 46.2 Hz 3JF ,H and 15.3 Hz). A control reaction in the absence of the 
enzyme, showed only starting material indicating that the new fluorine signal is fonned in 
the presence of L-PruA. The peak at -228.20 ppm was assumed to be the product of the 
aldolase catalyzed reaction, 5-PDXyuP 126. It was possible to convert this product to the 
free sugar by the action of a phytase. Accordingly, the product of the L-PruA reaction was 
lyophilised to remove the majority of residual fluoroacetaldehyde 48 (and fluoroethanol 
69). A small amount of the lyophilised sample was then treated with the commercial 
phytase (Aspergillus ficuum, EC 3.1.3.8) (10 ILl, 10 mg / ml) for 1 hr at 37 dc. This 
resulted in a small shift in the fluorine signal from -228.20 ppm to -228.53 ppm. This 
product was then compared to the 19p NMR signal of a reference sample of 5-PDXyu 125 
prepared by the xylose isomerase reaction (see Section 5.1.14). Scheme 4.6 outlines the 
two complementary enzymatic routes leading to the formation of 5-PDXyu 125. 
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Scheme 4.6 Two complementary methods for the formation of 5-FDXyu 125. 
The products of both enzymatic routes were identical by 19F NMR (-228.53 ppm, td, 2JF,H 
46.2 Hz and 31r,H 15.3 Hz) (Figure 4.5 (a and b)). This was also shown by admixing both 
samples. Of course this experiment does not formally rule out the possibility that opposite 
enantiomers were generated as products; however that outcome would be inconsistent with 
previous knowledge of the stereochemical course of these reactions with non fluorinated 
substrates. 167 
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Figure 4.5 I9F NMR spectra of (a), the xylose isomerase reaction product with 5-FDX 124 for 
3 hr at 60 °e and (b), L-FruA incubated with DHAP 123 and fluoroacetaldehyde 48 for 1 hr at 37 
°e, and supplemented with a phytase enzyme (10 pJ, 10 mg / ml) for 1 hr at 37 °e. 
A Class II L-FruA aldolase from Bacillus stearothermophilus (courtesy of Professor 
Littlechild, University of Exeter) was assayed under similar conditions to that outlined in 
Figure 4.4, except Zn2+ (1 mM) was added to the reaction. This experiment was carried out 
to explore further the stereo selectivity of the L-FruA reaction. The 19F NMR spectrum 
reinforced the results in Figure 4.4, showing a single organo-fluorine signal at -228.20 ppm 
corresponding to 5-FDXyuP 126. In summary, Class I and II L-FruA aldolases generated a 
common product consistent with the production of 5-FDXyuP 126 after incubation with 
fluoroacetaldehyde 48 and DHAP 123. 
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The next objective was to examine if this L-FruA product 5-FDXyuP 126 matched 
compound Bin S. cattleya. A comparison of chemical shifts and admixing of both samples 
showed identical fluorine signals. To further support this observation, an experiment was 
conducted whereby commercial Class I L-FruA was added to a pre-incubated CFE, which 
contained compound B (5-FDXyuP 126). A reduction of compound B and an increase in 
fluoroacetaldehyde 48, in a similar manner to that shown in the previous section, was 
envisaged. 
Accordingly, an active CFE (500 ILl) was incubated with synthetic 5 '-FDA 54 (10 mM) for 
6 hrs at 37°C. After this time, the CFE was denatured by heating to 100 °c for 3 min and 
the precipitated protein centrifuged. The supernatant was supplemented with 100 ILl of 
D20 and analysed by 19F NMR which showed a number of organo-fluorine signals 
(Spectra (a), Figure 4.6) including compound B. The second experiment consisted of the 
addition ofL-FruA to the denatured sample recorded in Spectrum (a) which was incubated 
for 2 hrs at 37°C and subsequently analysed by 19F NMR. (Spectrum (b), Figure 4.6). 
(a) (b) 
fluoroaceta1dehyde 48 
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Figure 4.6 19F {lH} NMR spectra of (a), CFE incubated with 5'-FDA 54 for 6 hrs at 37°C 
and (b), incubation of sample recorded in Spectrum (a) with L-FruA (2 mg) for 2 hrs at 37°C. 
The resulting 19F NMR spectrum in Figure 4.6(a) shows all of the fluorinated metabolites 
on the pathway including fluoroacetate 8 (-216.92 ppm) and 4-fluorothreonine 47 (-231.54 
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ppm). The two major signals belong to 5-FDRP 81 (-230.79 ppm) and 5'-FDI 55 (-230.87 
ppm). 5' -FDA 54 is not observed, indicating that it is completely metabolised by the 
simultaneous actions of PNP and deaminase activities. Fluoroacetaldehyde 48 (-231.03 
ppm) and 5-FDRibP 121 (-231.33 ppm) are clearly apparent. The organo-fluorine signal at 
-228.21 ppm corresponds to Compound B (5-FDXyuP 126). The 19F NMR spectrum 
recorded in Figure 4.6(b) shows the subsequent addition of the Class I L-FruA. 
Comparison of both samples clearly illustrates that the addition of L-FruA resulted in the 
consumption of the fluorine signal corresponding to compound B, with a corresponding 
increase in fluoroacetaldehyde 48 production. This confirms that compound Band 5-
FDXyuP 126 are one and the same. 
An experiment was conducted to further support this observation. This consisted of adding 
enzymatically prepared 5-FDXyuP 126 to the S. cattleya CFE for 16 hrs at 37°C. Analysis 
of the product by 19F NMR showed the transformation of 5-FDXyuP 126 to 
fluoroacetaldehyde 48, emphasizing the presence of an L-FruA operating in S. cattleya. 
L-FruA is an enzyme of primary metabolism,169 and therefore, there is some ambiguity 
about its role on this pathway. All activities are released in the CFE, and probably 
compound B (5-FDXyuP126) is not a relevant intermediate in the fully constructed cells. 
4.2.3 Monitoring both aldolase activities in S. cattleya by 19F NMR 
In order to study both aldolase reactions in real time, a time course experiment was 
performed in which a CFE (500 ILl) of S. cattleya was incubated with DHAP 123 (10 mM) 
and fluoroacetaldehyde 48 (20 mM containing residual fluoroethanol 69). Figure 4.7 
shows 19F NMR spectra recorded every 2 hours for an 8 hr period (at 37°C). The signal at 
-216.93 ppm which corresponds to fluoroacetate 8 is most obvious and arises due to the 
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aldehyde dehydrogenase which oxidises fluoroacetaldehyde 48 to fluoroacetate 8. 4-
Fluorothreonine 47 is also apparent at -231.51 ppm. The signals at -224.42 ppm and 
-231.04 ppm belong to fluoroethanol 69 and fluoroacetaldehyde 48 respectively. The two 
aldol products 121 and 126 at -228.20 ppm and -231.34 ppm are apparent after 2 hrs of 
incubation. Both of these signals begin to diminish over the 8 hr period showing the 
reversible nature of aldol reactions. 
lH coupled 19F NMR spectra after 2 hrs incubation 
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Figure 4.7 19F {lH} NMR spectra time course of cell-free extract incubated with DHAP 123 
and fluoroacetaldehyde 48. Expansions are lH coupled 19F NMR spectra. 
In conclusion, the results described in the last three sections suggest the action of L-FucA 
and L-FruA activities in CFE's of S. cattleya. The relationships between both aldolases 
and intermediates are shown in Scheme 4.7, based on the experiments and results 
conducted so far. The earlier idea that 121 and 126 are linked by an epimerase is now less 
relevant in the light of these experiments. 
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Scheme 4.7 Working hypothesis of the metabolic fate of 5-FDRP 81. 
4.2.4 Effect of EDT A on DHAP dependent aldolase activity in S. cattleya 
Having established both aldolase products in the CFE, the next objective was to detennine 
whether the enzymes that process them are Class I or II aldolases. A key experiment for 
detennination of Class II activity involves the addition of EDTA to sequester divalent 
metal ions. A CFE (500 ILl) was pre-incubated with EDTA (final conc. 30 mM) for 25 min 
at 37°C. After this time, DHAP 123 (10 mM) and fluoroacetaldehyde 48 (20 mM) were 
added to the reaction which was incubated for a further 2 hrs at 37°C. Figure 4.8 shows 
the resultant 19F NMR spectrum. 
fluoroacetaldehyde 48 
~ 
/ fluoroacetate 8 \ fluoroethanol 69 
--,---m-----.-------,_~ __ .------ I I i I 
ppm (11) -215.0 -220.0 -225.0 -230.0 -235.0 
Figure 4.8 19F CH} NMR spectrum showing the CFE incubated with DHAP 123 and 
fluoroacetaldehyde 48 for 2 hrs at 37 DC in the presence of EDT A. 
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It is clear from the spectrum and under controlled conditions that the addition of EDTA 
resulted in complete inhibition of aldolase activity. There are no 19F NMR signals 
corresponding to 5-FDRibP 121 (-231.34 ppm) or 5-FDXyuP 126 (-228.21 ppm). This 
result clearly supports the action of Class II aldolases in S. cattleya. This observation is 
also reinforced by the results generated in Section 3.3.2, which showed that the addition of 
EDTA to a CFE incubated with 5-FDRP 81 resulted in the accumulation of 5-FDRibP 121. 
A 19F NMR time course of this experiment is shown in Figure 4.9. 
lH coupled 19F NMR spectra after 6 hrs incubation 
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Figure 4.9 19F {lH} NMR time course recorded every hour for 8 hrs showing a CFE (500 Ill) 
incubated with (5-FDRP 81+5'-FDI 55) and supplemented with EDTA. 
It is clear from the 19F NMR spectra in Figure 4.9 that 5-FDRibP 121 accumulates and that 
there is no fluoroacetaldehyde 48 indicating inhibition of the aldolase by the addition of 
EDTA. A further experiment was conducted to show the conversion of 5-FDRibP 121 to 
fluoroacetaldehyde 48 by L-FucA. This involved preparing a partially purified protein 
extract containing PNP and isomerase activity (Section 2.3 and 3.5) from S. cattleya, 
which was supplemented with 5'-FDA 54. This allowed the direct transformation of 5'-
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FDA 54 to 5-FDRibP 121. Addition of over-expressed Class I L-FucA to this product 
promoted its conversion to fluoroacetaldehyde 48. The experimental details were as 
follows. An ammonium sulfate cut (35-50 %) of the CFE was incubated with 5' -FDA 54 
for 5 hrs at 37°C and subsequently analysed by 19F NMR. The resulting 19F NMR 
spectrum is shown in Figure 4.10(a). The Class I L-FucA was added to this sample (Figure 
4.10(a)) for 1 hr at 37°C. The result is shown in Figure 4.10(b). The 19F NMR spectrum 
in Figure 4.1 O( c) shows an increase in fluoroacetaldehyde 48 and can be compared to the 
sample from Figure 4.1 O(b) which has a lower level of fluoroacetaldehyde 48 . 
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Figure 4.10 lH coupled 19F NMR spectra of (a), 5'-FDA 54 incubated in a partially purified 
CFE for 5 hrs at 37 DC. (b), Supplemented with L-FucA and incubated for 16 hrs at 37 DC. (c), Co-
injection with 48. 
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The 19F NMR spectrum in Figure 4.1 O( a) shows three fluorinated compounds. Two of 
these correspond to 5'-FDI 55 and 5-FDRP 81. No signal for 5'-FDA 54 was observed 
indicating its rapid metabolism (PNP and deaminase) as discussed in Section 3.2. The third 
compound is 5-FDRibP 121 arising from the transformation of 5-FDRP 81 via isomerase 
activity. The spectrum in Figure 4.1 O(b) is the product after addition of the over-expressed 
Class I L-FucA to the sample in Figure 4.10(a). It is clear that 5-FDRibP 121 is completely 
consumed with a subsequent increase in fluoroacetaldehyde 48 production. To confirm the 
transformation of 121 to 48, Figure 4.10(c) shows a co-injection experiment with the 
addition of a synthetic sample of fluoroacetaldehyde 48 to the sample in Figure 4.1 O(b). 
With the presence of Class II aldolases in S. cattleya now established, it became an 
objective to purify these enzymes. Progress towards this is discussed in the next section. 
4.3 Purification of a DHAP dependent aldolase 
4.3.1 Assay for the detection of DHAP aldolase activity 
In order to purify aldolase enzymes, an appropriate assay was required. Unfortunately 5-
FDRibP 121 and 5-FDXyuP 126 are not commercially available. However, due to the 
reversibility of the aldol reaction, a 19F NMR assay was established for the detection of 
aldolase activity by the incubation of DHAP 123 and fluoroacetaldehyde 48. Although 
NMR is a time consuming assay method, the formation of the products 5-FDRibP 121 and 
5-FDXyuP 126 proved to be a sufficient assay to guide DHAP aldolase purification. The 
method described below has been used throughout the protein purification protocol when 
assaying for aldolase activity. 
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For the analysis of 121 and 126 by 19F NMR, protein fractions (200 JLI) were incubated 
with fluoroacetaldehyde 48 (20 mM), DHAP 123 (10 mM) and Zn2+ (1 mM) for 16 hrs at 
37°C. The sample was heated to 100°C for 3 min and the precipitated protein was 
removed by centrifugation. The supernatant was lyophilised to remove the majority of 
residual fluoroacetaldehyde 48 and fluoroethanol 69. It was possible to detect both 
stereo isomers by this method (Figure 4.11 ). 
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Figure 4.11 Aldolase assay: 19F CH} NMR showing a CFE incubated with fluoroacetaldehyde 
48 (20 mM) and DHAP 123 (10 mM) for 16 hrs at 37 DC. 
4.3.2 Aldolase purification by ammonium sulfate precipitation 
The CFE was sUbjected to ammonium sulfate precipitation to salt out the desired protein. 
This was previously shown in Section 2.3.2 and 3.5.2 to be a critical step during the 
purification of PNP and isomerase activities, therefore a similar approach was taken for 
aldolase purification. A total of three ammonium sulfate cuts were assayed (0-35 %, 35-50 
%,50-100 %) by the 19F NMR method outlined earlier. The resultant 19F NMR spectra are 
illustrated in Figure 4.12 
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Figure 4.12 19F {lH} NMR spectra of the ammonium sulfate cuts after the incubation with 
fluoroacetaldehyde 48 (20 mM) and DHAP 123 (10 mM) for 16 hrs at 37 °e. 
The results show that only the 50-100 % ammonium sulfate cut had aldolase activity. 
Interestingly, only diastereoisomer 5-FDXyuP 126 accumulated without 5-FDRibP 121 in 
any of the other cuts. Therefore, at this stage it would appear that L-FucA aldolase activity 
has been lost. Further purification using ammonium sulfate precipitation revealed that the 
addition of (NH4)2S04 at concentrations between 60-80 % contained the majority of the 
aldolase activity. 
4.3.3 Aldolase purification by hydrophobic interaction chromatography 
The next stage of purification involved hydrophobic interaction chromatography. A Phenyl 
HP (40 ml) column was equilibrated with phosphate buffer (50 mM, pH 6.8) containing 
1M (NH4)2S04. The resulting protein pellet after ammonium sulfate precipitation (Section 
4.3.2) was redissolved in buffer at a final concentration of ~ 12 mg / ml (5 ml). The sample 
was injected in duplicate volumes onto the equilibrated Phenyl HP column. The column 
was washed at 2 ml / min for three column volumes and subsequently eluted over a 
stepwise gradient from 1 M to 0 M (NH4)2S04 at a continuous flow rate of 2 ml / min. The 
resulting chromatogram is shown in Figure 4.13. 
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Figure 4.13 Chromatogram obtained after Phenyl HP (40 ml) column elution of the ammonium I I . 
sulfate (60-80 %) fraction. 
I 
The application of hydrophobic interaction chromatography proved successful as it 
removed a substantial amount of unwanted protein. The elution profile in Figure 4.13 
shows unwanted protein eluting at the start of the chromatogram. During the stepwise 
, . 
gradient elution the majority of protein eluted after 0.6 M (N'l4)2S04, a concentration that 
was maintained to elute the unwanted protein. The gradient was applied for a further 30 
ml to a concentration of 0.3 M (N'l4)2S04 and held until the protein peaks eluted. The 
majority of aldolase activity was contained within the highlighted protein peaks in Figure 
4.13. 
4.3.4 Aldolase purification by size exclusion chromatography 
The active fractions from the hydrophobic lIP column (14 ml) were concentrated (2 ml) 
and injected onto a size exclusion column (Superdex 200, 60 x 16, Amersham Biotech) 
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which was pre-equilibrated with phosphate buffer (50 mM, pH 6.8) containing 0.3 M KCl. 
For protein elution, a flow rate of 1 ml / min was used and the eluent collected in 2 ml 
fractions . The results from the chromatogram in Figure 4.14 show the presence of several 
protein peaks. 
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Figure 4.14 Chromatogram obtained by size exclusion using a Superdex 200 column (120 ml) 
after injection of2 ml sample from IDC purification. 
The collected fractions were assayed for aldolase activity, and activity was found in the 
highlighted peak, eluting between 60 and 72 m!. 
Size exclusion chromatography removed a substantial amount of unwanted protein. 
However, there is no baseline separation between the protein peaks indicating that the 
protein is not homogenous. Further protein purification was needed in order to improve 
the level of purity. 
4.3.5 Aldolase purification by anion exchange chromatography 
The next stage of purification involved anion exchange chromatography. The active 
fractions from the size exclusion step (12 ml) were concentrated (2 ml) and desalted using 
a desalting column (HiTrapTM desalting, 5 ml, Amersham) and were then re-concentrated 
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(~ 2 ml) . The sample was applied to a strong anion exchange column (15Q, 5 ml) 
equilibrated with tris buffer (50 mM, pH 7.2). A solvent gradient was applied from 100 % 
tris buffer (50 mM, pH 7.2) to 100 % tris buffer (50 mM, pH 7.2) containing 1 M KCI 
over 80 ml at a flow rate of 2 ml / min. The initial results showed one main peak eluting 
after 300 mM KCI along with a few minor peaks. The majority of the aldolase activity was 
found to be contained within the major peak. Conditions were optimised in order to 
remove the majority of the minor contaminants by employing a step wise gradient. To 
achieve this, the gradient was maintained after 300 mM KCI elution for a further 10 min in 
order to completely elute the desired protein. After this time, the gradient was applied in a 
step wise fashion in order to completely elute the remainder of the undesired proteins. 
Fractions (4 ml) were collected and assayed according to the procedure outlined in Section 
4.3.1. The highlighted area in the chromatogram in Figure 4.15 shows active aldolase 
activity. 
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Chromatogram obtained using a 15Q anion (5 ml) column after injection of 2 ml 
protein sample from size exclusion. The highlighted area shows the active aldolase fraction. 
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A total protein concentration of 0.2 mg / ml was achieved from the protein purification 
protocol. 
4.3.6 Analysis of DHAP aldolase purification by SDS-P AGE 
The aldolase purity after each purification step was monitored by SDS PAGE where it 
became clear that one major band with a molecular subunit mass of approximately 40 kDa 
became increasingly prominent. Figure 4.16 shows the SDS PAGE analysis of the various 
fractions and indicates that the L-FruA has been purified to homogeneity. 
Figure 4.16 
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SDS PAGE gel (4-12 % acrylamide) showing active protein fractions containing 
DHAP aldolase activity during each purification step. Lanes: 1 molecular markers, .2, ammonium 
sulfate precipitation (60-80 %); 3, hydrophobic interaction chromatography; 4, size exclusion 
chromatography; 5, anion exchange chromatography. 
4.3.7 Measuring the molecular mass of the aldolase 
The monomeric subunit of the fully purified aldolase analysed by SDS-P AGE showed a 
subunit mass of approximately 40 kDa by comparison with molecular weight markers. 
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The native mass of the enzyme was determined using a HiLoad 16/60 Superdex 200 size 
exclusion column. The column was calibrated with the following marker proteins; 
apoferritin [443 kDa], amylase [200 kDa], albumin [66 kDa] and cytochrome C [12.4 
kDa]. Passing the purified DHAP aldolase down the same pre-equilibrated column 
revealed a native molecular mass of approximately 160 kDa, indicating that the enzyme is 
a homotetramer. 
4.3.8 Effect of various metal ions on aldolase activity 
A putative L-FruA has been purified to homogeneity from S. cattleya. The enzyme requires 
Zn2+ as a cofactor. The effect of other metal ions on its activity was investigated by 
conducting an assay using a partially purified aldolase fraction (100 /.Ll, 1.5 mg / ml) 
obtained after size exclusion chromatography. In order to remove any metal ions already 
present in this fraction, EDTA (10 mM) was added and the protein stirred for 20 min at 4 
DC. After this time, the sample was dialysed against 4 L oftris buffer (50 mM, pH 7.2) for 
16 hrs at 4 Dc. The dialysed sample was then assayed after addition of various divalent 
metal ions including Zn2+, Mg2+, Mn2+, C02+, Ne+, Fe2+ and Ca2+. The resulting 19F NMR 
spectra showed aldolase activity with each of the metal ions added. Additionally, 
monovalent metal ions such as Na+, K+, resulted in no activity under the described 
conditions. 
4.3.9 Sequence analysis of the aldolase 
The purified protein was treated with trypsin. After the trypsic digest a small peptide (2059 
Da) was isolated and the amino acid sequence was determined to be; -Phe-Ala-Tyr-Pro-
Ala-Ile-Asn-Val-Thr-Ser-Ser-Gln-Thr-Leu-His-Ala-Ala-LeuArg-. A database search using 
NCBI BLAST showed a homology to a fructose 1,6-bisphosphate aldolase (L-FruA) from 
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Streptomyces galbus.180 This match to a L-FruA is consistent with the stereochemical 
course of this enzyme which generates 5-FDXyuP 126 rather than 5-FDRibP 121. 
N-terminus amino acid sequence analysis of the purified L-FruA using Edman degradation 
showed that the first 20 amino acids (determined using an Applied Biosystems Procise 491 
sequencing instrument) were; -Pro-Ile-Ala -Thr -Pro-Glu -Ile-Tyr -X -Glu -Met-Leu -Asp-Arg-
Ala-Lys-Ala-Gly-Lys-Phe. The results in Figure 4.17 show a sequence alignment using 
MultiAlin of the first 20 N-terminus amino acids of L-FruA from S. cattleya related to 
homologues. 
Figure 4.17 
1 10 21 1--------+---------+1 
S.cattleya HPIATPEIYNEHLDRAKAGKF 
S.coelicolor HPIATPEIYNEHLDRAKAGKF 
S.galbus HPIATPEIYNEHLDRAKAGKF 
S. avernitilis HPIATPEIYNEHLDRAKAGKF 
Nononuraea HPIATPEIYAEHLDRAKAGGF 
Consensus HPIATPEIYnEHLDRAKAGkF 
Sequence alignment of the first 20 N-terminal amino acids of L-FruA from S. 
cattleya with bacterial homologues . Residues that are highly conserved are in red. Weakly 
conserved residues are in blue. 
Sequence analysis clearly suggests that the aldolase from S. cattleya is an L-FruA which 
catalyses the formation of 5-FDXyuP 126. This may be an enzyme of primary 
metabolism. 181 The L-FucA aldolase remains to be purified. In the early stages of the 
purification such an activity was not apparent. Perhaps this can be rationalised by a high 
level of dehydrogenase activity present during ammonium sulfate precipitation (35-50 %) 
which would prevent the reverse aldol reaction to 5-FDRibP 121. This observation is 
supported by the results in Section 3.5.2 which showed a 35-50 % ammonium sulfate cut 
containing all of the biosynthetic enzymes to support fluoroacetate 8 and 4-fluorothreonine 
47 biosynthesis. Although the second aldolase has not been purified, putative L-FucA 
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genes have been identified in other streptomycetes such as S. coelicolor and S. avermitilis. 
The main function of this enzyme is the involvement in the L_fucoseI82 and D-arabinose 
pathways. 183 
The metabolic relationships and enzymes involved in the biosynthesis of fluoroacetate 8 
and 4-fluorothreonine 47 in S. cattleya that have been discussed throughout Chapters 2, 3 
and 4 are summarised in Scheme 4.8. 
t
NH2 
N !( I ~N 
F"('jN NJ 
He OH 
54 
PNP 
o 2-
FU···,OP03 
Hcf ~H keto-isomerase 
81 
I I'l.l 
(\! 
Ii 
11 !iii 
OH 0 2 F~OP03-
Class II 
L-FucA 
OH 
121 
o jJ Threonine 
( transaldolase,.. 
F 
48 
Aldehyde 
dehydrogenase 
fo 
F 
8 
Ho 
F NH3 
47 
Scheme 4.8 Overview of the possible routes taken by 5'-FDA 54 towards the biosynthesis of 
fluoroacetate 8 and 4-fluorothreonine 47. 
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4.4 Conclusion 
It has been shown that two DHAP dependent aldolases are present on the fluorometabolite 
pathway in S. cattleya. One of these aldolases has been identified as a putative L-FucA 
which catalyses a retro-aldol reaction of 5-FDRibP 121 to fluoroacetaldehyde 48 and 
DHAP 123. This enzyme is shown to be a Class II aldolase which requires a divalent metal 
ion for catalytic activity, and it is inhibited by the chelating agent EDTA. 
A second aldolase was shown to be L-FruA which catalyses an aldol reaction between 
DHAP 123 and fluoroacetaldehyde 48 to generate 5-FDXyuP 126. This enzyme is also a 
Class II aldolase, requiring a divalent metal ion such as Zn2+, Mg2+, Mn2+, Co2+, Ni2+, Fe2+ 
and Ca2+ for catalytic activity. This enzyme was purified to homogeneity using standard 
chromatography techniques. Analysis by SDS-PAGE showed a monomeric subunit mass 
of approximately 40 kDa, and a native mass of 160 kDa was observed by gel filtration. 
This L-FruA had high sequence similarity in selected regions to other bacterial L-FruA's. 
The action of this enzyme of primary metabolism in CFE's is probably adventitious. Our 
current hypothesis assumes that 5-FDXyuP 126 (Compound B) is a shunt product 
generated during fluoroacetaldehyde 48 production. The L-FucA aldolase, most relevant to 
fluorometabolite biosynthesis remains to be purified. 
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5 Experimental 
5.1 Biochemical experimental 
5.1.1 General methods 
All commercial reagents, chemicals or enzymes were purchased from Sigma Biochemicals, 
Berry and Associates (U.S.A), and F1uka unless otherwise stated. The following 
commercial enzymes were used. 5'-Adenylic acid deaminase (EC 3.5.4.6, from Aspergillus 
species, A 1907, 0.11 units / mg), phytase (EC 3.1.3.8, from Aspergillus ficuum, P 9792, 
3.5 units / mg), phosphatase (EC 3.1.3.1, from bovine intestinal mucosa, ammonium 
sulfate suspension, P-5521, 2,000-4000 DEA units / mg), fructose 1, 6-bisphosphate 
aldolase (EC 4.1.2.13, from rabbit muscle, lyophilized powder, A 2714, 10 units / mg), 
xylose isomerase (EC 5.3.1.5, Sweetzyme T, from Streptomyces murinus, G-4166, 350 
units / mg) and immobilised crude PNP (E. coli, donated by G1axoSmithKline, EC 2.4.2.1). 
The L-fuculose-1-phosphate gene was obtained as a pTrcHis C construct (ATCC number 
86984) purchased from Promochem. The gene was over-expressed in E. coli and purified 
by nickel chromatography (see Section 5.1.28). The competent cells BL21(DE3), 
C43(DE3), BL21Star™, BL21 (DE3)pLysS, BL21(DE3)pLysE and Rosetta2(DE3) were 
purchased from invitrogen in vials containing 50 ).11 aliquots. 
19F NMR analyses were performed on Bruker vance 500 MHz (operating at 470 MHz) or 
Varian unity 500 MHz (operating at 470 MHz) spectrometers. All 19F NMR spectroscopy 
was carried out using D20 (~ 10 %) as an internal reference. Chemical shifts are given in 
ppm and coupling constants (.1) are given in Hertz (Hz). Spectral coupling patterns are 
designated as follows; d: doublet and t: triplet. High performance liquid chromatography 
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(HPLC) analyses were carried out using a solvent delivery system (230 Prostar) with an 
analytical CI8 column (see Section 5.1.17). Electro-spray mass spectrometry (ES-MS) was 
performed on a Micromass LCT time of flight instrument. Gas chromatography mass 
spectrometry (GC-MS) was carried out by Dr. J. T. G. Hamilton at the Queen's University 
of Belfast. 
HPLC was carried out using a Varian prostar system containing a solvent delivery system 
(230, ProStar) and equipped with a dual wavelength UV-Vis detector (325, ProStar) and a 
ProStar 400 autosampler. For analytical purposes, a Hypersil 5 Ilm C-18 column (250 x 10 
mm, Phenomenex) was used. Typical flow rates were 1 ml / min and sample volumes were 
100-200 III in which 20 III was automatically injected. All solvents were HPLC grade and 
filtered prior to use. The mobile phases consisted of two solvents, A, 50 mM KH2P04: 
acetonitrile (95:5) and solvent B, 50 mM KH2P04: acetonitrile (80:20). Runs were 
monitored at 254 nm by gradient elution over 30 min from 0 % B to 100 % B. 
All microbiological work was carried out in a Gallenkamp flowhood under sterile 
conditions unless stated otherwise. Glassware, media and consumables were sterilised by 
autoc1aving. Cell cultures were incubated at 28°C in a Gallenkemp orbital incubator. 
Centrifugation (>1000 Ill) was carried out either on a Beckman JA 14 instrument at 14,000 
rpm, a JA 25.5 at 20,000 rpm or a JLA 9.1 at 9,100 rpm. For micro-centrifugation (20-
1000 Ill), an Eppendorf 5415C centrifuge was used. Cell-free extracts (CFE's) were 
prepared by disrupting the cells by sonication using Sonics & Materials Inc., Vibra Cell. 
Aqueous solutions were prepared using Ultra-pure water generated by a USF elga maxima 
water supply system. 
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5.1.2 Growth and maintenance of S. cattleya on agar 
Streptomyces cattleya NRRL 8057 was originally supplied by Prof. D. B. Harper at the 
Queens University of Belfast, Microbial Biochemistry Section, Food Science Department, 
Belfast. Cultures were maintained on agar plates containing soybean flour (2 % w/v) , 
mannitol (2 % w/v), agar (1.5 % w/v) and tap water. The plates were incubated at 30 DC 
for 28 days or until sporulation could be detected. The resultant static cultures were stored 
at 4 DC for future use. 
5.1.3 Culture medium and growth conditions of S. cattleya78 
Streptomyces cattleya seed and batch cultures were grown in conical flasks (500 ml) 
containing chemically defined medium (90 ml). The medium was prepared as follows. 
Sterile ultra-pure water (450 ml) was added to ion solution (150 ml), filtered carbon 
solution (75 ml), (see Section 5.1.4), sterile phosphate buffer (75 ml, 150 mM, pH 7.0) and 
sterile potassium fluoride (3 ml, 0.5 M). The seed cultures were prepared by transferring 
spores from a static culture as described above, and added to a conical flask (500 m!) 
containing chemically defined medium (90 ml). After incubation for 6 days at 28 DC on an 
orbital shaker (180 rpm), an aliquot (0.3 ml) of spores was used to inoculate the batch 
cultures. The batch cultures were incubated at 28 DC, on an orbital shaker at 180 rpm for 6-
8 days. 
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5.1.4 Media procedure for growing S. cattleya 
Ion solution 
The following reagents were added to ultra-pure water (900 ml). 
NH4Cl 6.75 g 
NaCl 2.25 g 
MgS04.7H20 2.25 g 
CaC03 1.13 g 
FeS04.7H20 0.113 g 
CoCh.6H2O 0.045 g 
ZnS04.7H20 0.045 g. 
The solution was sterilised by autoclaving prior to use. 
Carbon source solution 
The following reagents were added to ultra-pure water (900 ml). 
Glycerol (45 g) 
monosodium glutamate (22.5 g) 
myo-inositol (1.8 g) 
para-aminobenzoic acid (450 )11 of freshly prepared solution 1 mg 1 ml) 
The solution was sterilised by filtration into pre-sterilised Schott bottles. 
5.1.5 Preparation of resting cell cultures of S. cattleya 
After 6 days of growth, cells were harvested by centrifugation (9,100 rpm 125 min) and the 
resulting pellet was washed three times with phosphate buffer (50 mM, pH 6.8). After the 
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final wash, the bacterial pellet was stored at -80 DC or could be used directly for cell free 
extract (CFE) preparation. 
5.1.6 Preparation of cell free extract (CFE) of S. cattleya 
CFE was prepared in two ways; firstly by re-suspending 0.1 g cells / ml of phosphate 
buffer (50 mM, pH 6.8) and left to stir for 20 minutes at 4 DC. The cells were then 
sonicated 6-10 times at 60 cycles for 1 min. After sonication, the cells were centrifuged at 
(14,000 rpm I 20 min) and the resultant cell pellet was discarded and the supernatant 
retained as a CFE. For experiments on the biosynthesis of fluorinated metabolites, a CFE 
was prepared under parallel conditions except by re-suspending 0.2 g of cells I ml of 
phosphate buffer (50 mM, pH 6.8). 
5.1.7 Assay to determine biosynthetic activity in a CFE of S. 
cattleya 
CFE (500 ILl) was incubated with 5'-FDA 54 (100 ILl, 18.6 mM) in phosphate buffer (50 
mM, pH 6.8) for 16 hrs at 37 DC. The sample was subsequently heated at 100 DC for 3 min 
and the denatured protein micro-centrifuged at (14,000 rpm,S min). The protein pellet was 
discarded and the supernatant retained for analysis by 19F NMR spectroscopy (470 MHz, 
10 % D20). The production offluoroacetate 8, -216.97 (t, 2 JF,H 48.2) and 4-fluorothreonine 
47 -231.60 (t, 2 JF,H 46.8) confirmed the CFE retained all its biosynthetic activities. 
Reference compounds of fluoroacetate 8 and 4-fluorothreonine 47 confirmed this 
unambiguously. Control experiments were conducted under the same conditions except 
163 
Chapter 5 
using a denatured CPE. This showed that 5' -PDA 54 is stable over an incubation period of 
16 hrs at 37°C. 
5.1.8 Incubation of 5-fluoro-5-deoxy-n-ribose (5-FDR) in a CFE 
of S. cattleya 
Synthetic 5-PDR 80 was prepared as a reference compound by S. L. Cobb,1l8 University 
ofSt Andrews. 5-PDR 80 (100 Itl, 32.9 mM) was incubated with an active CPE (500 Itl) in 
phosphate buffer (50 mM pH 6.8) for 16 hrs at 37°C. After this time the protein was 
denatured by heating to 100°C for 3 min and the precipitated protein removed by micro-
centrifugation (14,000 rpm / 5 min). D20 (100 J..tl) was added to the supernatant and the 
sample analysed by 19p NMR. bF (470 MHz, 10% D20) 5-PDR 80 ~-anomer -228. 55 
(ddd, 2Jp,H 47.0 and 3Jp,H 26.4) and a-anomer -230.86 (ddd, 2JF ,H 46.9 and 3Jp,H 26.3). 
Control experiments were carried out under similar conditions except using a denatured 
CPE. Analysis by 19p NMR concluded that 5-PDR 80 is chemically stable after 16 hrs at 
37°C. 
5.1.9 Chemo-enzymatic preparation of 5-fluoro-5-deoxy-n-ribose 
-I-phosphate (5-FDRP) 
5'-PDA 54 (18.6 mM) and adenosine deaminase (2 mg) were suspended in phosphate 
buffer (50 mM, pH 6.8) in a total volume of 1 ml for 16 hrs at 37°C. After incubation the 
sample was heated to 100°C for 3 min and the denatured protein removed from the 
solution by micro-centrifugation (14,000 rpm / 15 min). Analysis by HPLC showed 100 % 
bioconversion to 5' -PDI 55. The supernatant sample was incubated with immobilised PNP 
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(2 mg resin) and incubated at 37°C for a further 16 hrs. After this time the sample was 
denatured at 100°C for 3 min and the precipitated protein removed by micro-
centrifugation (14,000 rpm / 5 min). The sample was analysed by 19F NMR spectroscopy 
and HPLC (UV detection); 5F (470 MHz; 10 % D20) (5-FDRP 81, ~ 40 %) -230.75 (dt, 
2h ,H 47.3 and 3h ,H 28.3) and (5'-FDI 55, ,.. 60 %) -230.85 (dt, 2h ,H 47.0 and 3JF ,H 28.9). 
HPLC (UV, Iv = 254 nm) analysis indicated the production of hypoxanthine 79 and the 
presence ofumeacted 5'-FDI 55. 
An aliquot (500 Ill) was lyophilised and treated with MSTF A prior to GC-MS analysis; m/z 
505 (16%), 382 (11),353 (14), 300 (24), 299 (100) and 147 (20). ES-MS (-ve) analysis; 5-
FDRP 81 mlz 231 (M-Hr, 5'-FDI 55 mlz 269 (M-Hr, 
5.1.9.1 Incubation of 5-FDRP with a CFE of S. cattleya 
5-FDRP 81 was prepared according to Section 5.1.9. The sample contained ~60 % 5'-FDI 
55. Control experiments showed that 5'-FDI 55 is not metabolised in a CFE of S. cattleya. 
Also incubation of a denatured CFE with 5-FDRP 81 at 37°C for 16 hrs showed no 
chemical breakdown. 5-FDRP 81 (200 ttl) was incubated with a CFE (500 f.ll) in 
phosphate buffer (50 mM, pH 6.8) for 16 hrs at 37°C. After the incubation period the 
protein was denatured (100°C / 3 min) and removed by centrifugation (14,000 rpm / 5 
min). D20 (100 Ill) was added to the supernatant, which was then analysed by 19F NMR. 
The identities of the new fluorinated products were confirmed by co-injection with 
reference compounds. 5F (470 MHz, 10 % D20) fluoroacetate 8, -216.96 (t, 2h,H 48.3),5'-
FDI 55, -230.85 (dt, 2h ,H 46.9 and 3h ,H 26.9) and 4-fluorothreonine 47, -231.58 (t, 2 h,H 
46.8). HPLC (UV) analysis showed the presence of hypoxanthine 79 and 5'-FDI 55. 
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5.1.10 Incubation of 2-deoxy-5'-FDA in a CFE of S. cattleya 
Synthetic 2-deoxy-5'-FDA 59 was prepared by S. L. Cobb,118 University of St Andrews. 
, 2-deoxy-5'-FDA 59 (100 ,.d, 18.6 mM) was incubated with a CFE (SOO ILl) for 16 hrs at 37 
0c. After this time the sample was denatured at 100°C for 3 min and subsequently micro-
centrifuged at (14,000 rpm, S min). The supernatant was analysed by 19F NMR. bF (470 
MHz, 10 % D20), 2-deoxy-S-FDR 83, -227.81 (dt, 2JF,H 47.0 and 3JF,H 22.9), 2'-deoxy-
S'-FDI 84, -230.60 (dt, 2JF,H 47.0 and 3h ,H26.4). HPLC analysis showed the presence of2-
deoxy-5'-FDI 84 and hypoxanthine which was confirmed by co-injection experiments 
using synthetic standards. Control experiments were carried out under parallel conditions 
using a denatured CFE. 19F NMR and HPLC analysis showed no chemical degradation of 
2-deoxy-S' -FDA 59 over the same time period. 
5.1.11 Effect of iodoacetamide on fluorometabolite production 
Experiment 1: A CFE (490 ILl) was pre-incubated with iodoacetamide (10 ILl, O.S M) for 
2S min at 37°C. After this time 5'-FDA 54 (100 ttl, 18.6 mM) was added to the pre-
incubated CFE and the incubation continued for 16 hrs at 37°C. After this time the sample 
was denatured at 100°C for 3 min and the precipitated protein removed by micro-
centrifugation (14, 000 rpm /5 min). The supernatant was analysed by 19F NMR. bF (470 
MHz, 10 % D20), 5'-FDI 55 230.91 (dt, 2 h,H 47.0 and 3h ,H 28.9) and 5-FDRP 81 -230.87 
(dt, 2JF,H 47.0 and 3h ,H 28.7). HPLC (UV) analysis indicated the presence of 5'-FDI 55 
and hypoxanthine 79. 
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Experiment 2: A CFE (490 Ill) was pre-incubated with iodoacetamide (10 Ill, 0.5 M) for 
25 min at 37°C. The addition of5-FDRP 81 (200 Ill) containing an excess of5'-FDI 55 
was added to the pre-incubated CFE for 16 hrs at 37°C. The resulting sample was then 
denatured at 100°C for 3 min and the precipitated protein micro-centrifuged (14,000 rpm I 
5 min). The supernatant was analysed by 19F NMR. bF(470 MHz, 10% D20), 5'-FDI 55 
-230.90 (dt, 2JF,H 47.0 and 3JF,H 28.7) and 5-FDRP 81 -230.86 (dt, 2JF,H 46.9 and 3JF,H 
28.6). HPLC analysis indicated the presence of 5' -FDI 55 and hypoxanthine 79. 
5.1.12 Effect of EDTA on fluorometabolite production 
Experiment 1: A CFE (500 Ill) was pre-incubated with EDTA (final cone. 30 mM) for 25 
min at 37°C. 5'-FDA 54 (100 Itl, 18.6 mM) was then added and the incubation was 
continued for 16 hrs at 37°C. After this time the sample was denatured at 100°C for 3 
min and the denatured protein removed by micro-centrifugation (14,000 rpm, 5 min). The 
supernatant was analysed by 19F NMR. bF (470 MHz, 10% D20), 5'-FDI 55 -230.83 (dt, 
2JF,H 47.0 and 3 Jp,H 29.8), 5-FDRP 81 -230.76 (dt, 2 Jp,H 47.3 and 3 JF,H 28.3) and 5-FDRibP 
121-231.28 (dt, 2Jp,H46.8 and 3JF,H 20.6). HPLC analysis indicated the presence of5'-FDI 
55 and hypoxanthine 79. This was confirmed by co-injection experiments using synthetic 
standards. No 5' -FDA 54 was observed under these conditions. 
Experiment 2: A CFE (500 Ill) was pre-incubated with EDTA at a final concentration of 
30 mM for 25 min at 37°C. 5-FDRP 81 (200 Itl) was then added and the incubation 
continued for 16 hrs at 37°C. After this time the sample was denatured at 100°C for 3 
min and the denatured protein removed by micro-centrifugation (14,000 rpm, 5 min). The 
supernatant was analysed by 19F NMR. bF (470 MHz, 10% D20), 5'-FDI 55 -230.85 (dt, 
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2h ,H 47.0 and 3JF,H 29.8), 5-FDRP 81-230.80 (dt, 2h ,H 47.3 and 3h ,H 28.3) and 5-FDRibP 
121 -231.30 (dt, 2 JF,H 47.0 and 3 h,H 20.7). HPLC analysis indicated the presence of 5'-FDI 
55 and hypoxanthine 79. This was confirmed by co-injection experiments using synthetic 
standards. 
5.1.13 Chemoenzymatic preparation and CFE incubation of 5-
fluoro-5-deoxy-n- ribulose (5-FDRib) 
Experiment 1: Synthetic 5-FDR 80 was prepared by Mayea. Onega,2 University of St 
Andrews. Immobilised xylose isomerase (3 mg) was incubated with 5-FDR 80 (100 Ill, 
32.9 mM) in a total volume of 700 III containing phosphate buffer (50 mM, pH 6.8) for 4 
hours at 60°C. After incubation, the enzyme was denatured at 100°C for 3 min and micro-
centrifuged at (14.000 rpm I 5 min). The supernatant was analysed by 19F NMR. 8F (470 
MHz, 10% D20) 5-FDR 80, a anomer -230.78 (dt, 2h ,H 46.9 and 3 h,H 26.3), 5-FDR 80, ~ 
anomer -228.47 (dt, 2h ,H47.0 and 3JF,H 26.4) and 5-fluoro-5-deoxY-D-ribulose 122, 
-231.17 (dt, 2h ,H47.0 and 3h ,H20.6). 
Control experiments were carried out in the absence of xylose isomerase which indicated 
that 5-FDR 80 was chemically inert over the time period. 
Experiment 2: 5-FDRib 122 (100 Ill) containing an excess of 5-FDR 80 (Experiment 1) 
was incubated with a CFE (500 Ill) for 16 hrs at 37°C. After this time the sample was 
denatured at 100°C for 3 min and the precipitated protein removed by micro-
centrifugation (14, 000 rpm I 5 min). The supernatant was analysed by 19F NMR. 8F (470 
MHz, 10% D20) 5-FDR 80, a anomer -230.80 (dt, 2h ,H 47.3 and 3 h,H 27.3), 5-FDR 80, ~ 
168 
Chapter 5 
anomer -228.50 (dt, 2JF,H47.3 and 3h ,H 25.8) and 5-FDRib 122, -231.18 (dt, 2JF,H47.0 and 
3JF,H20.7). 
5.1.14 Chemoenzymatic preparation and CFE incubation of 5-
fluoro-5-deoxy-D- xyulose (5-FDXyu) 
Experiment 1: Synthetic 5-fluoro-5-deoxY-D-xylose (5-FDX) 124 was prepared by Mayca 
Onega,161 University of St Andrews. A synthetic sample of 5-FDX 124 (100 p,l, 32.9 mM) 
was incubated with immobilised xylose isomerase (3 mg) in a total volume of 700 p,l 
containing phosphate buffer (50 mM, pH 6.8) for 4 hrs at 60°C. After incubation, the 
enzyme was denatured at 100°C for 3 min and the precipitate micro-centrifuged at (14,000 
rpm / 5 min). D20 (100 p,l) was added to the supernatant, which was then analysed by 19F 
NMR. bF (470 MHz, 10 % D20) 5-FDX 124, -228.46 (dt, 2JF, H 47.0 and 3JF, H 22.9),5-
FDX 124, -230.54 (dt, 2JF, H47.0 and 3h ,H 25.2) and 5-fluoro-5-deoxY-D-xyulose 125, 
-228.50 (dt, 2JF,H47.0 and 3JF,H 16.0). 
Control experiments were performed in the absence of xylose isomerase which indicated 
that 5-FDX 124 remains chemically inert to degradation over the 16 hrs incubation at 37 
0c. 
Experiment 2: Enzymatically prepared 5-fluoro-5-deoxY-D-xyulose (5-FDXyu) 125 (100 
p,l) was incubated with a CFE (500 p,l) for 16 hrs at 37°C. After incubation, the sample 
was denatured at 100 °c for 3 min and finally micro-centrifuged at (14,000 rpm 15 min) to 
remove the denatured precipitate. Addition of D20 (100 p,l) to the supernatant was then 
analysed by 19F NMR spectroscopy, bF (470 MHz, 10 % D20), 5-FDX 124, -228.47 (dt, 
2 JF, H 46.9 and 3 h, H 21.8), 5-FDX 124, -230.55 (dt, 2 h, H 47.0 and 3JF, H 24.0), 5-FDXyu 
125, -228.51 (dt, 2JF,H46.9 and 3JF,H 15.9). 
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S.1.1S Preparation of S-fluoro-S-deoxY-D-ribulose-l-phosphate (S-
FDRibP) 
Pluoroaceta1dehyde* 48 was prepared by S. L. Cobb,ll8 University of St Andrews. A 
typical protocol for preparing 5-FDRibP 121 is as follows. F1uoroaceta1dehyde 48 (30 ,d, 
140 mM) and DHAP 123 (70 {11, 55 mM) were incubated with L-PucA (200 {1l, 0.4 mg / 
ml) in a total volume of 700 {11 with phosphate buffer (50 mM, pH 6.8) for 1 hr at 37 DC. 
After this time the sample was denatured at 100 DC for 3 min and the precipitated enzyme 
removed by micro-centrifugation (14,000 rpm / 5 min). The resulting supernatant was 
lyophilised to remove the residual fluoroacetaldehyde 48 and fluoroethanol 69 present. 
The lyophilised sample was re-suspended in H20 (700 ILl) and analysed by 19p NMR. OF 
(470 MHz, 10 % D20), (5-fluoro-5-deoxY-D-ribulose-l-phosphate 121, 30 %), -231.34 (dt, 
2JF,H 47.0 and 3 JF,H 20.7), (diastereoisomer of 121, 70 %), -228.21 (dt, 2Jp,H 46.2 and 3 JF,H 
15.3). 
Control experiments were carried under the same conditions in the absence of L-PucA. The 
product was subsequently analysed by 19F NMR. OF (470 MHz, 10 % D20), 
fluoroacetaldehyde 48 -231.04 ppm and fluoroethanol 69 -224.50 ppm. 
* The preparation offluoroacetaldehyde 48 contained an excess offluoroethano169. 
S.1.16 Preparation of S-fluoro-S-deoxY-D-xyulose-l-phosphate 
(S-FDXyuP) 
A similar procedure to Section 5.1.15 was adopted for the preparation of 5-FDXyuP. 
Therefore, fluoroacetaldehyde 48 (30 {1l, 20 mM) and DHAP 123 (70 ILl, 10 mM) were 
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incubated with L-FruA (20 pJ, 2 mg / ml) in phosphate buffer (580 /11, 50 mM, pH 6.8) for 
16 hrs at 37°C. After this time the sample was denatured at 100°C for 3 min and the 
precipitated protein removed by micro-centrifugation (14,000 rpm / 5 min). The 
supernatant was subsequently lyophilised to remove the majority of residual fluoroethanol 
69 and fluoroacetaldehyde 48. The freeze-dried sample was re-suspended in H20 (700 /11) 
and analysed by 19F NMR. bF(470 MHz, 10 % D20) 5-FDXyuP 126 -228.20 (dt, 2JF,H46.2 
and 3 JF,H 15.3). 
Control experiments were carried under the same conditions in the absence of L-FruA. The 
product was analysed by 19F NMR. bF(470 MHz, 10 % D20), fluoroacetaldehyde 48 
-231.03 ppm and fluoroethano169 -224.51 ppm. 
5.1.17 Protein purification by ammonium sulfate precipitation 
A CFE was prepared according to Section 5.1.6. According to the volume of the 
supernatant, ammonium sulfate was slowly added to the desired % saturation level (see 
Table 5.1). After all the ammonium sulfate was dissolved by stirring for 20 minutes at 4 
.oc, the precipitated solution was centrifuged for 20 minutes at 14,000 rpm and the 
supernatant either discarded or kept for further precipitation. The protein pellet could then 
be used directly or kept at -80°C. 
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Final concentration of ammonium sulfate, % saturation at oDe 
20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 
g solid ammonium sulfate to add to 100 ml of solution 
o 10.7 13.6 16.6 19.7 22.2 26.2 29.5 33.1 36.6 40.4 44.2 48.3 52.3 56.7 61.1 65.9 70.7 
5 8.0 10.9 13.9 16.8 20.0 23.2 26.6 30.0 33.6 37.3 41.1 45.0 49.1 53.3 57.8 62.4 67.1 
10 5.4 8.2 11.1 14.4 17.1 20.3 23.6 27.0 30.5 34.2 37.9 41.8 45.8 50.0 54.4 58.9 63.6 
15 2.6 5.5 8.3 11.3 14.3 17.4 20.7 24.0 27.5 31.0 34.8 38.6 42.6 46.6 51.0 55.5 60.0 
20 0 2.7 5.6 8.4 11.5 14.5 17.7 21.0 24.4 28.0 31.6 35.4 39.2 43.3 47.6 51.9 56.5 
25 
30 
35 
40 
45 
50 
55 
60 
65 
70 
75 
80 
85 
90 
95 
100 
o 2.7 5.7 8.5 11.7 14.8 18.2 21.4 24.8 28.4 32.1 36.0 40.1 44.2 48.5 52.9 
o 2.8 5.7 8.7 11.9 15.0 18.4 21.7 25.3 28.9 32.8 36.7 40.8 45.1 49.5 
o 2.8 5.8 8.8 12.0 15.3 18.7 22.1 25.8 29.5 33.4 37.4 41.6 45.9 
o 2.9 5.9 9.0 12.2 15.5 19.0 22.5 26.2 30.0 34.0 38.1 42.4 
o 2.9 6.0 9.1 12.5 15.8 19.3 22.9 26.7 30.6 34.7 38.8 
o 3.0 6.1 9.3 12.7 16.1 19.7 23.3 27.2 31.2 35.3 
o 3 6.2 9.4 12.9 16.3 20.0 23.8 27.7 31.7 
o 3.1 6.3 9.6 13.1 16.6 20.4 24.2 28.3 
o 3.1 6.4 9.8 13.4 17.0 20.8 24.7 
o 3.2 6.6 10.0 13.6 17.3 21.2 
o 3.2 6.7 10.2 13.9 17.6 
o 3.3 6.8 10.4 14.1 
o 3.4 6.9 10.6 
o 3.4 
o 
7.1 
3.5 
o 
Table 5.1 Ammonium sulfate table showing grams of ammonium sulfate added to 100 ml of 
solution. 184 
5.1.18 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was perfonned on an Invitrogen XCell SureLock™ mini-cell apparatus 
connected to an Amersham Phannacia biotech EPS 301 power supply operating at a 
constant current of 125 rnA for 40 minutes. NuPAGE™ Bis-Tris 10 well gels were used 
which contained either 10 % or 4-12 % ofacrylamide. 
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5.1.19 Sample preparation for SDS-PAGE 
The protein sample was prepared as follows. To 20 /hI of a protein sample was added 5 /hI 
of NuP AGER LDS sample buffer under denaturing conditions. The solution was heated to 
100 DC for 3 min and subsequently 10-20 /hI was added to the sample wells of the pre-cast 
NuPAGE™ Bis-Tris gel. Protein markers (Mark 12 ™ standards, Invitrogen life 
technologies) used were; myosin [200 lcOa], ~-galactosidase [116 l<:Da], phosphorylase B 
[97.4 lcOa], BSA [66 lcOa] , glutamic dehydrogenase [55 lcOa], lactate dehydrogenase [36.5 
kDa], carbonic anhydrase [31 lcOa] , trypsin inhibitor [21.5 kDa], lysozyme [14.4 kDa], 
aprotinin [6 kDa]. 
5.1.19.1 Staining and destaining of SDS gels 
After each SDS-PAGE run, the gel was stained by soaking in a solution of Coomassie blue 
G250 dye for 30-60 min. After this time the gel was destained overnight in destain 
solution with constant agitation to remove any unbound dye. The composition of both 
stains was as follows, 
Stain solution Destain solution 
Coomassie blue G250 2.0 g Methanol 400ml 
Methanol 400ml Glacial acetic acid 70ml 
Glacial acetic acid 70ml Ultra pure water 530ml 
Ultra pure water 530ml 
173 
Chapter 5 
5.1.20 Protein concentration determination 
Protein concentrations were determined using a Bradford assay, (Bradford solution, Sigma 
Chemicals). In a microcuvette, the protein solution (50 /Ll) was added to Bradford reagent 
(1500 /Ll) and thoroughly mixed. After 5 minutes the absorbance was read at A max = 595. 
The result was compared to a standard curve using BSA from known concentrations 
(Figure 5.1). 
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Figure 5.1 Protein concentration detenninations from a standard curve 
5.1.21 Fast protein liquid chromatography (FPLC) 
Protein purification was carried out on an ACT A basic system at room temperature. The 
following techniques were employed; size exclusion chromatography using a High load 
16/60 Superdex 200 (Amersham Biosciences), hydrophobic interaction chromatography 
(HIC) using Phenyl Sepharose HP, 40 ml bed volume (Amersham Biosciences), anion 
exchange using a Q, 10 ml bed volume (Amersham Biosciences), anion exchange, ANX 
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sepharose 4 FF, 1 ml bed volume (Amersham Biosciences), DEAE sepharose FF, 20 ml 
bed volume (Amersham Biosciences), hydroxyapetite type I and II, 5 ml bed volume 
(BioRad) and cation exchange ISS, 10 ml bed volume (Amersham Biosciences). Typical 
flow rates were between 1 mIl min and 5 mIl min. 
5.1.22 Calibration of native protein masses by size exclusion 
chromatography 
The molecular weight of native proteins was measured by size exclusion chromatography 
using a HiLoad 16/60 Superdex 200, (Amersham Biosciences). The column was 
equilibrated with phosphate buffer (50 mM, pH 6.8) and calibrated with the following 
reference proteins; apoferritin (443 kDa), amylase (200 kDa), albumin (66 lilla), and 
cytochrome C (12.4 kDa). The void volume (Vo) of 44.0 ml was determined using blue 
dextran. The calibration curve of the relative elution volumes (log (Ve/Vo) against the 
molecular weights (log MW) ofthe reference proteins is shown in Figure 5.2. 
175 
Chapter 5 
5.8 
5.6 
5.4 
5.2 
~ 5 :E 
----~ 4.8 
4.6 
4.4 
4.2 
4 
0 0.05 0.1 0.15 
y =-6.2423x + 6.2291 
R2 = 0.999 
0.2 0.25 0.3 
log rJeNo) 
0.35 0.4 
Figure 5.2 Calibration curve of molecular weight proteins from HiLoad 16/60 
Superdex 200. 
5.1.23 Partial purification of a PNP from S. cattleya 
CFE (150 ml, ~4 mg 1 ml) was prepared as described under Section 5.l.6 and ammonium 
sulfate precipitation was carried out as described in Section 5.1.18. The protein pellet 35-
50 % was dissolved in phosphate buffer (5 ml, 50 mM, pH 6.8) containing 1 M (NH4)2S04 
at a final concentration of ~21 mg 1 ml. Prior to further purification, the re-suspended 
protein pellet was filtered through a 0.45 /hm HT TuffrynR membrane filter. 
To assay for PNP activity, 100 /hI of CFE or the partially purified fractions were incubated 
with 5'-FDA 54 (final cone. 1 mM) for 16 hrs at 37°C. After this time the sample was 
denatured at 100°C for 3 min and subsequently micro-centrifuged at (14,000 rpm 15 min). 
The clear supernatant (100 /hI) was used directly for HPLC analysis. 
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5.1.23.1 Step 2: Hydrophobic interaction chromatography (HIC) 
The dissolved pellet (5 ml) was injected onto a 40 ml Phenyl sepharose HP column 
(Amersham Biosciences) equilibrated with 2 column volumes of phosphate buffer (50 mM, 
pH 6.8) containing 1 M (NH4)2S04. The column was washed with a further two column 
volumes of this buffer and subsequently eluted by applying a step wise gradient at 2 ml / 
min from 1 M to 0 M (NH4)2S04. PNP activity eluted at the end of the gradient which was 
collected manually (12 ml, ~0.5 mg / mI). 
5.1.23.2 Step 3: Ion exchange chromatography (lEe) 
The eluent (~12 rul) from HIC was concentrated to 2 rul using a 10 l<Da AmiconR Ultra-IS 
centrifugal concentrator. The concentrated protein was then subjected to desalting using a 
HiTrap ™ desalting column, (5 ml) and finally re-concentrated to ~2 ml by the same 
method. The concentrated protein sample (2 ml) was applied to an anion exchange column 
(Q, 5 ml sepharose) which was pre-equilibrated with five column volumes of tris buffer 
(50 mM, pH 7.2). The loaded protein sample was washed with two column volumes and 
subsequently eluted using a step wise gradient oftris buffer (50 mM, pH 7.2) containing 1 
M KCI at a flow rate of 2 rul / min. The peak containing the activity eluted after a gradient 
elution of 250 roM KCI, ~8 ml (0.3 mg / ml). 
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5.1.24 Substrate specificity of PNP from S. cattleya 
PNP substrate specificity was assayed as follows. Partially purified PNP (100 /11, 0.3 mg / 
ml) after step 3, anion exchange chromatography (see Section 5.1.23.2) was incubated with 
each nucleoside analogue (10 /11,11 mM) (see Table 5.2) for 16 hrs at 37°C. 
R5 
R5 N£N f I <,N~N ~ NAR4 )lA) , 
R1W N R4 _ • R1~OPO, 
R2':: R3 -( PNP R2 R3 
Nucleosides 
*5'-fluoro-5'-deoxyadenosine 
5'-fluoro-5'-deoxyinosine 
*2,5 dideoxy-5'-fluoroadenosine 
*2-amino-5'-fluoro-5'-deoxyadenosine 
*5'-chloro-5'-deoxyadenosine 
*2,5-dideoxy-5'-chloroadenosine 
2-chloroadenosine 
*2-amino-5'-chloro-5'-deoxyadenosine 
*5'-bromo-5'-deoxyadenosine 
adenosine 
2-deoxyadenosine 
*3 '-deoxyadenosine 
*5'-deoxyadenosine 
*2',5'-dideoxyadenosine 
2-aminoadenosine 
2-amino-2-deoxyadenosine 
adenosine monophosphate 
5'-thiomethyl-5' -deoxyadenosine 
*5'-acetyl-5'-deoxyademosine 
inosine 
RT = average retention times (min) 
54 
55 
59 
91 
88 
86 
96 
97 
89 
71 
87 
99 
90 
98 
94 
OPO}-
R1 
F 
F 
F 
F 
CI 
CI 
OH 
CI 
Br 
OH 
OH 
OH 
H 
OH 
OH 
R2 
OH 
OH 
OH 
OH 
OH 
OH 
OH 
OH 
OH 
OH 
OH 
H 
OH 
OH 
OH 
R3 R4 R5 RT 
min 
OH H NH2 10.1 
OH H OH 7.5 
H H NH2 10.7 
OH NH2 NH2 9.5 
OH H NH2 12.7 
H H NH2 13.8 
OH CI NH2 12.1 
OH NH2 NH2 11.9 
OH H NH2 15.2 
OH H NH2 704 
H H NH2 7.8 
OH H NH2 8.2 
OH H NH2 9.6 
H H NH2 1004 
OH NH2 NH2 7.0 
95 OH OH H NH2 
H 
H 
H 
H 
NH2 
NH2 
NH2 
NH2 
OH 
7.7 
3.5 
15.0 
14.0 
5.3 
92 OP03 OH OH 
76 MeS OH OH 
93 OAc OH OH 
72 OH OH OH 
* Prepared by S. L. Cobb. I IS 
Substrate 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Table 5.2 Substrate specificity of the PNP for various nucleoside analogues; (+) indicates a 
substrate and (-) indicates no detectable activity. 
After this time the sample was denatured at 100°C for 3 min and the precipitated protein 
removed by micro-centrifugation at (14,000 rpm / 5 min). An aliquot (20 /11) was 
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subj ected to HPLC analysis. Table 2.1 shows a (+) sign indicating phosphorolytic 
cleavage with the generation of the "free" base. Co-injection experiments with the 
con'esponding bases confirmed this unambiguously. A (-) sign indicates no enzyme 
activity. 
Control experiments were carried out under analogous conditions using a denatured protein 
extract. This indicated that all compounds were stable and resistant to chemical 
degradation unless the PNP was active. 
5.1.24.1 Reversibility of the PNP 
Experiment 1: 5'-FDI 55 (18.5 mM) was incubated with immobilised PNP (2 mg resin) 
in a total volume of 1 ml containing phosphate buffer (50 mM, pH 6.8) for 16 hrs at 37°C. 
After this time the sample was denatured at 100°C for 3 min and the precipitated enzyme 
removed by micro-centrifugation (14,000 rpm I 5 min). The supernatant was analysed by 
19F NMR bF (470 MHz; 10 % D20) (5-FDRP 81, ~40 %) -230.78 (dt, 2JF,H 47.3 and 3JF,H 
28.3) and (5'-FDI 55, ~60 %) -230.85 (dt, 2JF ,H 47.0 and 3JF ,H 28.9). HPLC analysis 
showed production of hypoxanthine 79 and unreacted 5'-FDI 55. 
Experiment 2: Partially purified PNP (100 Itl, 0.3 mg I ml) from S. cattleya was 
supplemented with 5-FDRP 81 (100 Itl) prepared from experiment 1 and incubated with 
each purine base (3.7 mM) for 16 hrs at 37°C. After this time the sample was denatured at 
100°C for 3 min and the precipitated protein removed by micro-centrifugation (14,000 
rpm I 5 min). An aliquot, (20 Itl) of the supernatant was analysed by HPLC. Table 5.3 
shows a (+) sign indicating the generation of a nucleoside analogue. Co-injection 
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experiments with the corresponding nucleoside confirmed this unambiguously. A (-) sign 
indicates no PNP activity. 
R5 
(:CI
R4 ~ N 
Purine bases R4 R5 RT Substrate 
min 
adenine 75 H NH2 5.2 + 
hypoxanthine 81 H OH 3.8 
6-methylpurine 102 H CH3 7.4 
6-chloropurine 103 H CI 8.2 
2-amino-6-purinethiol 104 NH2 SH 5.6 
2,6-diaminopurine 101 NH2 NH2 4.8 + 
2-amino-6-chloropurine 106 NH2 CI 7.8 
2,6-dichloropurine 107 CI CI 17.8 
punne 105 H H 5.2 
Table 5.3 Substrate specificity of the PNP from S. cattleya with 5-FDRP 81. 
5.1.24.2 Generation of SAM analogues using the fluorinase in the 
reverse direction 
Preparation of 2-amino-SAM 
Experiment 1: Partially purified PNP from S. cattleya (100 pJ, 0.3 mg / m!) was 
incubated with 5-FDRP 81 (100 Ill) and 2-aminoadenine 101 (final cone. 3.7 mM) for 16 
hrs at 37°C. After incubation the sample was heated (100°C I 3 min) and the denatured 
protein removed by centrifugation (14,000 rpm / 15 min). HPLC analysis with a reference 
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compound indicated the production of 2-amino-5-FDA 111. ES-MS also indicated the 
production of2-amino-5' -FDA 111; mlz 284 (M + Ht. 
Experiment 2: 2-amino-5-FDA 111 (100 Jll) was incubated with the fluorinase (200 Ill, 
10 mg / ml) and L-methionine 56 (10 mM) at 37°C for 16 hrs. The product was heated 
(100°C / 3 min) and the denatured protein removed by centrifugation (14,000 rpm / 15 
min). HPLC analysis indicated the production of a new compound with a retention time of 
15.5 min. The compound was collected and lyophilised and the resultant powder dissolved 
in 1 ml of MeCN (1 ml) for ES-MS analysis; 2-amino-SAM 115; mlz 414 (M+Ht, 100 %) 
and 313 (M + H, - C4HgN02t. 
5.1.25 Partial purification of an isomerase from S. cattleya 
CFE (150 Jll) was prepared according to Section 5.1.6 and ammonium sulfate precipitation 
was carried out as described in Section 5.1.18. The protein pellet 35-50 % was dissolved 
in phosphate buffer (50 mM, pH 6.8) supplemented with 1 M (NH4)2S04 in a total volume 
of 6 ml with a protein concentration of ~20 mg / ml. Prior to further purification the re-
dissolved protein pellet was filtered through a 0.45 Jlm HT Tuffryn® membrane filter. 
Partially purified fractions (200 Jll) were incubated with 5-FDRP 81 (100 Jll) for 16 hrs at 
37°C to assay for isomerase activity. After this time the sample was denatured at 100°C 
for 3 min and the precipitated protein removed by centrifugation (14,000 rpm / 5 min). 
The supernatant was retained and assayed by 19F NMR for isomerase activity; bF (470 
MHz, 10% D20), 5'-FDI 55 -230.84 (dt, 2JF,H 47.0 and 3 JF,H 28.9), 5-FDRP 81 -230.77 (dt, 
2 h,H 47.3 and 3 h,H 28.3) and 5-FDRibP 121 -231.32 (dt, 2 JF,H 47.0 and 3 h,H 20.7). 
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5.1.25.1 Step 2: Hydrophobic interaction chromatography (HIC) 
The dissolved protein pellet (6 ml) was injected onto a 40 ml Phenyl sepharose HP column 
equilibrated with 2 column volumes of phosphate buffer (50 mM, pH 6.8) containing 1 M 
(NH4)2S04. The column was washed with a further two column volumes and subsequently 
eluted by applying a step wise gradient at 2 ml / min from 1 M to 0 M (NH4hS04. The 
isomerase eluted at the end of the gradient adj acent to the PNP fraction (Section 5.1.23.1) 
and was collected manually (12 ml, 1.3 mg / ml). 
5.1.25.2 Step 3: Size exclusion chromatography 
The eluent (~ 12 ml) from the Phenyl sepharose HP column was concentrated to 2 ml using 
a 10 kDa Amicon ® Ultra-IS centrifugal concentrator. The concentrated protein was loaded 
onto a 16/60 Superdex 200 gel filtration column equilibrated with tris buffer (50 mM, pH 
7.2) supplemented with 0.3 M KCI at a constant flow rate of 1 ml / min. Protein elution 
was carried out isocratically over 180 ml. Isomerase activity eluted between 72-80 ml with 
a protein concentration of 0.5 mg / ml. 
5.1.25.3 Step 4: Ion exchange chromatography (IEC) 
The eluent (8 ml) from the size exclusion column was concentrated to 2 ml using a 10 IcDa 
Amicon ® Ultra-IS centrifugal concentrator. The concentrated protein was then desalted 
using a HiTrapTM desalting column (5 ml) to remove KCl. The sample was then re-
concentrated to ~2 ml by the same method. 
The concentrated protein sample (2 ml) was applied to an anion exchange column (Q, 5 ml 
sepharose) which was pre-equilibrated with five column volumes of tris buffer (50 mM, 
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pH 7.2). The loaded protein sample was washed with two column volumes and 
subsequently eluted using a step wise gradient of tris buffer (50 mM, pH 7.2) containing 1 
M KCl at a flow rate of 2 ml / min. The peak containing isomerase activity eluted after a 
gradient of 250 mM KCI with a total protein concentration of 1.5 mg / m!. 
5.1.26 Purification of fructose-l ,6-bisphosphate aldolase 
Cell-free extract (150 ml) was prepared as described under Section 5.1.6 and ammonium 
sulfate precipitation was carried out as described under Section 5.1.18. The protein pellet 
(60-80 %) was dissolved in phosphate buffer (50 mM, pH 6.8) containing 1 M (NH4)zS04. 
Prior to further purification the re-suspended protein pellet was filtered through a 0.45 ILm 
HT Tuffryn® membrane filter. Aldolase activity was assayed according to the following 
procedure. The partially purified aldolase fractions (200 ILl) were incubated with 
fluoroacetaldehyde 48 (30 ILl, 20 mM) and DHAP 123 (70 ILl, 10 mM) with the addition of 
Zn2+ (1 mM) for 16 hrs at 37 DC. After this time the protein was denatured at 100 DC for 3 
min and the precipitate removed by centrifugation (14,000 rpm / 5 min). Analysis by 19F 
NMR showed; ElF (470 MHz, 10 % D20), fluoroacetaldehyde 48, -231.05 (dt, 2Jp,H 46.5 
and 3Jp,H 9.8), fluoroethanol 69 -224.51, 5-FDXyuP 126, -228.18 (dt, 2Jp,H 46.5 and 3JF,H 
15.3). 
5.1.26.1 Step 2: Hydrophobic interaction chromatography 
The dissolved pellet (5 ml, 12 mg I ml) from Section 5.1.26 was injected directly onto a 40 
ml Phenyl sepharose HP column equilibrated with phosphate buffer (50 mM, pH 6.8) 
containing 1 M (NH4)2S04. The column was washed with two column volumes of the 
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same buffer and was then loaded with the re-suspended protein pellet in duplicates. The 
column was washed with phosphate buffer (40 ml, 50 mM pH 6.8) containing 1 M 
(NH4)2S04. and eluted using a stepwise gradient over 80 ml at a flow rate of 2 ml I min 
from 1 M to 0 M (NH4hS04. The aldolase eluted after 70 % of phosphate buffer containing 
1 M (NH4)2S04. 
5.1.26.2 Step 3: Size exclusion chromatography 
The eluent (~ 14 ml) from a Phenyl sepharose HP column was concentrated to 2 ml using a 
10 kDa Amicon® Ultra-IS centrifugal concentrator. The concentrated protein was loaded 
onto a 16/60 Superdex 200 gel filtration column equilibrated with phosphate buffer (50 
mM, pH 6.8) at a flow rate of 1 ml/ min. Protein elution was carried out isocratically over 
180 ml. The aldolase was shown to elute between 62-72 ml with an average protein 
concentration of 0.5 mg / ml. 
5.1.26.3 Step 4: Ion exchange chromatography (lEe) 
The eluent (~16 ml) from size exclusion chromatography was concentrated to 2 ml using a 
10 lilla Amicon ® Ultra-IS centrifugal concentrator. The concentrated protein sample was 
applied to a 10 ml source 15 Q column which was equilibrated with tris buffer (50 mM, pH 
7.2). The loaded protein sample was washed with 20 ml of the same buffer at 2 mIl min. 
Elution of the enzyme was carried out over a linear gradient to 1 M KCl. The desired 
protein eluted after 300 mM KCI addition, and the final protein concentration of the 
purified protein was 2 ml, 0.2 mg / ml. 
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5.1.26.4 Effect of various metal ions on class II L-FruA activity 
After ammonium sulfate precipitation the partially purified L-FruA (6 ml, 15 mg I ml) was 
incubated with EDTA (final conc. 10 mM) for 20 min at 4 DC. The sample was then 
dialysed using dialysis tubing (MW 10 kDa cut off) against 4 L of phosphate buffer (50 
mM, pH 6.8) overnight at 4 DC. The dialysed sample was assayed against the following 
divalent metal ions Zn2+, Mg2+, Mn2+, Co2+, Ne+, Fe2+, Ca2+ and monovalent metal ions, 
Na+. Accordingly, partially purified aldolase (100 ILl, 1.5 mg / ml) was incubated with 
fluoroacetaldehyde 48 (30 ILl, 20 mM) and DHAP 123 (70 ILl, 10 mM) in the presence of 
each metal ion (final conc. 1 mM) for 16 hrs at 37°C. After this time the sample was 
denatured at 100°C for 3 min and was subsequently centrifuged (14,000 rpm /5 min). The 
supernatant was supplemented with D20 (100 ILl) and analysed by 19F NMR spectroscopy. 
5.1.27 
5.1.27.1 
Purine nucleoside phosphorylase (PNP) overexpression 
and purification 
Expression vector 
The pET28a(+) construct (supplied by Dr Joe Spencer, University of Cambridge), carries 
an N-terminal His Tag® I thrombin / T7 Tag® configuration plus an optional C-terminal His 
Tag sequence. It also encodes a gene for kanamycin resistance. As with all pET 
expression systems, target gene expression is induced by IPTG via a T7 promoter. The 
presence of this promoter requires a T7 RNA polymerase whose expression is induced by 
IPTG (Figure 5.3). 
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Figure 5.3 
p.88). 
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Protein expression from pET vectors (taken from Novagen catalogue 2002-2003, 
Transformation of competent cells with pET28a(+) construct 
Chemically competent E. coli cells were purchased from invitrogen. The competent cells 
were in vials containing 50 III aliquots. To transform these cells, each 50 III aliquot was 
placed on ice and allowed to thaw for 2-5 min, while gently mixing to evenly re-suspend 
the cells. After thawing, addition of 1 III (200 ng) of plasmid DNA was added directly to 
each aliquot, stirring gently and returning the vial on ice. The vial was incubated for a 
further 5 min. Heat shock was performed by heating the vials for exactly 30 sec in a 42°C 
water bath. The vials were then placed on ice for 2 min. SOC medium (250 Ill) was added 
to each vial on ice. The vials were then incubated at 37°C while shaking at 250 rpm for 60 
min. An aliquot (60 Ill) of the transformed cells was added to the agar plates containing 
the antibiotic kanamycin, and evenly distributed using a plate spreader. (Note: Prior to 
spreading, the agar plates were pre-incubated at 37°C). The plates were then incubated at 
37 °C for 16 hrs. 
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5.1.27.3 Expression ofjlB and purification of FIB 
(a) Expression trials 
Single colonies were picked and grown up in LB (10 ml) containing 50 p,g I ml of 
kanamycin at 37°C for ~16 hrs on an orbital shaker (200 rpm). After this time, aliquots 
(100 /11) were used to inoculate fresh growth media (10 ml) for the over-expression trials. 
The fresh inoculated LB containing kanamycin was incubated at 37°C for a further 4 hrs. 
Once the cell density reached OD600 = 0.6, expression was induced with IPTG. The 
following variables were altered to optimise expression of soluble PNP from the pET 
28a(+) construct. 
Temperature 
Growth Media 
Host strain 
IPTG cone. 
Expression times 
30 °c, 25°C, 18 °c, 16°C, 12 °c and 10 0c. 
Luria-Bertani, Tryptone phosphate, Terrific Broth and Overnight 
Express ™ Autoinduction System 1 (Novogen). 
BL21(DE3), BL21Star™, BL21 (DE3)pLysS, BL21 (DE3)pLysE, 
Rosetta(DE3) and C43(DE3). 
0.1 mM, 0.2 mM, 0.4 mM, 0.6 mM, 0.8 mM and 1 mM. 
1-42 hrs. 
For each expression trial, samples (1 ml) were taken at various intervals for analysis. Cells 
were harvested by centrifugation (14,000 rpm I 5 min) and the resulting pellet was re-
suspended in tris buffer (1 ml, 50 mM, pH 6.8) and the re-suspended cells were then lysed 
by sonication at 60 cycles for 20 sec. After sonication, the cells were centrifuged (14,000 
rpm I 20 min) and the resultant cell pellet and the supernatant were retained as the 
insoluble and soluble fractions respectively for SDS-PAGE analysis. 
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(b) Large scale expression of fiB 
Single colonies were picked and grown up in LB (30 ml) containing 50 p.,g / ml kanamycin 
at 37°C for ~ 16 hrs on an orbital shaker (200 rpm). After this time, aliquots (5 ml) were 
used to inoculate fresh LB medium (500 ml) using 6 x 2 L baffled flasks. The inoculated 
flasks were incubated at 37°C for 4-6 hours on an orbital shaker (200 rpm) at or until an 
O.D600 = 0.6 was reached. After this time the flasks were placed on ice for several minutes 
with subsequent addition of IPTG (final conc. 0.2 mM) to each flask. The flasks were then 
incubated at 10°C for 30-36 hrs. After this time the cells were harvested by centrifugation 
(9,000 rpm / 20 min) and the resulting pellet was either stored at -80°C or used directly for 
protein purification. 
(c) Purification of fiB 
Cells (0.1 g) were resuspended in 1 ml of buffer A consisting of tris buffer (50 mM, pH 
6.8) supplemented with 10 mM imidazole. The resulting solution was left to stir for 30 
min at 4°C. After this time, cells were disrupted by sonication, ten times at 60 % duty 
cycle for 60 seconds depending on the volume. Cell debris was removed by centrifugation 
at (9,100 rpm / 25 min) and the clear supernatant was retained as cell-free extract (CFE). 
Purification was carried out on a NiS04 charged resin on a fast flow sepharose column 
using the following buffers. 
Buffer A 
0.3 MNaCI 
10 mM imidazole 
20 mM tris pH 7.5 
Buffer B 
0.3 MNaCI 
30 mM imidazole 
20 mM tris pH 7.5 
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0.3 MNaCl 
250 mM imidazole 
20 mM tris pH 7.5 
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The sample was loaded onto the column at a constant flow rate of 1 ml I min pre-
equilbrated with buffer A. After this time the column was washed with several column 
volumes of Buffer B to remove any undesired proteins. The desired protein was then 
eluted by applying Buffer C. 
5.1.28 
.Expression 
L-Fuculose-l-phosphate aldolase (L-FucA) over-
expression and purification 
The following protocol was prepared by Dr Hai Deng, University of St Andrews. The 
pTrcHis C plasmid containing the fuculose-1-phosphate aldolase gene was purchased as a 
transformed E. coli stock (LGC Promochem). Gene expression was achieved by addition 
of cell stock (20 Ill) containing 50 % glycerol to LB (20 ml) containing 0.05 % (100 mg I 
ml) ampicillin and incubated at 37°C for 16 hrs. Aliquots (2.5 ml) were transferred to 
each 6 x 2 L flasks containing LB (750 ml) and incubate at 37°C for 4 hours or until an 
O.D 0.6 was reached. After this time the cells were harvested by centrifugation at 9,100 
rpm I 20 min, the supernatant discarded and the cell pellet was either stored at -80°C or 
used directly for further protein purification. 
Purification 
Cells (0.1 g) were resuspended in Buffer A containing tris buffer (1 ml, 50 mM, pH 6.8) 
supplemented with 10 mM imidazole and stirred for 30 min at 4°C. After this time the 
solution was sonicated six times at 60 cycles for one minute each. The cell debris was 
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removed by centrifugation at (9,100 rpm I 25 min) and the supernatant retained as a CFE. 
Purification was carried out on a NiS04 charged resin, fast flow sepharose column using 
the following buffers. 
Buffer A 
0.3 MNaCl 
10 mM imidazole 
20 mM tris pH 7.5 
Buffer B 
0.3 MNaCI 
30 mM imidazole 
20 mM tris pH 7.5 
Buffer C 
0.3 MNaCI 
250 mM imidazole 
20 mM tris pH 7.5 
The column was first pre-equilibrated with several column volumes of Buffer A at a 
constant flow rate of 2 ml I min. After this time the protein sample was loaded onto the 
column and was washed with several column volumes of Buffer A to remove endogenous 
proteins. Elution with Buffer B for a further 4 column volumes was followed by elution 
with buffer C (Figure 5.1). 
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Figure 5.1 
97 kDa 
66 kDa 
55 kDa 
36 kDa 
31 kDa 
21 kDa 
14 kDa 
· 6 kDa 
1 234 
L-FucA (~ 26 kDa) 
SDS PAGE gel analysis of L-FucA after nickel purification. Lanes 1; SDS 
markers, (Mark 12 TM standards, Invitrogen life technologies) used consisted of, myosin [200 kDa], 
I 
t-·l 
v . 
. , 
~) 
p-galactosidase [116 kDa], phosphorylase B [97.4 kDa], BSA [66 kDa], glutamic dehydrogenase L 
I , 
[55 kDa], lactate dehydrogenase [36.5 kDa], carbonic anhydrase [31 kDa], trypsin inhibitor [2l.5 
kDa], lysozyme [14.4 kDa], aprotinin [6 kDa], 2-4, L-FucA after purification via Ni-NTA affinity 
chromatography. 
191 
Chapter 6 
References 
1. J. R. Hanson, "Natural Products, the Secondary Metabolites", 15t Ed., Royal 
Society of Chemistry, 2003, pp 2. 
2. Alan Crozier, "Plant Secondary Metabolites in Diet and Health", 15t Ed., Blackwell 
publishing, 2006, pp 1. 
3. A. Rahman and P. L. Quesne, Ed., "Natural Products Chemistry," Vol. 3, Springer 
Verlag, Berlin, 1988, pp 10. 
4. M. C. Wani, H. L. Taylor, M. E. Wall, P. Coggin and A. T. McPhail, JAm. Chem. 
Soc., 1971,93,2325. 
5. M. E. Wall and M. C. Wani, Cancer Res., 1995,55, 753. 
6. E. Van Ge1dre, A. Vergauwe and E. Van der Eeckhout, Plant Mol. BioI., 1997,33, 
199. 
7. M. Hayashi, Folia Pharmacol. Japon, 1977,73,205. 
8. G. W. Gribble, J Chem. Educ., 2004, 81, 1441. 
9. M. Sancelme, S. Fabre and M. Prudhomme, J Antibiotics, 1994,47, 792. 
10. Y. Kan, B. Sakamoto, T. Fujita and H. Nagai, J Nat. Prod., 2000, 63, 1599. 
11. N. Sitachitta, B. L. Marquez, R. T. Williamson, J. Rossi, M. A. Roberts, W. H. 
Gerwick, V. A. Nguyen and C. L. Wills, Tetrahedron, 2000, 56, 9103. 
12. M. Sanada, T. Miyano, S. Iwadare, J. M. Williamson, B. H. Arison, J. L. Smith, 
A. W. Douglas, J. M. Liesch and E. Inamine, J Antibiotics, 1986,39,259. 
13. R. S. Beissner, W. J. Guilford, R. M. Coates and L. P. Hager, Biochemistry, 1981, 
20,3724. 
14. P. Messerschmidt, L. Prade and R. Wever, BioI. Chem., 1997,378,309. 
192 
Chapter 6 
15. M. Sundaramoorthy, J. Terner and T. L. Poulos, Chem. BioI., 1998,5,461. 
16. P. D. Shaw and L. P. Hager, J BioI. Chem., 1959,234,2565. 
17. L. P. Hager, D. R. Morris, F. S. Brown and H. Eberwein, J BioI. Chem., 1966,241, 
1769. 
18. S. L. Neidleman and J. Geigert, "Biohalogenation: Principles, Basic roles and 
Applications," 1986, p 46, Chicester: Ellis Horwood. 
19. H. Vilter, Phytochemistry, 1984,23, 1387. 
20. M. Almeida, S. Filipe, M. Humanes, M. F. Maia, R. Melo, N. Severino, J. A. L. da 
Silva, J. J. R. F. da Silva and R. Wever, Phytochemistry, 2001,57,633. 
21. K.-H. van Pee, Ann. Rev. Microbiol., 1996,50,375. 
22. M. Picard, J. Gross, E. Lubbert, S. Tolzer, S. Krauss, K.-H. van Pee and A. 
Berkessel, Angew. Chem. Int. Ed., 1997,36, 1196. 
23. B. Hofmann, S. Tolzer, 1. Pelletier, J. Altenbuchner, K. -H. van Pee and H. J. 
Hecht, J Mol. BioI., 1998,279, 889. 
24. T. Dairi, T. Nakano, K. Aisaka, R. Katsumata and M. Hasegawa, Biosci. Biotech. 
Biochem., 1995,59, 1099. 
25. S. Kirner, P. E. Hammer, D. S. Hill, A. Altmann, 1. Weislo, L. J. Lanahan, K. -H. 
van Pee and J. M. Ligon, J Bacteriol., 1998, 180, 1939. 
26. D. H. Williams and B. Bardsley, Angew. Chem. Int. Ed., 1999,38, 1172. 
27. J. Ahlert, E. Shepard, N. Lomovskaya, E. Zazopoulos, A. Staffa, B. O. Bachmann, 
K. Huang, L. Fonstein, A. Czisny, R. E. Whitwam, C. M. Farnet and J. S. Thorson, 
Science, 2002, 297, 1173. 
28. O. Puk, P. Huber, D. Bischoff, J. Recktenwald, G. Jung, R. D. Submuth, K. 
-H. van Pee, W. Wohlleben and S. Pelzer, Chem. BioI., 2002, 9, 225. 
29. P. C. Dorrestein, E. Yeh, S. Garneau-Tsodikova, N. L. Kelleher and C. T. Walsh, 
193 
Chapter 6 
Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 13843. 
30. S. Keller, T. Wage, K. Hohaus, M. Holzer, E. Eichhorn and K.-H. van Pee, Angew. 
Chem. Int. Ed., 2000, 39, 2300. 
31. D. M. Zeigler, Drug Metab. Rev., 2002, 34, 503. 
32. C. J. Dong, S. Flecks, S. Unversucht, C. Haupt, K.-H. van Pee and J. H. Naismith, 
Science, 309, 2216. 
33. E. Yeh, S. Garneau and C. T. Walsh, Proc. Nat!. Acad. Sci. U.S.A., 2005, 102, 
3960. 
34. C. Sanchez, I. A. Butovich, A. F. Brana, J. Rohr, C. Mendez and J. A. Salas, 
Chem. Biol., 2002, 9, 519. 
35. J. Hartung, Angew. Chem. Int. Ed., 1999,38, 1209. 
36. F. H. Vaillancourt, J. Yin and C. T. Walsh, Proc. Natl. Acad. Sci. U.S.A., 2005, 
102, 10111. 
37. F. H. Vaillancourt, E. Yeh, D. A. Vosburg, S. E. O'Connor and C. T. Walsh, 
Nature, 436,1191. 
38. E. L. Hegg and L. Jr Que, Eur. J Biochem., 1997,250,625. 
39. K. D. Koehntop, J. P. Emerson and L. Jr Que, J Biol. Inorg. Chem., 2005, 10, 87. 
40. J. C. Price, E. W. Barr, B. Tirupati, J. M. Jf. Bollinger and C. Krebs, Biochemistry, 
2003,42, 7497. 
41. J. U. Rohde, J.-H. In, M. H. Lim, W. W. Brennessel, M. R. Bukowski, A. Stubna, 
E. Munck, W. Nam and L. Que Jr, Science, 2003, 299, 1037. 
42. H. J. M. Bowen, 'Trace elements in biochemistry " Academic Press, London and 
New York, 1966, p 10. 
43. E. A. Paul and P. M. Huang, in 'Hand book of environmental chemistry " Vol 1, 
part A, Springer Verlag, Berlin, 1980, p 69. 
194 
Chapter 6 
44. B. E. Smart, 'Molecular structure and energetics', Ed., J. L. Leibman and A. 
Greenberg, VCH Publishers Inc., Deerfield Park, Florida, 1986, Vol 3, p. 141. 
45. C. Walsh, Adv. in Enzymology, 1982,55, 197. 
46. 1. S. C Marais, Onderstepoort J Vet. Sci. Anim. Ind., 1943, 18, 203. 
47. 1. S. C Marais, Onderstepoort J Vet. Sci. Anim. Ind., 1944,20,67. 
48. B. Vickery, M. L. Vickery and 1. T. Ashu, Phytochemistry, 1973,12, 145. 
49. D. O'Hagan, R. Perry, 1. M. Lock, 1. 1. M. Meyer, L. Dasaradhi, 1. T. G. 
Hamilton and D. B. Harper, Phytochemistry, 1993,33, 1043. 
50. B. Vickery and M. L. Vickery, Phytochemistry, 1972, 11, 1905. 
51. R. A. Peters, R. W. Wakelin, P. Buffa and L. C. Thomas, Proc. Roy. Soc. B, 1953, 
40,497. 
52. C. 1. Lovelace, G. W. Miller and G. W. WeHde, Atmos. Environ., 1968,2, 187. 
53. M. H. Yu and G. W. Miller, Environ. Sci. Technol., 1970,4,492. 
54. H. Luable, M. C Kennedy, M. H Emptage, H. Beinert and C. D. Stout, Proc. Natl. 
Acad. Sci. U.S.A., 1996,93, 13699. 
55. E. Kun, E. Kirsten and M. L. Sharma, Dev. Bioener. Biomemb., 1978,2,285. 
56. R. A. Peters and M. Shorthouse, Nature, 1967,216, 80. 
57. R. A. Peters and M. Shorthouse, Nature, 1971,231, 123. 
58. R. A. Peters and R. J. Hall, Biochem. Pharmacol., 1959,2,25. 
59. P. F. V. Ward, R. 1. Hall and R. A. Peters, Nature, 1964,201,611. 
60 R. A. Peters, R. J. Hall, P. F. V. Ward and N. Sheppard, Biochem. J, 1960,77,17. 
61. 1. T. G. Hamilton and D. B. Harper, Phytochemistry, 1997,44, 1129. 
62. T. Higa, J. Tanaka, A. Kitamura, T. Koyama, M. Takahashi and T. Uchia, Pure 
Appl. Chem., 1994,66,2227. 
195 
Chapter 6 
63. X.-H. Xu, G.-M. Yao, Y.-M. Li, J.-H. Lu, C.-J. Lin, X. Wang and C-H. Kong, J 
Nat. Prod., 2003, 66, 285. 
64. D. Robert, P. Edward and H. Charie, JAm. Chem. Soc., 1957, 79, 4559. 
65. S. Ozaki, Y. Watanabe, T. Hoshiko, H. Mizuno, K. Ishirawa and H. Mori, Chem. 
Pharm. Bull., 1984,32, 733. 
66. R. Ignoffo, JAm. Heaith-Syst. Pharm., 1999,56,2417. 
67. S. O. Thomas, V. L. Singleton, J. A. Lowery, R. W. Sharpe, L. M. Pruess, J. N. 
Porter, J. H. Mowat and N. Bohonas, Antibiotics Ann., 1957, 716. 
68. C. W. Waller, J. B. Patrick, W. Fulmor and W. E. Meyer, JAm. Chem. Soc., 1957 
79,1011. 
69. G. O. Morton, J. E. Lancaster, G. E. Van Lear, W. Fulmor and W. E. Meyer, JAm. 
Chem. Soc., 1969,91, 1535. 
70. 1. D. Jenkins, J. P. H. Verheyden and J. G. Moffatt, JAm. Chem. Soc., 1976, 98, 
3346. 
71. A. R. Maguire, W.-d. Meng, S. M. Roberts and A. J. Willetts, J Chem. Soc., Perkin 
Trans., 1, 1993, 1795. 
72. J. M. Williamson, E. Inamine, K. E. Wilson, A. W. Douglas, J. M. Liesch and G. 
Albers-Schonberg, J Bioi. Chem., 1985,260,4637. 
73. G. Albers-Schonberg, B. H. Arison, O. D. Hensens, J. Hirshfield, K. Hoogsteen, E. 
A. Kaczka, R. E. Rhode, J. S. Kahan, F. M. Kahan, R. W. Ratcliffe, E. Wilson, L. 
J. Ruswinkle, R. B. Morin and B. G. Christensen, JAm. Chem. Soc., 1978, 100, 
6491. 
74. R. Schoenheimer and D. Rittenberg, J Bioi. Chem., 1935, 111, 163. 
75. D. B Cowie, E. T Bolton and N. K Sands, J Bacteria!', 1950,60,233. 
196 
Chapter 6 
76. Roberts, R. B., P. H. Abelson, D. B. Cowie, E. T. Bolton, and R. J. Britten, 1955 
Carnegie Inst. Wash. Publ. 607, Washington, D.C. 
77. J. T. G. Hamilton, C. D. Murphy, A. R. Muhammad, D. O'Hagan and D. B. Harper, 
J Chem. Soc., Perkin Trans., 1, 1998, 759. 
78. K. A. Reid, J. T. G. Hamilton, R. D. Bowden, D. O'Hagan, L. Dasaradhi, M. R. 
Amin and D. B. Harper, Microbiology, 1995,141, 1385. 
79. S. J. Moss, C. D. Murphy, J. T. G. Hamilton, W. C. McRoberts, D. O'Hagan, C. 
Schaffrath and D. B. Harper, Chem. Commun., 2000, 2281. 
80. C. D. Murphy, S. J. Moss and D. O'Hagan, Appl. Environ. Microbiol., 2001, 67, 
4919. 
81. C. D. Murphy, C. Schaffrath and D. O'Hagan, Chemosphere, 2003,52,455. 
82. C. D. Murphy, D. O'Hagan and C. Schaffrath, Angew. Chem. Int. Ed., 2001, 
40,4479. 
83. 1. Grgurina and F. Mariotti, FEBS Lett., 1999,462, 151. 
84. A. M. Wuosmaa and L. P. Hager, Science, 1990,249, 160. 
85. D. L. Zechel, S. P. Reid, O. Nashiru, C. Mayer, D. Stoll, D. L. Jakeman, R. A. J. 
Warren and S. G. Withers, J. Am. Chem. Soc., 2001, 123,4350. 
86. C. Schaffrath, PhD thesis, 'Biosynthesis and enzymology of fluorometabolite 
production in Streptomyces cattleya', University of St Andrews, 2002. 
87. M. Flavin, H. Castro-Mendoza and S. Ochoa, J BioI. Chem., 1957,229,981. 
88. T. C. Chou and P. Talalay, Biochemistry, 1972, 11, 1065. 
89. C. Schaffrath, S. L. Cobb and D. O'Hagan, Angew. Chem. Int. Ed., 2002, 41,3913. 
90. S. L. Cobb, H. Deng, J. T. G. Hamilton, R. P. McGlinchey, D. O'Hagan and C. 
Schaffrath, Bioorg. Chem., 2005, 33, 393. 
197 
Chapter 6 
91. D. O'Hagan, C. Schaffrath, S. L. Cobb, J. T. G. Hamilton and C. D. Murphy, 
Nature, 2002, 416, 279. 
92. C. Schaffrath, H. Deng and D. O'Hagan, FEBS Lett., 2003, 547, 111. 
93. C. J. Dong, F. Huang, H. Deng, C. Schaffrath, J. B. Spencer, D. O'Hagan and J. H. 
Naismith, Nature, 2004, 427,561. 
94. A. M. Reeve, S. D. Breazeale and C. A. Townsend, J BioI. Chem., 1998, 273, 
30695. 
95. A. K. Ghosh and Y. Wang, J Chem. Soc., Perkin Trans. 1, 1999,3597. 
96. C. J. Dong, H. Deng, M. Dorward, C. Schaffrath, D. O'Hagan and J. H. Naismith, 
Acta Crystallogr., Sect D: BioI. Crystallogr., 2003, 60, 760. 
97. D. O'Hagan, R. J. M. Goss, A. Meddour and J. Courtieu, JAm. Chem. Soc., 2003, 
125, 379. 
98. C. D. Cadicamo, J. Courtieu, H. Deng, A. Meddour and D. O'Hagan, 
ChemBioChem, 2004, 5, 685. 
99. H. M. Senn, D. O'Hagan and W. Thiel, JAm. Chem. Soc., 2005, 127, 13643. 
100. H. Deng, S. L. Cobb, A. McEwan, R. P. McGlinchey, J. H. Naismith, D. O'Hagan, 
D. A. Robinson and J. B. Spencer, Angew. Chem. Int. Ed., 2005 (in press). 
101. M. M. Goodman. Automated Synthesis of Radiotracers for Positron Emission 
Tomography Applications, Clinical Positron Emission Tomography (PET), K. F. 
Hubner, E. Buonocore, J. Collmann and G. W. Kabalka (Eds). Mosby-Year Book, 
Inc., St. Louis, MO, 1991; plIO. 
102. M. R. Kilbourn. Fluorine-i8 labelling of Radiopharmaceuticals, National 
Academy Press: Washington, DC, 1990. 
103. C. G. Kim, D. J. Yang, E. E. Kim, A. Chrif, L. R. Kuang, C. Li, W. Tansey, C. W. 
Lui, S. C. Li, S. Wallace and D. A. Podoloff, J Pharmaceutical Sci., 1996, 85, 339. 
198 
Chapter 6 
104. Sz Lehel, G. Horvath, I. Boros, T. Marian and L. Tron, J Radioanalyst Nuc!. 
Chem., 2002, 245, 399. 
105. L. Martarello, C. Schaffrath, H. Deng, A. D. Gee, A. Lockhart and D. O'Hagan, J 
Label Compd. Radiopharm., 2003, 46, 1181. 
106. S. L. Cobb, H. Deng, J. T. G. Hamilton, R. P. McGlinchey and D. O'Hagan, Chem. 
Commun., 2004, 592. 
107. H. G. E. Lloyd, A. Deussen, H. Wuppermann and J. Schrader, Biochem. J, 1988, 
252,489. 
108. J. Barankiewiez and A. Cohen, J Bio!. Chem., 1984,259, 15178. 
109. J. L. Palmer and R. H. Abeles, J BioI. Chem., 1979,254, 1217. 
110. 1. 1. Mathews, M. D. Erion and S. E. Ealick, Biochemistry, 1998,37, 15607. 
111. M. J. Pugmire and S. E. Ealick, Biochem. J, 2002, 361, 1. 
112. M. D. Erion, K. Takabayashi, H. B. Smith, J. Kessi, S. Wagner, S. Honger, S. L. 
Shames and S. E. Ealick, Biochemistry, 1997,36, 11725. 
113. A. Sekowska and A. Danchin, BMC Microbiology, 2002, 2, 8. 
114. E. S. Furfine and R. H. Abeles, J BioI. Chem., 1988,263,9598. 
115. A. Sekowska, V. Denervaud, H. Ashida, K. Michoud, D. Haas, A. Yokota and A. 
Danchin, BMC Microbiology, 2004, 4, 9. 
116. J. D. Z. Feng and P. K. F. Yeung, Therap. Drug Monit., 2000, 22,177. 
117. E. Sottofattori, M. Anzaldi and L. O. T. Tonello, J Pharm. Biomed. Anal., 2001, 
24, 1143. 
118. S. L. Cobb, Ph.D thesis, 'The origin and metabolism of 5 '-FDA in Streptomyces 
cattleya, University of St Andrews, 2004. 
119. Q. Zhang and H.-W. Liu, Bioorg. Med. Chem. Lett., 2001,11, 145. 
199 
Chapter 6 
120. E. M. Bennett, C. Li, P. W. Allen, W. B. Parker and S. E. Ealick, J Biol. Chem, 
2003,278,47110. 
121. J. Neuhard, Utilization of performed pyrimidine bases and nucleosides. In 
metabolism ofnucleotides, nucleosides, and nucleobases in microorganisms. (A. 
Munch-Peterson, Ed.), 1983, pp. 95, Academic Press, London. 
122. P. Nygaard, Utilization of performed pyrimidine bases and nucleosides. In 
metabolism ofnucleotides, nucleosides, and nucleobases in microorganisms. (A. 
Munch-Peterson, Ed.), 1983, pp. 27, Academic Press, London. 
123. C. Seeger, C. Poulsen and G. Dandanell, J Bacterio!., 1995, 177, 5506. 
124. S. Senesi, G. Falcone, U. Mura, F. Sgarrella and P. L. Ipata, FEBS Lett.,1976, 64, 
353. 
125. N. Hori, M. Watanabe, Y. Yamazaki and Y. Nmikami, Agric. Bioi., 1989, 
53, 3219. 
126. T. A. Krenitsky, J. W. Mellors and R. K. Barclay, J Biol. Chem, 1965,240, 
1281. 
127. G. Cacciapuoti, M. Porcelli, C. Bertoldo, M. De Rosa and V. Zappia, J Bio!. 
Chem., 1994,269,24762. 
128. F. D. Ragione, A. Oliva, V. Gragnaniello, G. L. Russo, R. Palumbo and V. 
Zappia, J Bioi. Chem, 1990, 265, 6241. 
129. A. J. Ferro, N. C. Wrobel and J. A. Nicolette, Biochim. Biophys. Acta, 1979,570, 
65. 
130. T. A. Krenitsky, G. W. Koszalka and J. V. Tuttle, 1981, Biochemistry, 20, 3615. 
131. A. Bzowska, E. Kulikowska and D. Shugar, Z. Naturforsh., 1990,45,59. 
132. R. E. Parks JI. and R. P. Agarwal, The Enzymes, 3rd Ed., (P. D. Boyer, ed.), 1972, 
Vol 7, pp 483, Academic Press, Inc., New York. 
200 
Chapter 6 
133. K. Fabianowska-Majewska, J. Duley, L. Fairbanks, A. Simmonds and T. Wasiak, 
Acta Biochim Pol., 1994,41,391. 
134. V. Zappia, A. Oliva, G. Cacciapuoti, P. Galletti, G. Mignucci and M. Carteni-
Farina, Biochem. J, 1978,175,1043. 
135. T. M. Savarese, A. J. Cannistra, RE. Parks Jr, J. A. Secrist III, A. T. Shortnacyand 
J. A. Montgomery, Biochem. Pharmacol., 1987,36, 1881. 
136. J. A. Secrist III, W. B. Parker, P. W. Allen, L. L. Bennett, Jr, W. R Waud, J. W. 
Truss, A. T. Fowler, J. A. Montgomery, S. E. Ealick, A. H. Wells, G. Y. Gillespie, 
V. K. Gadi and E. J. Sorscher, Nucleosides and Nucleotides, 1999, 18, 745. 
137. R T. Borchardt, Y. S. Wu, J. A. Huber and A. F. Wycpalek, J Med. Chem., 1976, 
19, 1104. 
138. C. H. Schein and M. H. M. Notebom, Biotechnology (N Y), 1988,6,291. 
139. A. K. Chopra, A. R Brasier, M. Des, X. J. Xu and J. W. Peterson, Gene, 1994, 144, 
81. 
140. G. Georgiou and P. Valax, Current Opinion Biotechnol., 1996,7,190. 
141. E. Winograd, M. A. Pulido and M. Wasserman, Biotechniques, 1993,14,886. 
142. B. Miroux and J. E. Walker, J Mol. Bio!., 1996,260,289. 
143. P. C. Trackman and R. H. Abeles, J Bioi. Chem., 1983,258,6717. 
144. L. Y. Ghoda, T. M. Savarese, D. L. Dexter, R E. Parks, Jr., P. C. Trackman and R 
Abeles, J Bioi. Chem., 1984,259,6715. 
145. J. W. Wray and R H. Abeles, J Bioi. Chem., 1993,268,21466. 
146. R Meyers, J. W. Wray, S. Fish and R Abeles, J Bioi. Chem., 1993,268,24785. 
147. J. W. Wray and R H. Abeles, J Bioi. Chem., 1995,270,3147. 
148. H. Ashida, Y. Saito, C. Kojima, K. Kobayashi, N. Ogasawara and A. Yokota, 
Science, 2003, 302, 286. 
201 
Chapter 6 
149. N. T. Price, G. Francia, L. Hall and C. G. Proud, Biochim. Biophys. Acta, 1994, 
1217,207. 
150. A M. Cigan, J. L. Bushman, T. R. Boal and A G. Hinnebusch, Proc. Natl. Acad. 
Sci. U.S.A, 1993,90,5350. 
151. S. R. Kimball, Int. J Biochem. Cell BioI., 1999,31,25. 
152. M. Bumann, S. Djafarzadeh, A E. Oberholzer, P. Bigler, M. Altmann, H. Trachsel 
and U. Baumann, J BioI. Chem., 2004, 279, 37087. 
153. H. Tamura, H. Matsumura, T. Inoue, H. Ashida, Y. Saito, A Yokota and Y. Kai, 
Acta Cryst., 2005, F61, 595. 
154. P. Hadwiger, P. Mayr, B. Nidetzky, A E. Stutz and A Tauss, Tetrahedron 
Asymm., 2000, 11, 607. 
155. K. Bock, M. Mendal, B. Meyer and L. Weibe, Acta. Chim. Scand., 1983, B 37,101. 
156. A de Raadt, C. W. Ekhart and A E. Stutz, Adv. Detailed React. Mechan., 1995,4, 
175. 
157. A Berger, A de Raadt, G. Gradnig, M. Grasser, H. Low and AE. Stutz, 
Tetrahedron Lett., 1992,33, 7125. 
158. M. H. Fechter, A E. Stutz and A Tauss, Curro Org. Chem., 1999,3,269. 
159. M. H. Fechter and A E. Stutz, Carbo Research., 1999,319,55. 
160. M. Ebner and A E. Stutz, Carbo Research, 1998,305,331. 
161. M. Onega, Ph.D 1st year report, 'Exploring the isomerase and aldolase activity 
in Streptomyces cattleya University of St Andrews, 2005. 
162. G. M. Whitesides and C. -H. Wong, Angew. Chem. Int. Ed, 1985,25,617. 
163. E. J. Toone, E. S. Simon, M. D. Bednarski and G. M. Whitesides, Tetrahedron, 
1989,45,5365. 
164. P. G. Wang, W. Fitz and C. -H. Wong, CHEMTECH, 1995,22. 
202 
Chapter 6 
165. H. J. M. Gijsen, L. Qiao, W. Fitz and C. -H. Wong, Chem. Rev., 1996, 91, 
443. 
166. W. -D. Fessner and C. Walter, Angew. Chem. Int. Ed., 1992,31,614. 
167. R. Schoevaart, PhD thesis, "Applications of aldolases in organic synthesis," 
2000, Delft University of Technology. 
168. R. Schoevaart, F. van Rantwijk and R. Sheldon, J Org. Chem, 2000, 65, 6940. 
169. W. J. Rutter, Fed Proc, 1964,23, 1248. 
170. T. Gefflaut, C. Blonski, J. Perie and M. Willson, Prog. Biophys. Malec. Bioi., 1995, 
63,301. 
171. G. J. Thomson, G. J. Howlett, A. E. Ashcroft and A. Berry, Biochem. J.,1998, 331, 
437. 
172. E. Lorentzen, B. Siebers, R. Hensel and E. Pohl, Biochemistry, 2005, 44, 4222. 
173. A. R. Platter, S. M. Zgiby, G. L. Thomson, S. Qamar, C. W. Wharton and A. Berry, 
J Mol. Bioi., 1999,285,843. 
174. C. H. von der Osten, C. F. D. Barbas, C. H. Wong and A. J. Sinskey, Mol. 
Microbial., 1989,3, 1625. 
175. A. C. Joerger, C. Gosse, W. D. Fessner and G. E. Schulz, Biochemistry, 2000, 39, 
6033. 
176. W.D. Fessner, A. Schneider, H. Held, G. Sinerius, C. Walter, M. Hixon and J. V. 
Schloss, Angew. Chem. Int. Ed., 1996,35,2219. 
177. W. D Fessner, G. Sinerius, A. Schneider, M. Dreyer, G. E. Schulz, J. Badia 
and J. Aguilar, Angew. Chem. Int. Ed, 1991,30,555. 
178. A. Ozaki, E. J. Toone, C. H. von der Osten, A. J. Sinskey and G. M. 
Whitesides, JAm. Chem. Soc., 1990, 112, 4970. 
203 
Chapter 6 
179. M. D. Bednarski, E. S. Simon, N. Bischofberger, W-D. Fessner, M. J. Kim, 
W. Lees, T. Saito, H. Waldmann and G. M. Whitesides, J. Am. Chem. Soc., 
1989, 111, 627. 
180. U. D. Wehmeier, FEMS Microbial. Letters, 2001,197,53. 
181. B. L. Horecker, O. Tso1as and C. Y. Lai, "The Enzymes," 3rd Ed, Vol 7, pp 
213. Academic Press, New York. 
182. M. A. Gha1ambor and E. C. Heath, J. Bio!. Chem., 1962,237,2427. 
183. E. A. E1singhorst and R. P. Mort1ock, J. Bacterial., 1994,176, 7223. 
184. R. K. Scopes, 'Protein Purification, Principles and Practice,' 3rd Ed., 
Springer, New York, 1994, p. 346. 
204 
=J 
Appendix 
Appendix 
Publications 
1. S. L. Cobb, H. Deng, J. T. G. Hamilton, R. P. McGlinchey and D. O'Hagan, 
Chem. Commun., 2004,592. 
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C. Schaffrath, BioOrg. Chem, 2005,33,393. 
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D. Robinson and J. Spencer, Angew. Chem. Int. Ed., 2006, 45, 759. 
4. H. Deng, S. L. Cobb, A. Gee, A. Lockhart, L. Martarello, R. P. McGlinchey, D. 
O'Hagan and M. Onega, Chem. Commun., 2006, 652. 
Awards and prizes 
Oral presentation (1 st prize), 2nd Organic Chemistry PhD symposium, 
University of St Andrews. 
2nd June 2005 
Poster presentation (1 st prize ) ,Annual RSC Fluorine Subj ect, 
Group Postgraduate Meeting, University of Oxford. 
1 st_2nd September 2005 
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Presentations 
Poster presentation, Pro Bio Faraday, Biocatalysis for manufacture, Current 
Practice and Future Opportunities, University of Heriot-Watt. 5th_6th November 2003 
Oral presentation, 4th RSC Fluorine Subject Group Postgraduate Meeting, 
University of Durham. 2nd _3rd September 2004 
Poster presentation, Pro-Bio Faraday partnership, 
University ofWarwic1c. 
Poster presentation, 33rd RSC Scottish Organic Division Meeting, 
University of St Andrews. 
Oral presentation, Pro Bio Faraday biocatalysis research projects, 
Bradford. 
8th_9th November 2004 
20th December 2004 
21 st_22nd July 2005 
Oral presentation, ProBio Faraday Partnership Research Review Meeting, 
Bradford. 8th _9th June 2004 
Oral presentation, 2nd Organic Chemistry PhD symposium, 
St Andrews University. 
Poster presentation, RSC and BBSRC symposium on 
'The Chemistry and Biology of Natural Product Biosynthesis II', 
University of Bristol. 
Posterpresentation BIOTRANS 2005 -Delft, Netherlands 
i h International Symposium on Biocatalysis and Biotransformations. 
Poster presentation, 5th Annual RSC Fluorine Subject Group Postgraduate 
2nd June 2005 
15th July 2005 
3_8th July 2005 
Meeting, University of Oxford. I_2nd September 2005 
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Conferences attended 
RSC Bio-organic postgraduate symposium, St John's College, 
University of Cambridge. 
31 st Scottish Regional Perkin Division Meeting, Dundee University. 
2ihNov 2002 
18th Dec 2002 
Enzyme mechanism. A structural perspective, University of St Andrews. 12th_14th Jan 2003 
14th Scottish Graduate Symposium on novel organic chemistry, 
University of Aberdeen. 9th April 2003 
3rd RSC Fluorine Subject Group Postgraduate Meeting, 
University of St Andrews. 4th_5th Sept 2003 
1 st University of Glasgow/Organon Symposium on synthetic chemistry. 22nd Sept 2003 
RSC Organic Division and Chemical Biology Forum, 
University of Edinburgh. 31 st October 2003 
Pro Bio Faraday, Biocatalysis for manufacture, Current Practice and 
Future Opportunities, University of Heriot-Watt. 5th _6th November 2003 
32 rd Scottish Regional Perkin Meeting, University of Edinburgh 1 i h December 2003 
Pro Bio Faraday biocatalysis research projects, Bradford. 
4th RSC Fluorine Subject Group Postgraduate Meeting, 
University of Durham. 
14th International Isotope Society (UK group) symposium 
8th-9th June 2004 
2nd_3 rd September 2004 
Well come Genome Campus, Hinxton. 4th November 2004 
Pro Bio Faraday Biocatalysis, University of Warwick. 8th_9th November 2004 
33 rd Scottish Organic Division Meeting, University of St Andrews. 20th December 2004 
Pro Bio Faraday biocatalysis research projects, Bradford. 21 st_22nd July 2005 
2nd Organic Chemistry PhD symposium, University of St Andrews. 2nd June 2005 
RSC and BBSRC symposium, 'The Chemistry and Biology of Natural Product 
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Biosynthesis II', Bristol. 15th July 2005 
BIOTRANS 2005 -Delft, Netherlands, 7th International Symposium on 
Biocatalysis and Biotransformations. 3_8th July 2005 
5th Annual RSC Fluorine Subject Group Postgraduate Meeting, 
University of Oxford. I_2nd September 2005 
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